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chApter 1: introduction And outline
2IntroductIon
Nephrotic syndrome
A syndrome is a collection of symptoms which occur together and may point to 
a single underlying cause for these symptoms. In case of nephrotic syndrome the 
symptoms are massive protein loss via the urine (i.e. proteinuria of more than 3.5 
grams per 24 hours), low serum protein level, in particular low serum albumin, and 
as a consequence severe edema and high serum lipid levels.1 Due to loss of some 
serum proteins which have an anti-coagulatory function, the risk of thrombosis 
is increased in patients with nephrotic syndrome. Moreover, as antibodies are 
lost via urine, patients are at elevated risk of infections. Proteinuria, and thereby 
nephrotic syndrome is often a consequence of glomerular damage. When one of 
the components of the filtration barrier is damaged, its integrity is lost, and serum 
proteins pass into the pro-urine. In an attempt to salvage the proteins that are lost 
through the glomerulus, the tubular cells start reabsorbing more protein causing 
cell stress.2 If the protein load is too high or goes on for too long, the tubular cells 
may die, causing more damage to the kidney. Ultimately, persisting nephrotic 
syndrome can result in end stage kidney failure. A patient then needs renal 
replacement therapy, such as dialysis or a kidney transplant.
Membranous nephropathy
Membranous Nephropathy is one of the most common causes of nephrotic 
syndrome in adults. Its incidence is estimated to be a little over one case per 
100,000 persons per year in Caucasians.3 Membranous nephropathy itself was 
introduced as the description of a histological pattern, characterized by thickening 
of the glomerular basement membrane found in the microscopic examination of 
a kidney biopsy. The thickened glomerular basement membrane is composed of 
IgG containing immune complexes that are deposited in the subepithelial space. 
Protrusions, or spikes, of the glomerular basement membrane that surround 
the deposits are often visible as characteristic spikes in silver stained biopsy 
slides as well. The IgG deposits active complement and cause podocyte injury 
with subsequent effacement of the foot processes. In approximately one third 
of the patients a clear underlying cause for the membranous nephropathy can 
be identified. This may be an infection, drug use, cancer or another underlying 
systemic disease.4 In the remaining patients no underlying cause is found, and 
thus the membranous nephropathy is considered idiopathic –of unknown origin. 
In a rat model, membranous features were recreated.5 This so-called Heymann 
nephritis was produced by immunizing rats with an extract from proximal 
tubules. Their immune systems subsequently produced antibodies against 
their own megalin, a transporter protein found in the cell membrane of the rat 
podocyte and proximal tubular cell. This led researchers to believe that idiopathic 
membranous nephropathy was an auto-immune disease. However, human 
podocytes do not express megalin. Consequently, the causative antigen in human 
idiopathic membranous nephropathy remained unknown for decades. Recently, 
Beck and colleagues showed that 70% of idiopathic membranous nephropathy 
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3patients have circulating auto-antibodies against the M-type phospholipase A2 
receptor (PLA2R).6 This receptor is present on the human podocyte. Furthermore, 
a genome-wide association study found a link between a single nucleotide 
polymorphism associated with the PLA2R1 gene and the occurrence of idiopathic 
membranous nephropathy.7 Together these findings suggest that anti-PLA2R 
antibodies are causative for idiopathic membranous nephropathy in a large 
proportion of patients, and that it is indeed an auto-immune disease. Nevertheless, 
as the disease is historically known as idiopathic membranous nephropathy and no 
antigen has been identified in approximately  30% of all patients, it will be referred 
to as such throughout this thesis, even though it may no longer be of unknown 
origin for many patients.
Personalized treatment 
The natural course of idiopathic membranous nephropathy is quite variable. 
Patients who never develop nephrotic syndrome, i.e. their urine protein levels 
remain less than 3.5 g/day, almost always have a stable kidney function. 
Approximately 50% of the patients who do present with nephrotic syndrome will 
show a spontaneous remission of proteinuria and stabilization of kidney function.8 
The remaining patients will show progressive kidney failure and may ultimately 
require renal replacement therapy.9 At present, renal replacement therapy, by 
dialysis or a kidney transplantation, is one of the most expensive treatments 
in healthcare. Therefore, membranous nephropathy may weigh heavily on the 
healthcare budget, despite its relative rarity.
As the presence of nephrotic syndrome and proteinuria are strongly linked 
to kidney failure, the initial treatment of idiopathic membranous nephropathy 
is aimed at reducing proteinuria. Since the 1990s angiotensin converting 
enzyme (ACE) inhibitors and angiotensin two receptor blockers (ARB) are being 
used as supportive care, as these drugs reduce proteinuria as well as blood 
pressure. However, historically immunosuppressive treatment has been used, 
as membranous nephropathy was assumed to be an auto-immune disease. For 
example, in the late 1970s patients were treated with steroids. Although a first 
trial with steroids appeared successful,10 other studies failed to show a similar 
effect.11,12 Later, a seminal trial performed by Ponticelli and colleagues showed that 
suppressing patients’ immune system with chlorambucil, an alkylating agent used 
in cancer therapy, resulted in remission of proteinuria. Moreover, it reduced the 
risk of needing renal replacement therapy and overall mortality in treated patients 
compared to patients who received placebo.9 Later the same research group 
published a paper in which they showed that treatment with cyclophosphamide, 
another alkylating agent, gave similar results, but less severe side effects.13 
Nevertheless, cyclophosphamide is toxic. In particular, alkylating agents are 
associated with increased risk of infertility and cancer, and therefore their use 
remains debated to this day. 
The trials underpinning the evidence for efficacy of these agents assume that 
all patients would be treated. However, given the variable disease course, up 
to half of all patients could thus be unnecessarily exposed to these toxic drugs. 
Therefore, restrictive use of immunosuppression has been advocated.14 Indeed, 
the recently published Kidney Disease: Improving Global Outcome (KDIGO) 
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4guidelines recommend that all patients be treated with supportive care, and they 
only recommend immunosuppressive therapy in patients suffering nephrotic 
syndrome for at least six months, when kidney function deteriorates, or when 
severe symptoms of the nephrotic syndrome are present.1 However, there is very 
little direct evidence to support the recommendation for restrictive treatment. 
Moreover, long term consequences are largely unknown. Furthermore, restrictive, 
personalized therapy requires accurate prediction of prognosis, so that only 
patients who really need immunosuppressive therapy receive it, and patients who 
are likely to show a sponteneous resmission are spared from side effects. 
Predicting prognosis
The past decades of research in idiopathic membranous nephropathy have been 
marked by the search for prognostic markers to identify high risk patients.15-18 To 
this day, a sustained decrease in glomerular filtration rate has proven to be the 
most powerful marker of a poor prognosis.19 Conversely, remission of proteinuria, 
either spontaneous or after treatment, is associated with favorable outcome.20 
Unfortunately, a decrease in glomerular filtration rate or remission of proteinuria 
requires a long follow-up period, leaving the patient and physician in uncertainty. 
Furthermore, a decrease in glomerular filtration rate may be insidious. Delayed 
start of immunosuppression has been associated with higher complication rates 
and reduced efficacy, as irreversible damage may have already occurred.21,22 Other 
validated prognostic markers are used as well. However, these need reassessment 
as the clinical course of the idiopathic membranous nephropathy has changed since 
their introduction, mostly due to the now universal use of ACEi/ARBs.23,24 
The balancing act
In summary, cyclophosphamide therapy is effective in idiopathic membranous 
nephropathy. However, it can give severe side effects, and therefore restrictive 
treatment is recommended. Unfortunately, evidence supporting restrictive 
regimens is lacking. Moreover, the magnitude of risks associated with 
cyclophosphamide therapy in patients suffering from idiopathic membranous 
nephropathy is not well known. As a consequence, balancing the benefits and risk 
of therapy is difficult, both at the individual patient level and at the societal level.
thesIs outlIne
Given the background of idiopathic membranous nephropathy and its 
treatment, the following questions arise: 
1. How well can we predict prognosis and identify at high risk of progression in 
idiopathic membranous nephropathy?
2. Can we improve prediction of prognosis?
3. Is restrictive therapy with cyclophosphamide effective?
4. What in the malignancy risk of cyclophosphamide therapy?
5. Do the benefits of restrictive cyclophosphamide therapy outweigh the risks and 
costs?
In order to answer these questions, epidemiological studies and a decision 
analysis have been performed. The studies in this thesis build on previous work. 
C
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5Together with allied centers from the South and East of the Netherlands, the 
Radboud university medical centre has established a registry and biobank of 
patients with glomerular diseases. Urine and blood samples of these patients 
were obtained and stored in a standardized fashion. In Chapter 2 we give a brief 
overview of the methodology used in this thesis and describe the Glomerular 
Disease Registry and the standardized protocol according to which blood and urine 
samples have been obtained. 
Branten et al. described how urinary β2-microglobulin excretion can be used to 
identify patients with idiopathic membranous nephropathy at the highest risk of 
progression.24 However, as the procedures to measure urinary β2-microglobulin 
are cumbersome, the search for other markers continues. Alpha-1-microglobulin 
has been proposed as such a marker. Furthermore, despite validation, prognostic 
markers often do not live up to their expectations when introduced into clinical 
practice. For example, since the introduction of urinary β2-microglobulin into 
clinical practice, therapeutic blood pressure targets have been lowered, and ACEi 
and ARBs have become standard care. This may have altered the disease course of 
patients who have not been treated with immunosuppressive drugs. The predictive 
performance of urinary β2-microglobulin may have changed as a consequence. 
Therefore, in chapter 3.1, we evaluated the prognostic value of urinary β2-
microglobulin as well as α1-microglobulin in current clinical practice. 
International guidelines for the diagnosis and treatment of idiopathic 
membranous nephropathy recommend a prognostic algorithm as an alternative 
to urinary β2-microglobulin.
1 This algorithm, developed and validated by Cattran 
and colleagues,18,23 uses the minimal total urinary protein excretion over a six 
month period of maximal proteinuria in combination with the initial creatinine 
clearance and the change in creatinine clearance during that six month time frame. 
Compared to measuring β2-mciroglobulin, it requires a more prolonged follow-up. 
Which of the two prognostic strategies is most accurate has not been evaluated. We 
performed a head-to-head comparison of the urinary low molecular weight proteins 
α1- and β2-microglobulin and the prognostic algorithm by Cattran and colleagues, 
which we named the Toronto Risk Score. This study is described in chapter 3.2.
Once prognosis has been predicted, patients are monitored closely. Should 
complications of the nephrotic syndrome arise or if their kidney function shows 
signs of deteriorating, immunosuppressive therapy with cyclophosphamide is 
advised.1 Otherwise, patients are treated with ACEi and/or ARBs to control blood 
pressure and reduce proteinuria. This treatment strategy, recommended in the 
KDIGO guidelines, has already been used at the Radboud university medical centre 
and allied centers from 1995 onward. Now, over fifteen years later, we are in a 
position to evaluate the long term outcomes of this treatment strategy. Chapter 4.1 
describes rates of mortality and renal replacement therapy, being dialysis or kidney 
transplantation, as well as the occurrence of adverse events.
Even though alkylating agents, and especially cyclophosphamide, have 
been shown to be effective in the treatment of idiopathic membranous 
nephropathy,9,13,22,25 their use is not universal nor without criticism. 
Cyclophosphamide has long been used as chemotherapy in non-Hodgkin’s 
lymphoma, rheumatoid arthritis and anti-neutrophil cytoplasmic antibody 
(ANCA) associated vasculitis. It has been reported to increase the long term 
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6risk of malignancy in exposed patients.26-28 However, data from patients with 
other diseases cannot necessarily be extrapolated to patients with idiopathic 
membranous nephropathy. Furthermore, to balance the risk and benefits of 
cyclophosphamide therapy, an estimate of the magnitude of malignancy risk in 
treated idiopathic membranous nephropathy patients is required. Therefore, in 
chapter 4.2, we evaluated the incidence of malignancies in patients with idiopathic 
membranous nephropathy who were treated with cyclophosphamide compared to 
the incidence in untreated patients. 
Finally, in Chapter 5, the risks of progressive kidney failure, renal replacement 
therapy, death, malignancy and other complications and the benefits of universal 
or restrictive cyclophosphamide therapy are brought together in a Markov model. 
Additionally, we estimated healthcare related costs associated with possible 
treatments and outcomes. The model is to aid policy makers as well as individual 
physicians and patients in making a personalized and well informed decision about 
an optimal treatment strategy.
We provide a summary of the findings in this thesis in chapter 6. In addition, 
we put our findings into perspective with recent advances in the field of idiopathic 
membranous nephropathy. Chapter 7 provides a Dutch language summary of the 
main findings presented in this thesis.
C
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AbstrAct
This chapter describes study methods commonly used throughout this thesis. 
First an overview of the standardized and timed urine analysis and laboratory 
procedures is given on which the first two studies in the thesis are based. Second, 
the data collection for the biobank and patient registry created at the Radboud 
university medical centre is described. All studies presented in this thesis are 
based on data from this registry. The final section provides an overview of the 
epidemiologic and decision analytic methods used in the following chapters. This 
last section is intended as a basic introduction for the reader who is unfamiliar 
with the conduct and/or analysis of epidemiologic studies or decision analysis, 
respectively. 
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stAndArdIzed tImed urIne AnAlysIs
Since 1995 patients suffering from the nephrotic syndrome are referred to our 
clinic, either by family doctors in our catchment area or by allied internal medicine 
and nephrology clinics. These patients undergo a timed urine analysis. To date, 
over 1000 patients suffering from glomerulonephritis have attended. The goals of 
the timed urine analysis are twofold, on the one hand results are used to predict 
prognosis, and support clinical decision making. On the other, samples and data 
collected are used for scientific studies to improve the treatment of various forms of 
glomerulonephritis. 
The standardized timed urine analysis has been described previously.1,2 In 
summary: prior to undergoing the urine analysis, patients are asked to fast 
overnight. In addition, they are instructed to collect two 24 hour urine samples in 
the days before the visit. Furthermore, patients take 4000 milligrams of sodium 
bicarbonate on the evening before attending our clinic to ensure that urinary pH 
exceeds 6.0, as β2-microglobulin degrades in acidic urine. Patients are not allowed 
to take any diuretics on the morning of the measurement. Other medications are 
taken as usual. Upon arrival to the clinic, patients are given 375 to 500 milliliter 
of tap water to enforce diuresis. Patients remain supine for one hour except for 
voiding. Blood pressure is measured ten times with an interval of 5 minutes using 
an automated device (Dinamap, Critikon, Tampa FL, USA). In the middle of the 
urine collection period, a blood sample is drawn. 
In the blood samples, sodium, potassium, urea, creatinine, calcium, phosphate, 
hemoglobin, hematocrite, cholesterol, triglyceride, HDL-cholesterol, LDL-
cholesterol, albumin, IgG, transferrin and β2-microglobulin levels are determined. 
Likewise, sodium, potassium, creatinine, total protein, albumin, IgG, transferrin, 
α1- and β2-microglobulin concentration are measured in the timed urine samples. 
Sodium, urea, total protein and creatinine levels are determined in the 24 hour 
urine samples. Most concentrations are measured using standard automated 
techniques. Concentrations of α1-microglobulin, albumin, transferrin, IgG are 
measured by immunonephelometry using on a BNII nephelometer (Behring, 
Marburg, Germany). Beta-2-microglobulin concentrations were measured using an 
ELISA.2 In addition, blood and urine samples for every patient are taken and stored 
at -80 °C. 
the glomerulAr dIseAse regIstry
Parallel to the standardized urine analysis a prospective registry of referred 
patients with glomerulonephritis is kept. At the visit for standardized urine 
analysis, demographic parameters such as date of birth, ethnicity and gender 
are registered. Additionally, the date of biopsy, biopsy identification number for 
the PALGA registration and the names of the referring centre and physician are 
recorded. 
Follow-up data are collected periodically from medical records at the referring 
centers. Blood pressure and weight are recorded from out-patient records. In 
addition, laboratory data including serum creatinine, albumin, urea and cholesterol 
Population and Methods
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as well as urinary protein and creatinine concentrations are obtained. Prescribed 
ACE inhibitors, ARBs, diuretics and other antihypertensive medication, lipid 
lowering medication, anti-coagulation and non-steroidal anti-inflammatory 
drugs are recorded as well. Finally, immunosuppressive treatment regimens are 
registered. For cyclophosphamide the total cumulative dose per treatment episode 
is included as well. Recorded complications during follow-up include infections, 
fever, liver function abnormalities, malignancies, incident cardiovascular disease, 
cerebrovascular accidents, embolism, leucopenia and thrombopenia. If a patient 
develops end stage kidney disease during follow-up, this is recorded as well. 
Finally, upon death of a patient, the date and cause of death as reported by the 
treating physician are registered.
study desIgns 
The following section provides a brief introduction on the research designs 
and analyses presented in this thesis. This section is aimed at readers who are 
unfamiliar with epidemiologic research and/or economic evaluations in healthcare.
Predictive studies 
The ultimate goal of predictive studies, either diagnostic or prognostic, is to 
accurately predict the occurrence of an event.3 Events may be the presence or onset 
of a disease or the occurrence of a long term outcome, such asrenal replacement 
therapy. The gold standard design for predictive studies is a cohort. Patients 
are included at similar time in the course of their disease. Subsequently a test is 
performed to predict either diagnosis (having a disease right now) or prognosis 
(having a disease or other event sometime in the future). The example in table 1 
shows such a test. In this example body temperature is measured to establish the 
presence of an infection. At each 0.5 °C increase of body temperature a threshold 
for test positivity can be placed, six in total. Using the resulting test characteristics, 
a receiver-operating characteristics (ROC) curve can be plotted.4 For each 
threshold, the ROC curve plots the true positive rate (sensitivity) against the false 
positive rate (1 – specificity) at each threshold. Subsequently, an area under the 
ROC curve can be calculated. An area of 1 signifies perfect discrimination, and thus 
Table 1. Body temperature in persons with and without an infection.
Temperature Number of 
diseased 
persons
Number of 
undiseased 
persons
Risk of infection
≥38.0 13 1 93%
37.5-37.9 8 5 62%
37.0-37.4 4 19 17%
36.5 -36.9 2 25 7%
<36.5 1 12 8%
Total 28 72
C
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a prefect test. An area of 0.5 is similar to tossing a coin, completely random, and 
thus a useless test. Figure 2.1 shows the ROC curve for body temperature as a test 
for infection, based on the data in table 1. The area under the curve of 0.87 means 
that if we are faced with two patients and measure body temperature, we will 
correctly point out the person who is at highest risk of having an infection 87% of 
the time. Note that ROC analysis only gives ranks and does not provide information 
on the magnitude of difference in risk. Furthermore, whether an area under the 
ROC curve of 87% provides sufficient discrimination depends on the consequences 
of the decision. For example, in idiopathic membranous nephropathy, patients 
may be treated with toxic drugs. In this case we would like to minimize the number 
of patients with a false positive test result. However, we do not want to wait with 
treatment until irreversible damage has occurred. There is very little leeway in this 
decision, and thus a very high discriminatory power is required.
Rather than a just a single test variable, numerous possibly predictive variables 
can be related to an event of interest using a regression model, such as logistic 
or Cox regression.4 Conceptually, a regression model is the lump sum of many 
simultaneous tests and can be viewed as a test itself. It yields a dimensionless score 
which can be recalculated into the predicted probability of the event occurring.  
Subsequently, the observed probability of the event can be plotted against its 
predicted probability, which is based on the test, for several groups of patients 
divided by their predicted probability of the event.4 In the example patients have 
been categorized in five groups with increasing predicted risk of an event. Their 
actual risk is show in table 1. In the case of optimal calibration, the observed and 
predicted probabilities closely match. It means that persons with a predicted high 
Figure 1. Receiver-operating characteristics curve for body temperature as a test 
for infection. The diagonal reference line signifies an uninformative test, such as 
tossing a coin. See table 1 for the data on which the curve was based. The point 
estimates from left to right mark the following thresholds: classifying none as 
diseased, ≥38.0, ≥37.5, ≥37.0, ≥36.5 and classifying all patients as diseased.
Population and Methods
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risk are at a substantially higher risk of the event compared to low risk patients. 
However, if the observed (i.e. actual) probability of the event increases little with 
a marked increase in the predicted chance of an event, the test may not be very 
helpful –even if discrimination is good. In that case an increase in test result 
does not result in any clinically relevant difference in risk. Figure 2.2 shows the 
calibration plot for our body temperature example. Here we can see that the 
actual risk of infection increases with predicted risk of infection based on body 
temperature. However, in the lower ranges of predicted risk, calibration is rather 
poor. At levels lower than 37.5 °C, the observed risk of an infection increases very 
little despite increasing body temperature. Therefore, we can conclude that our test 
is only clinically useful at higher body temperatures. 
Following the creation of a test or a predictive model, it needs to be validated.5 
This is done using the same design and similar analysis methods, but in different 
patients. The most accepted and valid method is using a different cohort of 
contemporary patients. Another option is temporal validation, in which a new 
cohort is created after the test has been introduced. Other options such as internal 
validation may be useful, but are considered inferior to external validation. 5 
For further reading on the subject, consider the excellent treatises by Altman, 
Royston, Moons and Vergouwe.3-6
Etiologic studies
In etiologic studies the goal is to provide an accurate, unbiased description of 
the association between an exposure and subsequent disease or outcome. Basically, 
a population is followed for a period of time and during this time events occur. 
Subsequently, if we have a dichotomous (yes/no) exposure, like in chapter 6 where 
patients were either treated with cyclophosphamide or not, the number of events 
can be divided by the total amount of follow-up time accrued by all patients in 
Figure 2. Calibration plot for body temperature as a test for infection. An ideal 
test closely fits the diagonal line.
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either exposure group. This is called the incidence.7 Then a ratio of incidences 
can be calculated to investigate the effect of a certain exposure on the outcome of 
interest. In a second paper VandenBroucke and Pearce give an insightful example, 
a slightly adapted version will be presented here.8 
As a thought experiment we will consider the possible effect of oral 
contraception use on the occurrence of deep venous thrombosis in women of a 
reproductive age. Say we have a dynamic population of 1.2 million women of a 
reproductive age during the year 2012, one thirds of whom use oral contraceptives. 
Furthermore, we assume that the population is in a steady state. In other words, 
we assume that the number of women in either exposure groups stays virtually the 
same over the year. This is often a realistic assumption.7 Subsequently, we observe 
400 new cases of deep venous thrombosis within the oral contraceptive using 
women and 200 in the unexposed women during the year. The resulting incidence 
in the exposed women is 400 / 400,000 = 10 per 10,000 women years. Likewise, 
the incidence in the unexposed women in 200 / 800,000 = 2.5 per 10,000 women 
years. Consequently the incidence ratio equals 4.0, which means that women who 
use oral contraceptives are four times more likely to have deep venous thrombosis 
compared to unexposed women. The precision with which this incidence ratio 
is estimated can be expressed as a 95% confidence interval. Here the confidence 
interval ranges from 3.4 to 4.8, which means that we can say with 95% certainty 
that upon repeating the study in a similar population an incidence ratio between 
3.4 and 4.8 will be found. Or, in simpler, broadly correct terms: the ‘true’ incidence 
ratio for deep venous thrombosis due to oral contraceptive use most likely lies 
between 3.4 and 4.8. We now know that if we were to remove oral contraceptive 
use, the incidence of deep venous thrombosis in our hypothetical population 
would decrease. Essentially, this is the goal of etiologic studies. Finding exposures 
that result in disease so that we may be able to prevent or treat the disease by 
intervening on that exposure.
If there are no other factors related to both the exposure and outcome, the 
calculations described above result in an unbiased effect estimate of the exposure 
on the outcome. This is the case when an investigator randomly assigns the 
exposure, as is done in clinical trials. However, in an observational setting, 
potential risk factors for disease often occur in clusters. This makes attributing 
differences in incidence to a single exposure murky business. In other words, the 
association between the exposure and outcome of interest may be confounded. One 
way to deal with such confounding is to perform stratified or standardized analyses. 
However, regression analysis, such as logistic or Cox regression, is more efficient 
when many confounders act simultaneously. Please note, that although regression 
analysis is used in predictive studies as well, the goals of an etiologic study are 
completely different. Rather than optimizing a prediction, the regression is used 
to remove confounding bias from the estimated incidence ratio for the exposure of 
interest on the outcome. Therefore, only an incidence ratio is reported, adjusted for 
the confounding effects of other risk factors if need be, and no mention is made of 
ROC curves or calibration plots. 
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Medical decision making and economic evaluation 
The previously described research methods fall within the realm of 
epidemiology, whereas decision models are considered health economics and 
are a part of health technology assessment. As such, this study design is the 
odd one out within this thesis. Nevertheless, health technology assessment, like 
epidemiology, studies and aids medical decision making, albeit more directly. In 
chapter 5 a cost-effectiveness analysis has been performed. In essence, the goal of 
a cost-effectiveness analysis is to make explicit the possible benefits, costs, risks 
and uncertainties underlying a decision and weigh these in order to choose the 
optimal course of action from two or more alternatives. The perspective from which 
a decision is being made impacts the inputs for the cost-effectiveness analysis.9 For 
instance, if a patient is making the decision, only costs for the patient him or herself 
are relevant. Likewise, the quality of life associated with possible outcomes should 
be rated by the patient. Conversely, when a healthcare perspective is chosen, total 
healthcare costs and not just costs made by the patient are relevant. Moreover, for 
an analysis from a societal perspective productivity losses and other indirect costs 
(and benefits) need to be estimated. Similarly, in both the healthcare and societal 
perspective the general population, instead of the patient, is asked to value health 
states, as society as a whole is paying for the consequences of a decision. Costs can 
be determined bottom up by obtaining and summing the costs of, for example, each 
drug, intervention, taxi ride and day of absenteeism for each patient. Conversely, a 
top down calculation can be performed using averages from healthcare budgets or 
reimbursement claims. 
Possible health states which are the consequences of a decision can be described 
in terms of health utility. Utility is a measure for the preferences of health outcomes 
ranging from 0 (death) to 1 (perfect health). To compare relative utility of different 
outcomes, quality adjusted life years (QALYs) can be calculated. A single QALY 
is the equivalent of a life year in perfect health. Utility scores for health states 
can be obtained by asking subject to rate a health state on a visual analog scale, 
with a standard gamble or through a time trade off. Each has its pros and cons, as 
discussed by Hunink and Glasziou.9 
Both dimensions of cost-effectiveness can be brought together as the ratio costs 
per QALY gained. Subsequently, various alternatives can be compared by means of 
an incremental cost-effectiveness ratio. This is calculated by dividing the difference 
in costs by the difference in effectiveness for two alternatives. Unfortunately, 
both costs and effectiveness of the alternatives are often estimated with an 
amount of uncertainty. This uncertainty can be expressed in a cost effectiveness 
plane, as shown in figure 2.3.9 Despite a greater effectiveness, a treatment may 
not be acceptable if it is far too costly. The constraints of healthcare budgets can 
be formulated as a willingness-to-pay threshold. At present, we as a society are 
willing to pay €80,000 for a QALY gained.10 Anything less efficient is generally 
not accepted. One can plot the probability that a certain alternative would be cost-
effective by varying thresholds for the willingness-to-pay, giving a cost effectiveness 
acceptability curve.11 Such a plot is useful when comparing cost-effectiveness across 
health systems.
Average outcome and costs for alternative strategies are obtained from decision 
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tree analysis. A decision tree describes the possible clinical pathways that a patient 
may follow.12 Probabilities for events can be assigned at each branch, as can costs. A 
limitation of decision trees is that they assume that a patient travels down a clinical 
pathway instantaneously. In reality costs and benefits will accumulate over time. 
Furthermore, probabilities for certain outcomes may vary over time or between 
patients with different characteristics. Markov modeling, which is procedurally 
closely related to decision tree analysis, overcomes the time limitation.12 In a 
Markov model, simulated patients can cycle through various health states over 
a period of time. Such a cycle may last a year, for example. During that time a 
patient gathers quality adjusted life time and costs associated with the health state. 
Additionally, a patient may switch between health states and different amounts of 
quality adjusted life time and costs are collected. At the end of the Markov process, 
the accumulated costs and QALYs are summed. This process can be performed 
for thousands of simulated patients simultaneously in order to obtain average 
QALYs gained and costs made. Although more realistic than the decision tree 
Figure 3. Example of a cost effectiveness plane. The ellipse is an example of the 
joint distribution of cost and effectiveness for the comparison of two alternatives, 
a so-called cost effectiveness plane. It is build up from the estimated incremental 
costs and effectiveness obtained from a Monte-Carlo simulation. The diagonal 
line signifies the willingness-to-pay threshold. The cost effectiveness plane can 
be divided into six components. Starting at the top right and going clockwise: 1) 
more costly and more effective; 2) less costly and more effective, thus superior; 3) 
less costly, but less effective. In these three cases the alternative would be accepted 
as they all fall below the willingness-to-pay threshold. 4) less costly and less 
effective; 5) more costly and less effective, thus inferior; 6) more costly and more 
effective. In the last three cases the alternative is above the willingness-to-pay 
threshold, and therefore not accepted. 
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approach, this Markov cohort still assumes that all patients are equal. Furthermore, 
the cohort approach assumes that probabilities and costs associated with events 
in the model have been estimated with a high degree of certainty. To deal with 
heterogeneity of patients and uncertainty of parameter estimates, sensitivity 
analyses can be performed. A powerful form of sensitivity analysis is the Monte-
Carlo simulation.11 Instead of cycling an entire cohort of patients through the 
Markov model at once, patients enter the model one at a time. Costs, utilities and 
probabilities may be drawn from underlying distributions and tables to reflect both 
uncertainty and heterogeneity. As a result, estimated costs and possible outcomes 
more closely reflect the uncertainty of clinical practice.
Cost-effectiveness analyses often require many assumptions. Prudent checking 
of these assumptions and the (face) validity of the model as a whole is required 
to assess whether it adequately reflects clinical practice. If modeling assumptions 
are incorrect, its results may not be useful. Note, however, that if specified 
correctly, assumptions also underlie the decision for which a model is constructed. 
Disregarding any model just because it makes many assumptions is flawed 
reasoning. If anything, a correct, but uncertain model underpins the need for more 
information. 
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AbstrAct
Background: Accurate prediction of prognosis in idiopathic membranous 
nephropathy (iMN) allows restriction of immunosuppressive therapy to patients 
at high risk for end stage renal disease. Here we re-evaluate urinary low molecular 
weight proteins as prognostic markers and explore causes of misclassification.
Design, setting, participants, and measurements: In a cohort of 129 patients with 
serum creatinine concentration <135 μmol/l and proteinuria ≥3.0 g/10 mmol, 
urinary α1- (uα1m) and β2-microglobulin (uβ2m) excretion rate was determined. 
Urinary α1m and uβ2m/creatinine ratio was also obtained. We defined progression 
as a rise in serum creatinine ≥50% or ≥25% and an absolute level ≥135 µmol/l. 
Results: Median survival time was 25 months and 47% of patients showed 
progression. The area under the receiver-operating characteristics curve for uβ2m 
was 0.81 (95% CI: 0.73 – 0.89). Using a threshold value of 1.0 μg/min, sensitivity 
and specificity were 73 and 75%. Similar accuracy was observed for the uβ2m/
creatinine ratio with sensitivity and specificity of 75% and 73% at a threshold of 
1.0 mg/10 mmol creatinine. Similar accuracy was found for uα1m and uα1m/
creatinine ratio. Blood pressure and cholesterol contributed to misclassification. 
Repeated measurements improved accuracy in patients with persistent proteinuria, 
the positive predictive value of uβ2m increased from 72% to 89% and the negative 
predictive value from 76% to 100%.
Conclusions: Urinary excretion of α1- and β2-microglobulin predict prognosis 
in iMN. A spot urine sample can be used instead of a timed sample. A repeated 
measurement after 6 to 12 months increases prognostic accuracy.
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IntroductIon
Idiopathic membranous nephropathy (iMN) is an important cause of nephrotic 
syndrome in adults.1 Spontaneous remission of proteinuria occurs in 30 to 50% 
of patients.2,3 Despite treatment with angiotensin converting enzyme inhibitors 
(ACEi), angiotensin-II receptor blockers (ARB) and statins, between 25 and 
50% of patients show progressive loss of renal function.4,5 Although alkylating 
drugs improve outcome in patients with iMN,6-8 these agents often have adverse 
effects such as bone marrow depression, infections and increased risk of cancer.8 
Therefore one should restrict their use to patients at highest risk of progression to 
end stage renal disease. 
There has been an extensive search for tools that differentiate between 
patients with a favorable and poor prognosis.9 Histological markers appeared 
to be of limited value, whereas the severity of proteinuria is a better marker for 
outcome.2-4,10 Remission of proteinuria or increased serum creatinine concentration 
during follow-up are the most powerful predictors of outcome, however these are 
late events.11,12 In past decades, several specific urinary proteins were evaluated 
as early prognostic markers. Candidates such as TGF-β, βNAG, IgG, complement 
factors, α1- and β2-microglobulin (uα1m and uβ2m) have been proposed.
13-19 In a 
previous study of 57 patients we showed that uIgG and uβ2m can accurately predict 
prognosis.20 Since conservative treatment and prognosis may have changed in 
recent years, we re-evaluated the data.
Here we report the value of uα1m, uβ2m and uIgG as predictors of outcome 
in a cohort of 129 patients with iMN. In addition we evaluated the role of these 
markers in clinical practice using low molecular weight protein/creatinine ratios. 
We also analyzed possible causes of misclassification and the value of repeated 
measurements. 
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PAtIents And methods
Population
Patients with biopsy proven iMN who attended our clinic for urinary analysis 
between January 1995 and June 2009 were assessed for this study. Inclusion 
criteria were normal renal function, defined as serum creatinine <135 µmol/l 
(≈ 1.5 mg/dL), proteinuria ≥3.0g/10mmol creatinine, and an interval between 
biopsy and urinary analysis <3 years. Exclusion criteria were participation in the 
intervention arm of a immunosuppressive therapy trial,21 follow-up duration <1 
year or treatment with immunosuppressive drugs prior to urinary analysis. Follow-
up was completed until an end point was reached or until June 2010. Patients 
were followed at our hospital or by nephrologists in referring centers. Patients 
were treated with diuretics, given dietary sodium restriction, ACE inhibitors and/
or angiotensin II receptor blockers and statins according to existing guidelines. 
Immunosuppressive therapy was advised only in patients with deteriorating 
kidney function or severe untreatable nephrotic syndrome. Patients with persistent 
proteinuria were invited for a repeated evaluation after 6 to 12 months.
Data collection
Details of our protocol for the evaluation of patients with iMN are described 
elsewhere.20 Patients were instructed to fast overnight and take sodium bicarbonate 
on the evening before urinary analysis in order to alkalinize urine, because β2m 
disintegrates in acidic urine. They did not take diuretics on the morning of urinary 
analysis. Timed urine samples were collected and blood samples were taken. 
IgG and uα1m were measured using a BNII nephelometer (Behring, Marburg, 
Germany) and uβ2m was measured using ELISA.22 The excretion of total protein 
and low molecular weight proteins was standardized against urinary creatinine 
concentration, to obtain a urine protein-creatinine ratio. Data on serum creatinine 
concentration, urinary protein and creatinine excretion during follow up and use of 
immunosuppressive therapy, ACE inhibitors, ARBs and lipid lowering drugs were 
gathered from medical records. 
Definition of end-points
We defined progression as 1) a rise in serum creatinine >50%, 2) a rise in 
serum creatinine >25% and an absolute level ≥135 µmol/l or 3) the need for 
immunosuppressive therapy because of severe nephrotic syndrome as judged by 
the treating physician.23 Partial remission of proteinuria was defined by urinary 
protein excretion <2.0 g/10 mmol creatinine with stable serum creatinine. We 
also applied the definition of partial remission as suggested by Troyanov et al 
(proteinuria <3.5 g/day and a reduction of >50% with a stable kidney function).2 
Remission was considered complete when protein excretion was <0.2 g/10 mmol 
creatinine. Spontaneous remission means it occurred without immunosuppressive 
therapy.
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Statistical analyses
Median values and inter quartile ranges were calculated. Incidence of patient 
outcomes was plotted using a competing risks method. The area under the receiver-
operator characteristic curve (ROC-AUC) was calculated to compare prognostic 
value of urinary markers. In order to evaluate calibration, quintiles of predicted 
risk were created for each urinary marker, both for timed excretion and related to 
urinary creatinine concentration. Subsequently, the observed risk of progression 
within risk quintiles was obtained and plotted against the mean predicted 
probability of progression within each quintile. The Hosmer-Lemeshow goodness-
of-fit using five groups was calculated to provide an overall measure of calibration.
Subsequently, we determined cut-off values so that false positive and false 
negative rates would be minimal and the proportion of correctly classified 
patients maximized and we calculated sensitivity, specificity, positive and negative 
predictive values. Finally we created a logistic model using a backward stepwise 
algorithm with exclusion at p>0.10 and re-inclusion at p<0.05. The model’s ROC-
AUC was compared to the AUC for either uα1m or uβ2m to evaluate if it added to 
discriminatory power. Sources of misclassification were explored by tabulation 
of baseline characteristics by classification and outcome. One way ANOVA or Χ2 
tests were used to compare the four groups. Classification according to repeated 
measurements was cross tabulated by outcome to explore the value of repeated 
measurements.
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results
Population characteristics
Between January 1995 and June 2009 we evaluated 300 patients with biopsy 
proven iMN. 169 patients met criteria for enrollment (Figure 3.1.1). In 17 patients 
follow-up was less than 12 months. No follow-up data were available for 23 
patients. Thus, 129 patients were available for analysis. Baseline characteristics 
are presented in Table 3.1.1. The majority of patients was male and middle aged. 
Median serum creatinine concentration was 88 µmol/l (inter quartile range 76 - 
103) and median proteinuria 8.0 g/10 mmol creatinine (IQR 5.6 - 10.7). Urinary 
excretion of low molecular weight proteins was increased, with median urinary 
α1- and β2-microglobulin excretion of 41 (reference < 10) and 0.6 (reference < 0.2) 
μg/min, respectively. Virtually all patients (99%) received ACE inhibitors and/
or ARBs during follow-up and the majority (90%) was treated with lipid lowering 
medication.
Outcomes
Clinical outcome is reported in Table 3.1.1 and illustrated in Figure 3.1.2. Sixty 
patients (47%) showed progression. In 30 patients serum creatinine concentration 
increased by >50%, in 24 patients serum creatinine concentration increased >25% 
Figure 3.1.1 Flowchart of the inclusion of patients.
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Table 3.1.1. Baseline characteristics of patients with idiopathic membranous 
nephropathy
Variables
n (% male) 129 (68%)
age at time of biopsy (years) 51 (43 – 61)
time between biopsy and urine analysis (months) 2 (1 – 4)
Survival time (months) 25 (13 – 51)
MAP  (mmHg) 97 (86 – 106)
Laboratory
serum creatinine (µmol/l) 88 (76 – 103)
serum albumin (g/l) 23 (19 – 28)
serum cholesterol (mmol/l) 7.3 (5.7 – 9.2)
eGFR-MDRD4 (ml/min/1.73m2) 75 (60 – 87)
Urine samples
proteinuria (g/10 mmol creatinine) 8.0 (5.6 – 10.7)
proteinuria < 4.0 g/10 mmol 9%
proteinuria ≥ 4.0 and < 8.0 g/10 mmol 41%
proteinuria ≥ 8.0 and < 12 g/10 mmol 35%
proteinuria ≥ 12 g/10 mmol 15%
β2-microglobulin (µg/min) 0.6 (0.2 – 4.8)
α1-microglobulin (µg/min) 41 (23 – 72)
IgG (mg/24h) 257 (116 – 490)
β2-microglobulin (mg/10 mmol creatinine) 0.9 (0.3 – 7.0)
α1-microglobulin (mg/10 mmol creatinine) 36 (57 – 113)
IgG (mg/10 mmol creatinine) 262 (110 – 485)
Selectivity index 0.19 ± 0.09
Medication
ACEi/ARB use at time of biopsy  22%
ACEi/ARB use during follow-up 99%
Statin use at time of biopsy 13%
Statin use during follow-up 90%
Outcomes
Progression 47%
50% rise in serum creatinine (n) 30
25% rise and serum creatinine ≥ 135 μmol/l (n) 24
clinical progression (n) 6
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Spontaneous remission 47%
partial remission [< 2 g/10 mmol] 61
partial remission [< 3.5 g/10 mmol & 50% reduction] 63
complete remission 26
Data are presented as median (interquartile range). MAP: mean arterial 
pressure. ACEi: angiotensin converting enzyme inhibitor. ARB: angiotensin-II 
receptor blocker. eGFR-MDRD4: estimated GFR calculated with the abbreviated 
MDRD formula.
and reached values ≥ 135 μmol/l, and 6 patients started immunosuppressive 
therapy because of severe nephrotic syndrome. Of the patients showing 
progression, 47% did so within 12 months, 72% within 24 months and all within 5 
years. In 63 patients proteinuria spontaneously decreased by >50% and reached 
values <3.5 g/day. With the exception of two cases, proteinuria in these patients 
decreased to concentrations <2.0 g/10 mmol creatinine. Twenty three percent of 
patients who developed spontaneous remission (<2.0 g/10 mmol creatinine) did 
so within 12 months, 59% within 24 months, and 97% within 5 years. Forty three 
percent of the patients who went into partial remission eventually had a complete 
remission of proteinuria. 
Table 3.1.2. Test characteristics for urinary low molecular weight protein excretion to predict 
progression in 129 iMN patients.
Threshold value sensitivity specificity PPV NPV false 
positives 
(n)
false 
negatives 
(n)
test 
positives 
(n)
β2m
≥ 0.5 µg/min 80% 67% 68% 79% 23 12 71
≥ 1.0 µg/min 73% 75% 72% 76% 17 16 61
≥ 1.5 µg/min 65% 83% 76% 73% 12 21 51
≥ 2.0 µg/min 58% 83% 76% 70% 12 24 47
≥ 2.5 µg/min 55% 84% 75% 68% 11 27 44
α1m
≥ 40 µg/min 77% 71% 70% 78% 20 14 66
≥ 50 µg/min 65% 83% 76% 73% 12 21 51
≥ 60 µg/min 57% 86% 77% 69% 10 26 44
≥ 70 µg/min 45% 88% 77% 65% 8 33 35
≥ 80 µg/min 42% 90% 78% 64% 11 27 44
PPV: positive predictive value, NPV: negative predictive value, uβ2m: urinary β2-
microglobulin, uα1m:urinary α1-microglobulin. Test positives are the number of patients 
with a urinary α1- / β2-microglobulin excretion greater than the threshold value.
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Prognostic value of urinary α1-microglobulin and urinary 
β2-microglobulin
We plotted a ROC curve for the prognostic accuracy of uα1m, uβ2m and uIgG 
excretion (Figure 3.1.3, left panel). ROC-AUC was 0.81 (95% confidence interval: 
0.73 -0.88) for uα1m, 0.81 (0.73 – 0.89) for uβ2m and 0.75 (0.66 – 0.84) for uIgG. 
ROC curves for uα1m and uβ2m and uIgG creatinine ratios are presented in Figure 
3, right panel. The ratios yielded similar ROC-AUCs: 0.80 (0.72-0.87), 0.80 (0.72-
0.88) and 0.74 (0.66 – 0.83) for uα1m, uβ2m and uIgG respectively. The optimal 
cut off value for the excretion of uβ2m based on our current data is 1.0 μg/min 
(Table 3.1.2). At this threshold, the positive predictive value (PPV) and negative 
predictive value (NPV) were 72% and 76%, respectively. For uα1m, a threshold 
value was determined at 50 μg/min, with a PPV of 76% and NPV of 73%. When 
excretion was standardized for urinary creatinine concentration, threshold values 
were 1.0 mg/10 mmol creatinine and 75 mg/10 mmol creatinine for uβ2m and 
uα1m respectively (supplementary Table S1). 
Calibration plots for the low molecular weight protein markers and IgG are 
shown in figure 3.1.4. The left panels show calibration for timed excretion and 
the right hand panels show excretion related to urinary creatinine concentration. 
Table 3.1.3 shows mean predicted by observed risk of progression for the predicted 
risk quintiles of the prognostic markers. Uβ2m overestimated observed risk in the 
lower quintiles of predicted risk, whereas it slightly underestimated risk in the 
highest quintile. The resulting predicted risk gradient is steeper than the optimal 
calibration line. The Hosmer-Lemeshow test for IgG does not show an overall 
Figure 3.1.2. Patient outcomes. The black line represents renal survival without 
progression. The grey, short dashed line represents < 3.5 g/day and <50% since 
baseline, the dark grey, long dashed line partial remission (proteinuria <2.0 g/
day), and the light grey line complete remission (proteinuria < 0.2 g/day).
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statistically significant difference between predicted and observed risk using IgG as 
a prognostic marker. However, IgG does show poor calibration. It underestimates 
observed risk at the tails of predicted risk, whereas it overestimates risk in the 
middle quintiles. Finally, α1m appeared to show fairly good calibration across all 
quintiles of predicted risk.
Sources of misclassification
To evaluate potential sources of misclassification we tabulated baseline 
characteristics by classification based on uβ2m excretion rate (Table 3.1.4). In 
general, progressors had higher median serum creatinine (110 and 90 μmol/l 
versus 80 and 86 μmol/l) and cholesterol concentrations (8.4 and 8.5 versus 6.5 
and 6.1 mmol/l) than non-progressors. MAP (94 mmHg versus 93 mmHg) and 
proteinuria (5.5 versus 6.2 g/10 mmol creatinine) were remarkably similar between 
misclassified progressors and correctly classified low risk patients, whereas serum 
albumin levels were markedly higher in non progressing patients whose uβ2m 
was <1.0 μg/min than in progressors (27 g/l versus 23 g/l). To further improve 
prognostic accuracy we created two models, one based on uβ2m, the other on uα1m. 
We included baseline MAP, serum cholesterol, serum creatinine, serum albumin 
and proteinuria. All predictors were log transformed and a stepwise backward 
selection algorithm was used. The model including uβ2m also retained serum 
cholesterol and creatinine as independent predictors. Its ROC-AUC was 0.85 (0.79 
– 0.92). A similar model including uα1m had a ROC-AUC of 0.86 (0.80 – 0.93). 
Figure 3.1.3. Left Panel: ROC curves for prognostic accuracy of urinary excretion 
rate of α1- (dark grey) and β2-microglobulin (black) and IgG (light grey). Both 
α1- and β2-microglobulin excretions rates are expressed in μg/min and IgG in 
mg/24h. Areas under the curve were: uα1m: 0.81 (0.73 – 0.88), uβ2m: 0.81 (0.73 
– 0.89) and IgG: 0.75 (0.66 – 0.84). Right Panel: ROC curves for the prognostic 
accuracy of α1- (dark grey) and β2-microglobulin (black) and IgG (light grey). 
When expressed as mg / 10 mmol creatinine. Areas under the ROC curve were: 
uα1m/creat: 0.80 (0.72 – 0.87), uβ2m/creat: 0.80 (0.72 – 0.88) and uIgG/creat: 
0.74 (0.66 – 0.83).
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Figure 3.1.4. Calibration plots for progression by urinary markers. The left panels 
show the results for the timed markers and the right panels for the markers 
related to urinary creatinine concentration. The dots are the point estimates for 
mean predicted risk of progression, the shaded area is the 95%confidence interval 
around the mean predicted risk. The diagonal line is the reference line for perfect 
calibration
Low Molecular Weight Proteins as Prognostic Markers for progression in Idiopathic Membranous Nephropathy
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Table 3.1.3. Predicted versus observed probability of progression by quintiles of the 
predicted probability.
Marker Risk quintiles
Progression Hosmer- 
Lemeshow pPredicted Observer
uβ2m I 31% 20% 0.03
µg/min II 32% 16%
III 34% 40%
IV 48% 68%
V 87% 88%
uα1m I 19% 8% 0.42
µg/min II 27% 35%
III 38% 38%
IV 59% 62%
V 88% 92%
uIgG I 26% 15% 0.07
mg/24h II 32% 27%
III 41% 58%
IV 54% 62%
V 82% 72%
uβ2m I 31% 20% 0.004
µg / 10 II 32% 16%
mmol III 34% 40%
creat IV 48% 68%
V 87% 88%
uα1m I 19% 8% 0.32
µg / 10 II 27% 35%
mmol III 38% 38%
creat IV 59% 62%
V 88% 92%
IgG I 26% 15% 0.11
mg / 10 II 32% 27%
mmol III 41% 58%
creat IV 54% 62%
V 82% 72%
The Hosmer-Lemeshow goodness-of-fit test gives an overall p-value for the 
difference between observed and predicted risk over the predicted risk quintiles. 
Higher p-values indicate better overall calibration. uβ2m: β2-microglublin 
excretion, uα1m: α1-microglobulin excretion
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The final models are presented in Supplementary Table S2.
We questioned if tubule-interstitial damage could be of value. In 95 patients the 
interval between kidney biopsy and urine analysis was <3 months. Biopsies of 
47 were available for review. Tubulo-interstitial injury (scored 0-3) correlated 
with uβ2m (r=0.58). However the tubule-interstitial injury score did not improve 
the predictive accuracy in individual patients and did not explain discordances 
(Supplementary Table S3).
Repeated measurements
We analyzed data of 44 patients with persistent proteinuria who underwent 
repeated urinary measurements. Baseline characteristics did not differ from total 
study population characteristics (Supplementary Table S4). At the time of repeated 
measurements, patients generally had lower blood pressure (MAP 95 versus 
89 mmHg) and serum cholesterol values (7.8 versus 6.0 mmol/l) compared to 
baseline, likely due to intensified conservative treatment. Median serum creatinine 
concentrations (85 versus 97 μmol/l) and uβ2m (0.5 versus 1.1 μg/min) were 
higher. We tabulated uβ2m at baseline and repeated measurement by outcome in 
Table 3.5. Patients with a uβ2m above 1.0 μg/min at both measurements invariably 
showed progression (n=11). In contrast, none of the 17 patients with uβ2m < 1.0 μg/
min at two measurements showed progression. Fifteen (88%) of them went into 
spontaneous remission. Four patients with uβ2m >1.0 at baseline, had uβ2m below 
the threshold at the repeated measurement. Three of them did show progression.  
In all three patients blood pressure was greatly reduced at the time of the repeated 
measurement, with a decrease in MAP of 7, 16 and 22 mmHg respectively, leading 
to very low MAP of 69 and 81 mmHg in two of them. In summary, when uβ2m was 
≥ 1.0 μg/min in at least 1 of two measurements, PPV for progression was 89% and 
when uβ2m < 1.0 μg/min at both occasions, the NPV was 100%.  
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Table 3.1.5. Classification according to uβ2m excretion at baseline and repeated 
measurement versus patient outcome in 44 patients with repeated measurements.
Measurement Outcome (n)
Baseline Repeated Progression No progression
uβ2m ≥ 1.0 μg/min uβ2m ≥ 1.0 μg/min 11 0
uβ2m ≥ 1.0 μg/min uβ2m < 1.0 μg/min 3 1
uβ2m < 1.0 μg/min uβ2m ≥ 1.0 μg/min 10 2
uβ2m < 1.0 μg/min uβ2m < 1.0 μg/min 0 17
The positive predictive value for patients with a least one measurement ≥ 1.0 μg/
min was 89%. The negative predictive value for patients with both measurements 
< 1.0 μg/min was 100%. Of the 11 patients who were classified as progressors and 
had uβ2m > 1.0 μg/min, 3 had a 50% rise in serum creatinine, 7 had a 25% rise 
and serum creatinine > 135 μmol/l and 1 patient had severe nephrotic syndrome.
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Table 3.1.4. Baseline characteristics for progressors and non-progressors classified 
Variables Progressors
b2m≥1.0 b2m<1.0
n (% male) 44 (75%) 16 (62%)
age at time of biopsy (years) 57 (47 - 64) 49 (44 - 58)
time between biopsy and urine analysis (months) 2 (1 - 4) 2 (0 - 2)
Survival time (months) 11 (6 - 25) 16 (7 - 25)
MAP  (mmHg) 100 (89 - 112) 94 (81 - 105)
Laboratory
serum creatinine (µmol/l) 110 (97 - 119) 90 (68 - 95)
serum albumin (g/l) 20 (17 - 24) 23 (18 - 26)
serum cholesterol (mmol/l) 8.4 (7.0 - 9.8) 8.5 (5.7 - 9.3)
eGFRMDRD4 (ml/min/1.73m2) 58 (53 - 67) 75 (65 - 97)
Urine samples:
proteinuria (g /10 mmol creatinine) 10.7 (9.3 - 12.7) 5.5 (4.8 - 8.7)
β2-microglobulin (µg/min) 7.8 (2.3 - 13.8) 0.3 (0.1 - 0.5)
α1-microglobulin (µg/min) 106 (61 - 131) 31 (20 - 44)
IgG (mg/24h) 511 (356 - 776) 157 (74 - 217)
Selectivity Index 0.27 ± 0.08 0.11 ± 0.05
Medication
ACEi/ARB use at time of biopsy  36% 20%
ACEi/ARB use during follow-up 100% 100%
Statin use at time of biopsy 20% 7%
Statin use during follow-up 93% 93%
Outcomes
Progression 100% 100%
50% rise in serum creatinine (n) 18 12
25% rise and serum creatinine >135 μmol/l (n) 24 0
clinical progression (n) 2 4
Spontaneous remission
partial remission:< 2.0 g/10 mmol 0% 0%
partial remission: <3.5 g/10 mmol and ≥50% reduction 0% 0%
complete remission 0% 0%
Data are presented as mean ± sd or median (interquartile range). MAP: mean arterial  
receptor blocker. Misclassified progressors are those patients who did show progression but  
the four groups and X2 tests to compare medication use and gender.
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according to initial excretion of β2-microglobulin ≥ 1.0 μg/min
Non progressors p
b2m<1.0 b2m≥1.0
52 (65%) 17 (65%) 0.69
49 (38 - 60) 56 (51 - 64) 0.02
1 (1 - 4) 2 (1 - 4) 0.88
53 (28 - 84) 41 (24 - 54)
93 (86 - 104) 99 (92 - 104) 0.16
80 (70 - 87) 86 (82 - 91) <0.001
27 (23 - 31) 22 (17 - 25) <0.001
6.5 (5.5 - 7.7) 6.1 (5.3 - 7.3) 0.004
85 (78 - 93) 75 (67 - 80) <0.001
6.2 (4.7 - 8.5) 9.1 (5.9 - 11.0) <0.001
0.1 (0.2 - 0.4) 2.6 (1.3 - 7.7)
22 (12 - 37) 50 (39 - 83)
119 (62 - 219) 351 (158 - 607)
0.15 ± 0.07 0.21 ± 0.08 <0.001
16% 6% 0.03
98% 100% 0.68
10% 6% 0.26
84% 94% 0.43
0% 0%
90% 82%
94% 82%
40% 29%
pressure. ACEi: angiotensin converting enzyme inhibitor.ARB: angiotensin-II  
had uβ2m < 1.0 μg/min. ANOVA was used to compare continuous data between
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dIscussIon
We evaluated urinary excretion of α1- and β2-microglobulin as prognostic 
markers in a cohort of 129 iMN patients with nephrotic range proteinuria and 
normal serum creatinine concentration. Approximately half of the patients showed 
progression and the other half went into spontaneous remission. This illustrates 
that the “rule of thirds” does not apply to iMN patients who present with the 
nephrotic syndrome and normal kidney function.24 The majority of patients (61%) 
reached either disease progression or partial remission within 24 months and 92% 
within 5 years of follow-up.
Our data indicate agreement between two commonly used definitions of 
partial remission, i.e. proteinuria <2 g/day versus 3.5 g/day and a decrease >50% 
from baseline.2 In our population concordance between the two definitions was 
almost perfect, only time to remission varied slightly. Patients with high baseline 
proteinuria tend to achieve remission sooner when the latter definition is used, 
whereas patients with limited baseline proteinuria have proteinuria less than 2 
grams per day before a reduction of 50% is achieved. Thus our data support the use 
of the definition proposed by Troyanov et al.2 
We confirmed the prognostic value of uβ2m. However the AUC was lower 
than reported in our previous study, 0.81 (95% CI: 0.73 – 0.89) versus 0.94 
(0.87 – 1.00).20 This difference may be caused by a distinction in the definition 
of endpoints. In our previous study renal death was defined as a rise in serum 
creatinine ≥50% or an absolute level over 135 μmol/l. In the current study, the 
second criterion also included a 25% rise in serum creatinine, since an absolute 
value could lead to biased results.19 Secondly, we used stricter inclusion criteria in 
the current study; excluding patients with limited proteinuria. Furthermore, when 
we inspected baseline characteristics of patients in our current cohort by year of 
referral, we noted a decline in baseline serum creatinine, albumin and cholesterol, 
a lower MAP over time and shortened time between biopsy and urine analysis 
(Supplementary Table S5). Higher referral rates and lower baseline ACEi/ARB use 
in recent years point toward earlier referrals by participating nephrologists.
Timed urine samples are not routinely taken in all hospitals and uβ2m should 
be measured after alkalinization of urine by overnight bicarbonate intake. Our 
current data suggest that a timed measurement of low molecular weight protein 
excretion may not be necessary. Both α1m and β2m related to urinary creatinine 
concentration had the same prognostic power as the timed excretion. Contrary to 
uβ2m, uα1m measurement does not require alkalinization and it can be measured 
using a nephelometric assay, thus spot urine taken at the out-patient clinic for 
measurement of uα1m/creatinine ratio may be sufficient to predict prognosis. 
We attempted to find explanations for the discordance between predicted 
and actual progressive disease by comparing patient characteristics stratified for 
prediction and outcome. We observed notable differences in serum cholesterol, 
creatinine and the ratio between serum albumin and proteinuria. A model that 
included these variables slightly improved prognostic power. We hypothesize 
that the higher cholesterol values reflect increased hepatic synthesis and are 
indicative of higher unmeasured protein losses due to tubular hypermetabolism. 
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Alternatively, the high cholesterol levels may contribute to progressive renal injury. 
Although based on a limited number of biopsies, our data suggest evaluation of 
tubulo-interstitial damage is of no added value.
We evaluated if repeated measurements of uα1m and uβ2m would improve 
prognostic accuracy. Repeated measurements were done in patients with persistent 
proteinuria. When one of the measurements was above the uβ2m threshold 
value of 1.0 μg/min 89% of patients showed progression. Conversely, when 
both measurements were <1.0 μg/min none of the patients showed progression 
(NPV=100%). Noteworthy, the data show that changes in blood pressure can 
influence the results. Low levels of uβ2m and uα1m in the face of very low blood 
pressure cannot be used with confidence. Alternatively the opposite may also hold 
true, although we do not have hard data to confirm this.
Compared to α1m, β2m shows poor calibration of predicted risk to the observed 
risk of progression. If low-molecular-weight protein excretion were to be used as 
continuous or categorical test variables, this would be problematic. In that case 
α1m would be the preferred marker. However, in the case of a dichotomous test 
result, the problem of a too steep risk gradient is less pressing. It does not hinder 
dichotomizing test results, as lower than expected risk in the lowest predicted risk 
quintiles is inconsequential. Such a result just provides all the more reason not to 
treat patients with immunosuppression when uβ2m excretion is low. The inverse 
holds true for high uβ2m excretion. 
Our study has several limitations. Our end point to define renal failure 
can be criticized. However, we feel that it is not justified to delay start of 
immunosuppressive therapy until doubling of serum creatinine. If we calculate 
eGFR using the abbreviated MDRD formula 88% of the patients who fulfilled 
our definition of renal failure had an eGFR value below 60 ml/min/1.73m2. We 
performed additional analyses with occurrence of eGFR < 60 ml/min/1.73m2 as 
end point. ROC-AUCs for uβ2m and uα1m remained similar and were 0.84 (0.77 
– 0.92) and 0.84 (0.76 – 0.92) for uβ2m in μg/min and mg/10 mmol creatinine 
respectively. For uα1m ROC-AUCs were 0.82 (0.74 – 0.89) and 0.82 (0.75 – 
0.90) for μg/min and mg/10 mmol respectively. Many patients were referred to 
our centre for urinary analysis, but followed and treated elsewhere, and we were 
unable to collect follow up data for all patients. Also, the data we presented on 
repeated measurements have to be interpreted with some caution as these were 
performed on a subset of patients with persistent proteinuria. Finally, we were not 
able to calculate a proteinuria risk score for the cohort, which requires multiple 
measurements of serum and urine creatinine and proteinuria during each six 
month period during follow-up.4 These data were not available.
Conclusions
We have advocated that treatment decisions in the individual patient with iMN 
must be based on an individualized assessment of risks and benefits.21 The risks 
of prolonged nephrotic syndrome should be balanced against those of progression 
and treatment related complications. Urinary α1- or β2-microglobulin measurement 
can be of value in this balanced decision since they allow an early prediction of 
prognosis in iMN. A spot urine sample can be used instead of a timed sample. 
Blood pressure may affect excretion rates. A repeated measurement after six to 12 
months increases prognostic accuracy.
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AbstrAct
Background: Accurate prediction of prognosis may improve management of 
patients with idiopathic membranous nephropathy (iMN). This study compared the 
Toronto Risk Score and urinary low-molecular-weight proteins. 
Design, setting, participants, and measurements: 104 patients with biopsy-
proven iMN who presented between 1995 and 2008 with a well preserved kidney 
function and nephrotic range proteinuria were included. Urinary β2- (uβ2m) and 
α1-microglobulin (uα1m) were obtained by timed, standardized measurements and 
the Toronto Risk Score was calculated using data obtained from medical records. 
The endpoint was progression, defined as an increase in serum creatinine >50% or 
>25% with a concentration >135 μmol/l. 
Results: 49 patients showed progression. The area under the receiver-operating 
characteristics (ROC-AUC) curve was 0.78 (95% confidence interval 0.69 to 0.88) 
for the risk score versus 0.80 (0.71 to 0.89) and 0.79 (0.71 to 0.88) for uβ2m 
and uα1m, respectively. Differences in ROC-AUC were not significant. Persistent 
proteinuria did not add accuracy to the Toronto Risk Score. Conversely, its 
accuracy was not reduced when data from the first six months of follow-up was 
used. Furthermore, a score based on glomerular filtration rate estimated with the 
six variable MDRD (eGFR-MDRD6) equation, calculated in the first six months of 
follow-up, gave a ROC-AUC of 0.83 (0.74 to 0.92), not statistically different from 
the AUC of the other markers.
Conclusions: The prognostic accuracy of the Toronto Risk Score and urinary low 
molecular weight proteins were not significantly different. The risk score can be 
calculated within six months after diagnosis, and a simplified risk score using 
eGFR-MDRD6 may be sufficient. 
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IntroductIon
Idiopathic membranous nephropathy (iMN) is a common cause of adult onset 
nephrotic syndrome. Untreated, approximately 50% of patients with iMN and 
nephrotic range proteinuria will develop end stage renal disease.1 Conversely, 
almost 50% of patients with nephrotic iMN develop a spontaneous remission of 
proteinuria. However, it may take anywhere from a few months up to five years to 
occur.2 Thus, a delay in treatment would expose the patient to the complications of 
the nephrotic syndrome such as edema, thrombosis and infections. This dilemma 
can be tackled through accurate and early prediction of prognosis, as it would allow 
early treatment and rapid disappearance of the nephrotic syndrome in high risk 
patients, whilst avoiding unnecessary exposure to toxic therapy in low risk patients.
Almost two decades ago, Pei et al. showed that the magnitude and duration of 
proteinuria during follow up predicted prognosis better than baseline proteinuria 
alone.3 Subsequently, Cattran and colleagues created and validated a risk score for 
the prediction of progression in iMN which was based on the level of proteinuria 
during a 6 month period of maximum proteinuria, creatinine clearance at the start 
of that period and the change in creatinine clearance over the course of those six 
months.4 Although accurate, this Toronto Risk Score has some disadvantages. 
One cannot determine in advance when the period of maximum proteinuria 
will occur; thus, prolonged observation is necessary. Refraining from therapy 
prolongs patients’ exposition to risks associated with the nephrotic syndrome. In 
addition, patients are kept in uncertainty. Alternatively, urinary markers have been 
suggested to predict progression in iMN.5-9 We showed that urinary excretion of β2-
microglobulin (uβ2m) or α1-microglobulin (uα1m) accurately predicted progressive 
loss of kidney function.10;11 When re-evaluated, both markers showed somewhat 
lower sensitivity and specificity than before. This may either be related to changes 
in patient characteristics at presentation or to improved conservative therapy.2 
Obviously, these factors may also affect prognostic value of the Toronto Risk Score. 
Therefore, we compared the prognostic power of the Toronto Risk Score to that 
of uβ2m and uα1m. In addition, we attempted to adapt the Toronto Risk Score to 
improve its suitability in clinical practice.
Prognostic value of Risk Score and Urinary Markers in Idiopathic Membranous Nephropathy
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PAtIents And methods
Population
Patients with biopsy-proven iMN who attended our clinic for urinary analysis 
between January 1995 and June 2009 were screened. As per standard care, 
potential secondary causes were ruled out by the treating physician, using chest 
X-ray, serology and routine laboratory investigations as detailed elsewhere.12 
Inclusion criteria were a serum creatinine <135 µmol/l (≈1.5 mg/dL), proteinuria 
≥3.0 g/10 mmol creatinine, and time between biopsy and urinary analysis less than 
one year. Patients with renal insufficiency, who invariably have a worse outcome, 
and patients with persistent non-nephrotic proteinuria, who almost never progress, 
were thus excluded. Exclusion criteria were participation in the intervention arm 
of a therapeutic trial,13 follow up duration of less than one year, or treatment with 
immunosuppressive drugs prior to urinary analysis. Follow up data were obtained 
until an end point was reached or until June 2010. Patients were followed at 
our hospital or by nephrologists in referring centers. Patients were treated with 
diuretics, given dietary sodium restriction, ACE inhibitors and/or ARBs and statins 
according to existing guidelines. Immunosuppressive therapy was advised only 
in patients with evidence of deteriorating kidney function or severe untreatable 
nephrotic syndrome. Data of 46 patients were also used in our previous study of 
low molecular weight proteins.10
Data collection and urinary analysis
The study protocol was approved by the RUMC institutional review board and 
patients provided informed consent. Details of our protocol for the evaluation 
of patients with iMN were described elsewhere.10 In summary, patients were 
instructed to fast overnight; omit the use of diuretics and to take sodium 
bicarbonate on the evening before and on the morning of the urinary analysis in 
order to raise urinary pH, as β2-microglobulin degrades in acidic urine. Timed 
urine samples were collected and blood samples were taken. Urinary α1m was 
measured using a BNII nephelometer (Behring, Marburg, Germany) and uβ2m 
was measured using ELISA.14 Medical records were used to obtain follow-up data 
on serum creatinine concentration, urinary protein and creatinine excretion and 
medication use.
Calculation of the Toronto Risk Score
The risk score created by Cattran et al. was calculated as:4  
Toronto Risk Score = ex / (1 + ex); where x = 1.26 + 0.3 ∙ persistent proteinuria 
– 0.3 ∙ slope creatinine clearance – 0.05 ∙ initial creatinine clearance. Persistent 
proteinuria, initial creatinine clearance and the slope were calculated during either 
the first six months of follow up or during the six month period of maximum 
persistent proteinuria. Creatinine excretion was calculated using the baseline 24 
hour urine sample. The total daily urinary excretion of creatinine was assumed to 
be constant. Glomerular Filtration Rate (GFR) was estimated with the 6 variable 
MDRD formula,15 as the MDRD4 equation is not appropriate in persons with 
C
hapter 3.2
49
hypoalbuminemia.16 Persistent proteinuria was assessed using protein creatinine 
ratios obtained from spot urine samples collected during routine follow up. Since 
spot and 24 hour proteinuria may differ, we compared the protein creatinine 
ratio and 24 hours proteinuria at baseline. The sampling methods showed good 
correlation (r=0.75) and proportional increase (24 hours proteinuria [g/24h] = 
0.93 x protein creatinine ratio [g/10 mmol creatinine]. Finally, we chose to limit 
risk score calculation to the first two years of follow-up, since more than 75% of 
patients in the study by Cattran et al. had their period of maximum persistent 
proteinuria during the first two years of follow-up.4 Moreover, calculations beyond 
two years of follow up may defeat the purpose of an early marker, as many patients 
show progression within three years.2
Outcome
We defined progression as a rise in serum creatinine of more than 50%, or a rise 
in serum creatinine of more than 25% and an absolute level higher than 135 µmol/l, 
or the need for immunosuppressive therapy because of severe nephrotic syndrome 
as judged by the treating physician.17 Two of the authors (JH and JvdB) checked 
all data to establish that the rise in serum creatinine was consistent, persistent and 
independent of the use of other medication.
Statistical analyses
All analyses were performed using Stata 10.1 (Statacorp LP, TX, USA). Means 
and standard deviations were calculated for normally distributed variables, 
and median with interquartile range were used for skewed variables. To obtain 
an updated prognostic value of the risk score we created receiver-operating 
characteristic (ROC) curves and calculated the area under the curve (AUC) with 
95% confidence intervals (95%CI). The ROC-AUCs were also used to compare 
the risk score to uβ2m, uα1m and eGFR based risk scores. In order to evaluate 
calibration, quintiles of predicted risk were created for uβ2m, uα1m and the 
Toronto Risk Score. Subsequently, the observed risk of progression within risk 
quintiles was obtained and plotted against the mean predicted probability of 
progression within each quintile. The Hosmer-Lemeshow goodness-of-fit using five 
groups was calculated to provide an overall measure of calibration.
Subsequently, we created a logistic regression model containing the individual 
predictors used in the risk score. Models containing the baseline and change in 
eGFR-MDRD6 instead of creatinine clearance were created as well. We used 
these models to calculate the integrative discrimination index (IDI) and relative 
IDI (rIDI).18 The IDI quantifies the added discriminatory power of a biomarker 
to a panel of markers already present in a logistic model, thus it could be used 
to evaluate the relative contribution of each component of the risk score to the 
prediction of progression. Finally, we plotted Kaplan-Meier curves by tertiles of the 
eGFR-MDRD6 risk score to check its calibration with the estimated probability of 
progression. 
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results
Population characteristics
Between January 1995 and June 2009, 300 patients with biopsy-proven iMN 
were screened. Figure 3.2.1 shows that 163 patients met the inclusion criteria. In 
total 40 patients were excluded because they had less than 12 months of follow-
up or follow-up data were unavailable. Additionally, baseline creatinine clearance 
could not be determined in two patients, seven patients did not have sufficient data 
before they reached an endpoint and ten patients did not have sufficient data points 
within the first 24 months of follow-up. Therefore, our analyses were restricted to 
104 patients. 
Table 3.2.1 shows the baseline characteristics of our study population. The 
majority of patients was male (64%), and mean (±SD) age was 52 ± 13 years. 
In general, patients had well preserved kidney function (endogenous creatinine 
clearance was 93 ± 31 ml/min/1.73m2) and severe nephrotic syndrome with a 
mean proteinuria of 8.5 ± 3.3 g/10 mmol creatinine and a serum albumin of  
23 ± 6 g/l. Table 3.2.2 shows that conservative treatment was initiated or 
intensified shortly after biopsy in the majority of patients. Ultimately, all patients 
used ACE inhibitors or ARBs and 87% used a statin during follow-up.  We followed 
all patients for a median of 4.1 years (inter quartile range [IQR] 2.4 to 6.9). During 
that time, 47% of the patients showed progression, resulting in a median survival 
time of 25 months (IQR 12 to 49).
Figure 1. Flowchart for the inclusion of patients with idiopathic membranous 
nephropathy in the study.
C
hapter 3.2
51
Comparison of the Toronto Risk Score and urinary low 
molecular weight proteins
Since intensified supportive treatment influences proteinuria, the magnitude 
and timing of maximum persistent proteinuria may have changed, and thus the 
prognostic value of the risk score may have changed as well. Therefore, ROC 
curves were created to evaluate the prognostic power of the risk score to predict 
progression. The ROC-AUC was 0.78 (95%CI 0.69 to 0.88), and neither the ROC-
AUC for uβ2m nor that for uα1m differed significantly from the ROC-AUC of the 
risk score (Figure 3.2.2, Table 3.2.3). The calibration of the Toronto Risk Score 
and low molecular weight proteins was fairly poor, table 3.2.5, figure 3.2.4. Even 
though the Toronto Risk Score appeared to show a fair overall calibration, it 
overestimated progression risk in the first two quintiles and the top predicted risk 
quintiles. Conversely, it underestimated risk in the third and fourth quintile of 
the score. Likewise, uβ2m tended to overestimate risk at lower excretion rates and 
underestimate risk in the higher quintiles for excretion. As mentioned previously 
this does not hamper dichotomizing uβ2m test. On the other hand, uα1m showed 
the closest overall calibration to observed risk.
Table 3.2.1. Baseline characteristics of patients with idiopathic membranous 
nephropathy
Variables Estimates
n (% male) 104 (64%)
Age at time of biopsy (years) 52 ± 13
Time between biopsy and urine analysis (months) 1 (1 - 3)
Survival time (months) 25 (12 - 49)
MAP (mmHg) 98 ± 16
Laboratory
serum creatinine (µmol/l) 89 ± 19
serum albumin (g/l) 23 ± 6
serum cholesterol (mmol/l) 7.8 ± 2.5
endogenous creatinine clearance (ml/min/1.73m2) 93 ± 31
Urine samples:
proteinuria (g/10 mmol creatinine) 8.5 ± 3.3
β2-microglobulin (µg/min) 0.65 (0.22 - 2.97)
α1-microglobulin (µg/min) 42 (24 - 76)
β2-microglobulin (mg/10 mmol creatinine) 0.89 (0.30 - 6.49)
α1-microglobulin (mg/10 mmol creatinine) 57 (36 - 113)
Progression 47%
Data are presented as mean ± standard deviation, median (interquartile range). 
MAP: mean arterial pressure. To convert serum creatinine concentration from 
μmol/l to mg/dl divide by 88.4. To convert mg/10 mmol creatinine to mg/g 
creatinine divide by 1.13. To convert serum cholesterol values to mg/dl multiply 
by 38.67.
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Prognostic value of the 6 month Toronto Risk Score 
compared to the Risk Score recalculated during follow-up 
Subsequently, analyses were performed in an attempt to improve the original 
risk score’s clinical usefulness. First and foremost, the goal was to determine if 
recalculating the risk score at later stages of follow up was necessary. A risk score 
at the start of follow-up could not be calculated for 15 patients, as insufficient data 
points were available in these first six months. In the remaining 89 patients, the 
risk score calculated over the first six months was compared to that obtained at the 
period of maximum persistent proteinuria. The bottom part of table 3.2.3 shows 
the ROC-AUC for the risk score calculated during the first six months of follow-up, 
which was 0.76 (95%CI 0.65 to 0.86) and not significantly different from the AUC 
of the original Toronto Risk Score (p=0.46). In addition, the table shows that the 
eGFR-MDRD6 risk scores discriminated between stable patients and progressors 
better than the original, creatinine clearance based risk score. However, the 
difference was not statistically significant. 
Prognostic value of the Toronto Risk Score’s individual 
parameters 
The risk score was broken down into its individual parameters in order 
to investigate which of these contributed most to an accurate prediction of 
progression. Table 3.2.4 shows the logistic regression coefficients, IDI and rIDI 
for the original and eGFR–MDRD6 based risk scores calculated at the start of 
follow-up. The IDI is “the difference in means of predicted probabilities for events 
and non-events.”18 However, it is unclear what the magnitude of difference means. 
Therefore, we also calculated the relative IDI, which is the ratio in discrimination 
slopes for a model with and a model without a marker of interest. In a model which 
has 4 markers and perfectly predicts outcome, one expects the average contribution 
from each marker to the discrimination of events and non-events to be roughly 
25%. With the introduction of another marker, each of the five markers should 
contribute 20%. A strong deviation, signifies a respectively high or low relative 
importance of a marker. 
Table 3.2.2. Period of maximum persistent proteinuria and initiation of supportive 
therapy.
 Time since 
urine analysis
Period maximum 
proteinuria
ACEi/ARB 
start
Statin 
start
0-6 months 65% 88%* 61%*
7-12 months 14% 4% 13%
13-18 months 16% 4% 7%
19-24 months 4% 0% 1%
>24 months § 3% 6%
not started § 1% 13%
ACEi, angiotensin converting enzyme inhibitor; ARB angiotensin II receptor 
blocker; Statin, HMG-CoA-reductase inhibitor; § calculation of the maximum 
persistent proteinuria was restricted to 24 months; *Start of medication was 
either before biopsy or during the first six months.
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Figure 3.2.2. ROC curves for the Toronto Risk Score (solid), uβ2m (dots and 
dashes), uα1m (long dashes). The ROC-AUCs for progression were 0.78 (0.69 to 
0.88) for the risk score, 0.80 (0.71 to 0.89) for uβ2m, 0.79 (0.71 to 0.88) for uα1m, 
respectively. None of the areas under the curve differed significantly.
Table 3.2.3. Area under the receiver operating characteristic curves for the Toronto 
Risk Score and urinary markers to predict progression of idiopathic membranous 
nephropathy
Marker ROC-AUC 95% Confidence Interval p
Toronto Risk Score 0.78 0.69 0.88 ref 
uβ2m 0.80 0.71 - 0.89 0.84
uα1m 0.79 0.71 - 0.88 0.85
Toronto Risk Score first 6 months 0.76 0.65 - 0.86 0.46
MDRD6 risk score 0.83 0.74 - 0.91 0.25
MDRD6 risk score first 6 months 0.83 0.74 - 0.92 0.37
uβ2m, urinary β2-microglobulin (μg/min); uα1m, urinary α1-microglobulin (μg/
min); ref, reference for the analyses. The MDRD6 risk score was calculated as 
1.26 - 0.3 ∙ ΔeGFR-MDRD6 – 0.05 ∙ eGFR-MDRD6 at baseline or at the start of the 
period of maximum persistent proteinuria, respectively.
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Figure 3. Survival until progression by tertiles of the eGFR-MDRD6 based 
Toronto Risk Score without proteinuria, calculated during the first 6 months of 
follow up. The eGFR-MDRD6 risk score was calculated as the logistic function of 
1.26 – 0.3 ∙ ΔeGFR-MDRD6 – 0.05 ∙ eGFR-MDRD6 at baseline. For the Kaplan-
Meier plot follow-up duration has been truncated at 60 months. The eGFR-
MDRD6 Risk Score was < 0.10 for the low risk tertile (solid line),  0.10 to 0.30 for 
the medium risk tertile (dots and dashes) and >0.30 for the highest risk tertile 
(long dashes), respectively.
Table 4. Relative contribution of the risk score parameters for the prediction of 
progression.
Predictor ln(OR) IDI rIDI
eCcreat -0.02 (-0.04 - -0.005) 0.07 (p=0.01) 10%
ΔeCcreat -0.52 (-0.81 - -0.23) 0.21 (p<0.001) 35%
persistent proteinuria 0.09 (-0.04 - 0.22) 0.01 (p=0.54) 1%
GFR-MDRD6 -0.06 (-0.09 - -0.03) 0.22 (p<0.001) 39%
ΔGFR-MDRD6 -0.35 (-0.62 - -0.08) 0.11 (p<0.001) 14%
persistent proteinuria 0.05 (-0.09 - 0.18) -0.01 (p=0.33) -1%
ln(OR) is the natural logarithm of the odds ratio obtained with a logistic 
regression model; IDI: Integrative Discrimination Index; rIDI: relative 
Integrative Discrimination Index. eCcreat: endogenous creatinine clearance; Δ: 
change in endogenous creatinine clearance or GFR during the first six months of 
follow-up.
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Persistent proteinuria did not 
substantially contribute to the 
prediction of progression.The change 
in creatinine clearance was more 
important than baseline creatinine 
clearance, whereas the opposite was 
true for the eGFR-MDRD6 based 
model. Note that the models in Table 
3.2.4 are not iterations of the same 
model with a different number of 
predictors, therefore the rIDI can only 
be used to compare predictors within a 
model and not between models.
Finally, since proteinuria did 
not contribute to the prediction of 
prognosis and the eGFR-MDRD6 based 
risk score appeared to outperform the 
creatinine based score, we evaluated 
if the eGFR based risk score without 
proteinuria could be used to accurately 
predict prognosis. Figure 3.2.3 shows 
Kaplan-Meier survival curves by tertiles 
of the eGFR-MDRD6 based risk score 
calculated using the first 6 months of 
follow up. The overall p-value for the 
logrank test was <0.001. The highest 
tertile differed significantly from the 
first, Hazard Ratio (HR)=17.6 (7.0 to 
44.3). However, the middle tertile did 
not differ statistically from the lowest 
tertile, HR= 2.0 (0.7 to 5.6).Figure 3.2.4. Calibration plots for uβ2m 
(top), uα1m (middle) and Toronto Risk 
Score (bottom). The Toronto Risk score 
calibrates fairly well with the observed 
risk, as does uα1m. Urinary β2m shows 
a too high predicted risk in low risk 
patients, and too low in high risk 
patients. 
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Table 5. Predicted versus observed probability of progression by quintiles of the 
predicted probability.
Marker Risk quintiles Progression Hosmer-Lemeshow p
Predicted Observed
Toronto I 23% 14% 0.24
Risk II 29% 24%
Score III 41% 55%
IV 63% 71%
V 83% 75%
β2m I 34% 19% 0.004
µg/min II 35% 14%
III 37% 45%
IV 46% 75%
V 83% 80%
α1m I 21% 5% 0.07
µg/min II 30% 48%
III 40% 43%
IV 59% 53%
V 89% 90%
The Hosmer-Lemeshow goodness-of-fit test gives an overall p-value for the 
difference between observed and predicted risk over the predicted risk quintiles. 
Higher p-values indicate better overall calibration.
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dIscussIon
To the best of our knowledge, the current study is the first to directly compare 
the two most accurate, validated markers for the prognosis of iMN in patients 
who present with the nephrotic syndrome. We show that the Toronto Risk Score 
and urinary α1- and β2-microglobulin have similar prognostic value. However, 
uα1m showed better calibration throughout the measured range. In the low 
quintiles of β2m excretion, the risk was markedly lower than the a priori 50% 
risk of progression. Similarly, the risk in the highest quintiles was 75% and 80%, 
respectively. Therefore, uβ2m can be applied as a test dividing patients in low 
intermediate and high risk categories. In addition, we showed that the risk score 
can be adapted to improve its clinical applicability. Firstly, accuracy is not higher 
for risk scores calculated at later stages of follow up, thus a risk assessment can 
be made after six months of follow up. Secondly, to calculate the risk score, eGFR 
may be used instead of endogenous creatinine clearance. Moreover, proteinuria did 
not contribute to the prediction of prognosis. Since serum samples can be readily 
obtained at out-patient departments, and eGFR-MDRD6 can be automatically 
reported, our study suggests that a more practical risk score can be used in a 
clinical setting.
The present study only included patients who presented with the nephrotic 
syndrome, whereas a considerable proportion of the population (24%) in the 
Toronto validation study were not nephrotic at presentation.4 Patients with 
persistent, limited proteinuria are known to have a favorable prognosis. Perhaps 
this difference in case mix may explain why proteinuria did not significantly 
contribute to the prediction of prognosis in our study. Another explanation may 
be that we used protein-creatinine ratios obtained from spot samples rather than 
24 hour proteinuria. However, data from 44 patients who underwent repeated 
measurements in our previous study show that the variation for protein-creatinine 
ratio and 24 hour proteinuria is similar at initial and repeated measurement. 
In addition, the change in protein-creatinine ratio from initial to repeated 
measurement is strongly correlated (r=0.75) to change in 24 hour proteinuria. 
Therefore, we concluded that both collection methods are appropriate for 
prognostic purposes.
In addition, progression was defined as an increase in serum creatinine >50% 
or >25% with a concentration of at least 135 μmol/l, whereas Cattran et al. used 
an endogenous creatinine clearance <60 ml/min/1.73m2 as outcome. However, 
when analyses were repeated and only those patients who fulfilled both definitions 
were considered progressors, prognostic accuracy of all markers increased slightly; 
differences between the Toronto Risk Score and low molecular weight proteins 
remained the same; recalculating the risk score still did not add prognostic power; 
and the eGFR-MDRD6 based risk score without proteinuria remained as strong a 
predictor for prognosis as the original Toronto Risk Score. In conclusion, the choice 
of end point did not substantially influence our results. 
Aggressive use of renin-angiotensin blockers may explain the fact that 
calculation of the risk score at later stages of follow up does not increase accuracy 
in the current study. Since these drugs reduce proteinuria, they may influence 
Prognostic value of Risk Score and Urinary Markers in Idiopathic Membranous Nephropathy
58
occurrence of maximum persistent proteinuria, and thus the prognostic power of 
the risk score. Indeed, in our cohort the 6 month period of maximum proteinuria 
fell within the first year of follow-up in 79% of patients. By comparison, in the 
study by Cattran et al. this was the case in only 53% of patients.4 Unfortunately, 
since data on the use of ACE inhibitors and ARBs was not reported, we can only 
speculate. 
We were unable to calculate the risk score for all patients who met the inclusion 
criteria. These patients were thus excluded. However, the present study population 
did not differ from the cohort reported previously.2 Therefore, we consider 
selection bias due to lack of early follow-up data unlikely.
Finally, although we used the validated multiplication factors from the original 
paper by Cattran and colleagues, our modifications of the Toronto Risk Score, most 
notably the use of eGFR-MDRD6 instead of creatinine clearance, have not been 
externally validated. Therefore, the modified Toronto Risk Score may not perform 
as well in other patient populations. 
Our data show that both urinary low molecular weight proteins and the Toronto 
Risk Score are suitable to predict prognosis. We prefer the use of urinary markers, 
since these provide an estimate obtained in a single outpatient visit. Still, if the 
assay is not available use of the Toronto Risk Score is equally accurate.  
It has been suggested that information from the renal biopsy  may aid in 
predicting prognosis. Especially the extent of tubule-interstitial injury has 
prognostic value.19 These findings were confirmed in a recent study.20 However, 
histology did not independently predict outcome when proteinuria and serum 
creatinine were taken into account.
In contrast to the original Toronto Risk Score, the eGFR-MDRD6 based risk 
score does not calculate the predicted probability of progression. Rather, it should 
be viewed as a dimensionless discriminant score. The higher the score, the more 
likely progression. The most appropriate way to implement this adaptation of 
the Toronto Risk Score is to use risk strata. In the present study tertiles of the 
eGFR-MDRD6 risk based score correspond to discriminant values of <0.10, 0.10 
to 0.30, and >0.30, which results in a 20%, 40% and 100% mean five year risk of 
progression for low, medium and high risk strata, respectively. 
Considerable improvements have been made in the prediction of prognosis of 
iMN patients over the last decades. Proteinuria remains an important predictor. 
However, when patients present with the nephrotic syndrome, the level of 
proteinuria does not discriminate between those with a poor prognosis and 
those with a favorable outcome. Other biomarkers, like those presented in this 
paper, provide better discrimination in these patients. However, a subset is still 
misclassified. Therefore, future research should focus on more accurate early 
markers for disease progression or spontaneous remission, specifically for the 
patients who are still misclassified with markers presented in this study. Repeated 
measurements of uβ2m or uα1m may be useful, but more data are still required.
2 A 
particularly promising marker is the anti-phospholipase A2 receptor antibody level, 
as it is associated with disease activity in iMN.21 
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Conclusion
Prognosis of iMN patients who present with the nephrotic syndrome can be 
predicted with either urinary low molecular weight markers or the Toronto Risk 
Score as these have similar prognostic accuracy. The prognostic power of the risk 
score is not improved by adding proteinuria. Importantly, a score merely based on 
the eGFR-MDRD6 equation proved an reasonably accurate predictor. Thus only 
serum parameters need to be used to predict prognosis of iMN patients, which 
greatly improves the practical applicability of the Toronto Risk Score. Future 
studies should focus on the subset of patients who are still misclassified.
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AbstrAct
Background: Recently published KDIGO guidelines recommend to limit the use 
of immunosuppressive drugs in idiopathic membranous nephropathy to patients 
at the highest risk of kidney failure. However, recommendations are based on 
natural history rather than direct assessment of a restrictive treatment strategy. 
We describe the long term outcomes of a large cohort of idiopathic membranous 
nephropathy patients treated according to such a restrictive treatment policy.
Design, setting, participants, and measurements: We analyzed data of 254 
patients who visited our outpatient clinic between 1995 and 2009. All patients 
were treated with angtiotensin converting enzyme inhibitors and/or angiotensin 
receptor blockers. Immunosuppressive therapy was recommended in case of 
deteriorating renal function or untreatable nephrotic syndrome. Primary outcomes 
for the present study were renal replacement therapy and death. Secondary 
outcomes included adverse events during follow-up and remission of proteinuria. 
Results: In total, 124 patients (49%) received immunosuppressive therapy, which 
predominantly consisted of cyclophosphamide combined with steroids. Ten year 
cumulative incidence rates were 3% and 10% for renal replacement therapy and 
death, respectively. Partial remission rates were 39%, 70% and 83% after one, 
three and five years. Additionally, one, three and five year complete remission 
rates were 5%, 24% and 38%. A serious adverse event occurred in 23% of all 
patients. The most notable complications were infections (17%), leucopenia (18%), 
cardiovascular events (13%) and malignancies (8%). 
Conclusions: In conclusion, the use of a restrictive treatment strategy in idiopathic 
membranous nephropathy patients yields favorable outcomes, whilst limiting the 
number of patients exposed to toxic drugs. These results support current KDIGO 
guidelines. 
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IntroductIon
Idiopathic membranous nephropathy (iMN) is the most common cause of adult 
onset nephrotic syndrome in Caucasians. Recent data show that iMN is an auto-
immune disease, with antibodies against PLA2R present in about 70% of patients.1 
The natural course of the disease is variable, with spontaneous remission occurring 
in 30% to 50% of patients, whereas another 30% to 50% show progressive renal 
failure.2,3 In order to avoid progression to end stage kidney disease, patients can 
be treated with immunosuppressive drugs. Two randomized, controlled trials 
evaluated the efficacy of the alkylating agents chlorambucil and cyclophosphamide. 
4,5 These trials included patients with iMN of recent onset, with normal renal 
function and nephrotic range proteinuria and showed increased remission rates 
and improved renal survival in treated patients. However, outcome was favorable 
in 60% to 65% of the untreated patients. Since most physicians are reluctant to 
use a treatment schedule which exposes many patients to unneeded, toxic therapy, 
the use of immunosuppressive therapy in iMN is heavily debated. Accordingly, the 
recently published KDIGO guidelines recommend to use alkylating agents only in 
patients at high risk for kidney failure.6 Thus, in patients with iMN and nephrotic 
proteinuria the risk of progression to kidney failure should be balanced against 
the risks and benefits of immunosuppressive therapy.7 Unfortunately, few studies 
have evaluated the safety and effectiveness of a restrictive strategy in iMN patients. 
Studies that were performed included small numbers of patients and had a limited 
follow-up duration.8-10
The present study describes the long term outcome in a large cohort of patients 
with iMN who were treated according to a restrictive treatment strategy. 
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PAtIents And methods
Patients and treatment
We included adult patients with biopsy proven idiopathic membranous 
nephropathy who were referred to our clinic between 1995 and 2009. Secondary 
causes were ruled out per standard policy.7 Written informed consent was obtained 
and the study was performed in accordance to the Declaration of Helsinki. Many 
patients participated in predictor studies described previously and were treated 
according our restrictive strategy.2,7 Patients who were not treated restrictively, for 
instance during a clinical trial on the effects of early treatment, were excluded.11 A 
detailed description of the strategy can be found elsewhere.7 In summary, patients 
with serum creatinine concentrations less than 135 μmol/l (≈1.5 mg/dL) received 
supportive treatment. This treatment consisted of blood pressure control and 
proteinuria reduction with ACEi and/or ARBs, and further blood pressure lowering 
drugs, if needed, to achieve target levels below 130/80 mmHg. Additionally, 
statins were given to treat hypercholesterolemia and anti-coagulant therapy was 
initiated in patients with severe hypoalbuminemia (<20 g/l). In patients with 
serum creatinine concentrations above 135 μmol/l at presentation or during 
follow-up, immunosuppressive therapy was advised. Severe, debilitating nephrotic 
syndrome as judged by the treating physician was considered an indication to start 
treatment with alkylating agents as well. Oral cyclophosphamide (1.5 mg/kg daily 
for twelve months) and pulse intravenous methylprednisolone (1 gram on days one 
to three, 61 to 63 and 121 to 123) in combination with high dose oral prednisone 
(0.5 mg/kg every other day for five months before tapering) was the preferred 
immunosuppressive treatment. Occasionally, other drugs were prescribed either 
as part of a clinical trial or when cyclophosphamide was contra indicated. 11,28 From 
1999 onward, trimethoprim-sulfamethoxazole was added to the regimen to prevent 
pneumocystis jiroveci pneumonia.11
Outcomes 
Primary outcomes were death, renal replacement therapy, defined as start 
of chronic dialysis therapy or (pre-emptive) kidney transplantation, and a 
combination of both. Renal survival was defined as surviving until either renal 
replacement therapy or mortality, whichever came first. Survival times of patients 
who did not reach such end-points were censored at the date of the last follow-up 
visit.
Secondary outcomes were: 
1.  Pre-specified adverse medical events including those which were either 
known or suspected to be associated with immunosuppressive therapy, regardless 
of the therapeutic regimen that the patient received. These pre-specified events 
were: subfertility (the inability to conceive without medical intervention such as 
in vitro fertilization), osteonecrosis, hemorrhagic cystitis, malignancies, thrombo-
embolic and cardiovascular events (including stroke, deep venous thrombosis 
and pulmonary embolism, both fatal and non-fatal myocardial infarction and 
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interventions for peripheral vascular disease). 
2.  Severe kidney failure, defined as a serum creatinine concentration of 265 
μmol/l (≈ 3 mg/dl) or more. This concentration was chosen, because it represents a 
doubling of serum creatinine from the level at which start of treatment in high risk 
patients was advised, which was 135 μmol/l (≈ 1.5 mg/dl). 
3.  Partial remission of proteinuria was defined as a decline in protein : 
creatinine ratio of at least 50% since biopsy to a level less than 3.5 g/10 mmol 
creatinine with a stable kidney function. 
4.  Complete remission of proteinuria was defined as a protein : creatinine 
ratio of less than 0.2 g/10 mmol creatinine. 
5.  Relapse of proteinuria was a protein : creatinine ratio greater than 3.5 
g/10 mmol creatinine and a 50% increase from the lowest level of proteinuria after 
remission had occurred.
Data on the primary outcomes and adverse events were obtained from medical 
records and correspondence. Severe kidney failure, partial remission, complete 
remission and relapse of proteinuria were determined using laboratory data 
collected during routine follow-up. Unfortunately, no follow-up laboratory data 
were available for seven patients. Therefore these patients were only included in 
the analyses for the primary outcomes.
The follow-up time was calculated from the date of biopsy until outcome or 
end of follow-up for all analyses, except for relapse of proteinuria. Patients were 
considered at risk of a relapse only if remission was achieved and until relapse 
occurred or until end of follow-up. The time from the first remission until a relapse 
or the end of follow-up was used for the analysis of relapses. 
Statistical methods
Baseline data were expressed as proportions, means and standard deviations or 
medians and interquartile range, where appropriate. 
Cumulative incidence rates were calculated using Kaplan-Meier estimates. 
However, since mortality risk may be competing with renal replacement risk, a 
competing risks method was used to calculate the cumulative incidence of renal 
replacement therapy. Similarly, severe kidney failure was deemed competing for 
the cumulative incidence of both partial and complete remission. 
Two sensitivity analyses were performed. First, the main analyses were repeated 
after excluding patients who initially received immunosuppressive therapy other 
than cyclophosphamide.
Secondly, in order to assess the potential influence that lacking outcome data 
may have had on our results, we attempted to obtain vital status for those patients 
with lacking follow-up data. As a worst case scenario we assumed patients whose 
status we could not ascertain to be deceased. The date on which we checked vital 
status was taken as the date of death. Subsequently five and ten year mortality rates 
were calculated using Kaplan-Meier estimates. Furthermore, we checked if any of 
the patients whose outcome could not be obtained were registered to have received 
renal replacement therapy according to the Dutch renal replacement therapy 
registry (www.renine.nl).
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results
Patient characteristics and treatment
Patient inclusion is shown in Figure 4.1.1. Between 1995 and 2009, 305 patients 
were evaluated at our centre. Fourteen patients were included in a trial and 
allocated to an early treatment,11 and seventeen more were treated prior to referral. 
Primary outcomes were all cause mortality, renal replacement therapy, being 
chronic dialysis or transplantation, and a composite of both. Secondary outcomes 
were: 1) severe kidney failure, defined as a serum creatinine ≥265 μmol/l; 2) a 
partial remission of proteinuria, defined as proteinuria less than 3.5 g/10 mmol 
creatinine and a decline of at least 50% from baseline combined with a stable 
serum creatinine; 3) a complete remission of proteinuria, defined as proteinuria 
less than 0.2 g/10 mmol; 4) a relapse of proteinuria, defined as the reoccurrence 
of proteinuria to a level of more than 3.5 g/10 mmol combined with an increase of 
at least 50% from the lowest level during remission; and 5) adverse medical events 
during follow-up. Primary outcomes for 20 patients could not be obtained, thus 
254 patients were included in the analyses of outcomes and complications. 
Table 4.1.1 presents baseline patient characteristics, therapy and outcome data. 
Most patients were male and mean age was 53 (standard deviation: ±14) years. 
Figure 1. Flowchart for the patient inclusion in the cohort assessing long term 
outcomes of a restrictive treatment strategy.
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The majority of patients (n=226, 89%) had nephrotic syndrome when presenting 
for urinary analysis, and median estimated Glomerular Filtration Rate (eGFR) 
according to the four variable Modification of Diet in Renal Disease equation was 
71 (inter quartile range: 53 - 85) ml/min/1.73m2. Patients were followed for a 
median of 57 months with an interquartile range of 32 to 90 months. At the time 
of first referral 90% of patients used angiotensin converting enzyme inhibitors 
(ACEi) and/or angiotensin II receptor blockers (ARBs), and 62% received lipid 
lowering medication (statins). During follow-up, ACEi/ARB use increased to 96%. 
In addition, 36% of patients used other blood pressure lowering medication as well. 
Likewise, statin use increased to 82%, and oral anti-coagulants were prescribed 
to 36% of all patients. In total 124 patients were treated, 77 because of a serum 
creatinine greater than 135 μmol/l (1.5 mg/dl). These patients had evidence of 
renal function deterioration with serum creatinine rising by at least 25% in all, 
and by >50% in 55 patients. In 47 patients the start of treatment was considered 
necessary, because of persistent deterioration of eGFR of >5 ml/min per 1.73m2 per 
year (n=13), persistent severe hypoalbuminemia (a serum albumin concentration 
<20 g/l for six months, n= 13), or complications of the nephrotic syndrome 
(infections and thrombosis, n=6). The rationale for treatment was persistence 
of the of the nephrotic syndrome itself in the remaining 15 patients. In total, 91 
(36%) patients received combined cyclophosphamide/steroid treatment, whereas 
33 (13%) received other immunosuppressive drugs, being mycophenolate mofetil 
(n=19), azathioprine (n=1) or synthetic adrenocorticotrope hormone (ACTH) 
(n=13). Importantly, 130 patients (51%) received conservative therapy only.
Renal replacement therapy and mortality
The top panel of figure 4.1.2 shows both survival until renal replacement 
therapy and overall survival. In addition, table 4.1.2 shows cumulative incidence 
of the primary and secondary outcomes at one, three, five and ten years after 
first referral. In total, seven patients required renal replacement therapy during 
follow-up, resulting in a cumulative incidence of 3% (95% confidence interval: 
1% to 7%) after ten years. Additionally, the five and ten year mortality rates were 
6% (3% to 10%) and 10% (5% to 17%). By comparison, five and ten year mortality 
rates for the general Dutch population with a mean age of 54 years were 3% and 
7%.12 Overall renal survival was 92% (86% to 95%) and 86% (78% to 92%) after 
five and ten years. In total, 26 patients’ serum creatinine concentration reached 
values over 265 μmol/l, resulting in severe kidney failure incidence rates of 10% 
(7% to 16%) and 16% (10% to 24%) after five years and ten years. Patients who 
required immunosuppressive therapy had higher incidences of renal replacement 
therapy, mortality and severe kidney failure compared to patients who only needed 
conservative treatment (table 4.1.2).
Remission and relapse of proteinuria
In total, 206 (83%) out of 247 patients (seven patients did not have any follow-
up laboratory data) showed a remission of proteinuria. As shown in figure 4.1.2 and 
table 4.1.2, partial remission rates were 39% (33% to 45%), 70% (64% to 76%) and 
83% (77% to 87%) at one, three and five years. Moreover, 97 of the 206 patients 
with partial remission improved further and attained a complete remission, 
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resulting in a ten year cumulative incidence of 52% for complete remission. Half 
of the patients who achieved a remission were treated supportively, 37% were 
treated with cyclophosphamide and the remaining 13% were treated with other 
immunosuppressive drugs.
A relapse occurred in 46 of the remitting patients, fifteen of whom had had 
a complete remission. Thus, cumulative incidences of relapse were 13% (9% to 
19%), 19% (14% to 26%) and 27% (20% to 36%) at one, three and five years after 
remission was first achieved. In total, 25 of the 46 (54%) relapsing patients had 
re-attained a partial remission of proteinuria at the end of follow-up. Notably, three 
patients who had had a partial, but no complete remission progressed to renal 
replacement therapy.
Figure 4.1.2. Outcomes of patients treated with either immunosuppressive 
and supportive therapy. The thick lines represent patients treated with 
immunosuppressive drugs, and the thin lines represent patients treated 
conservatively. The top panel shows survival until renal replacement therapy 
(solid lines) and mortality (dotted lines). Death was considered competing 
for renal replacement therapy in the analyses. The bottom panel shows the 
cumulative incidence of partial (solid lines) and complete remission (dotted lines). 
Severe kidney failure was considered competing for remission.
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Severe kidney failure
Severe kidney failure, defined as a serum creatinine concentration over 265 
μmol/l, was observed in 26 patients. Seven of these patients progressed to end 
stage kidney failure. We analyzed the course of disease in the other nineteen 
patients to ascertain whether these patients had progressive disease and thus 
would be likely to require renal replacement therapy in the near future. Such 
patients could be considered to have a poor outcome. The clinical details of these 
nineteen patients and the course of eGFR are illustrated in the table and figures 
in the supplementary appendix. In summary, five of these nineteen patients were 
not treated with any immunosuppressive drugs, two of whom refused treatment, 
and one was not treated due to severe co-morbidity. Furthermore, in nine patients 
treatment was initiated after eGFR dropped below 30 ml/min/1.73m2, and in 
five patients treatment was started when eGFR was still over 30 ml/min/1.73m2. 
Inspection of the individual eGFR curves suggested that progressive disease 
was present in nine of the nineteen patients who did not develop RRT (see 
supplementary figure s4.1.1), three of whom were treated with cyclophosphamide, 
two were treated with other immunosuppressive drugs and four were treated 
conservatively. 
KDIGO guidelines recommend that patients with a severely decreased kidney 
function should not be treated due to the elevated risk of complications and unclear 
efficacy of immunosuppression in these patients. In total 27 of our patients treated 
with immunosuppression had an eGFR less than 30 ml/min per 1.73m2 at the 
start of therapy. Median annual decline eGFR was of 8 ml/min per 1.73m2 since 
baseline. In 19 patients (70%) eGFR stabilized after the start of therapy to an eGFR 
decline of less than 1 ml/min per 1.73m2 per year over a median follow-up of 5.1 
(IQR 2.6 to 10.8) years from the initiation of treatment onward.
Complications
Overall, 58 patients (23%) suffered a serious adverse event, see Table 
4.1.3. Notable complications were infections (n=42, 17%), cardiovascular 
events (including thrombosis, n=33, 13%)and malignancies (n=20, 8%). As 
expected serious adverse events were more frequent in patients treated with 
immunosuppression as compared to those treated conservatively. During follow-
up, a malignancy was reported in 20 patients (lung cancer, n=5; hematological 
malignancy, n=5; gastro-intestinal cancer, n=4; prostate cancer, n=2; bladder 
cancer, n=2; renal cell carcinoma, n=1; breast cancer, n=1). Malignancies occurred 
more frequently in cyclophosphamide treated patients. 
In total, 21 (8%) patients died, two of whom had required renal replacement 
therapy during follow-up. Furthermore, eight of the patients who developed 
a malignancy died during follow-up, five of whom as a result of the cancer. 
Additionally, four patients died due to cardiovascular causes and a single patient 
died following an infection. Unfortunately, cause of death could not be ascertained 
for the other deceased patients. 
Long term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy
76
Ta
bl
e 
4.
1.
2.
 I
nc
id
en
ce
 o
f p
ri
m
ar
y 
an
d 
se
co
nd
ar
y 
ou
tc
om
es
O
u
tc
o
m
e 
p
er
 
ti
m
e 
p
er
io
d
 
(y
rs
)
C
u
m
u
la
ti
ve
 in
ci
d
en
ce
 f
or
 
th
e 
to
ta
l 
co
h
o
rt
  (
9
5
%
 C
I)
 
(n
=
2
5
4
)
C
u
m
u
la
ti
ve
 in
ci
d
en
ce
 f
or
 t
h
e 
su
p
p
o
rt
iv
e 
th
er
a
p
y 
gr
o
u
p
 
(9
5
%
 C
I)
 
(n
=
13
0
)
C
u
m
u
la
ti
ve
 in
ci
d
en
ce
 f
or
 t
h
e 
im
m
u
n
o
su
p
p
ri
ve
 t
h
er
a
p
y 
gr
o
u
p
 (
9
5
%
 C
I)
 
(n
=
12
4
)
R
en
al
 r
ep
la
ce
m
en
t t
he
ra
py
1
0%
n
/
a
0%
n
/
a
0%
n
/
a
3
1%
0%
-
4%
1%
0%
-
4%
2%
0%
-
6%
5
3%
1%
-
5%
1%
0%
-
4%
4%
1%
-
9%
10
3%
1%
-
7%
1%
0%
-
4%
6%
2%
-
12
%
M
or
ta
lit
y
1
0%
0%
-
2%
0%
n
/
a
1%
0%
-
4%
3
3%
1%
-
6%
1%
0%
-
5%
5%
2%
-
11
%
5
6%
3%
-
10
%
4%
1%
-
11
%
8%
4%
-
14
%
10
10
%
5%
-
17
%
4%
1%
-
11
%
15
%
7%
-
25
%
C
om
bi
ne
d
1
0%
0%
-
3%
0%
n
/
a
1%
0%
-
6%
3
5%
2%
-
8%
2%
0%
-
7%
7%
4%
-
14
%
5
8%
5%
-
14
%
5%
2%
-
13
%
12
%
7%
-
20
%
10
14
%
8%
-
22
%
5%
2%
-
13
%
20
%
12
%
-
33
%
Se
ru
m
 c
re
at
in
in
e 
>
26
5 
μm
ol
/l
1
3%
2%
-
6%
0%
n
/
a
7%
3%
-
13
%
3
7%
4%
-
11
%
2%
0%
-
7%
12
%
7%
-
19
%
5
10
%
7%
-
16
%
4%
2%
-
12
%
16
%
10
%
-
25
%
10
16
%
10
%
-
24
%
13
%
5%
-
31
%
20
%
13
%
-
30
%
C
hapter 4.1
77
Pa
rt
ia
l R
em
is
si
on
1
39
%
33
%
-
45
%
41
%
32
%
-
50
%
37
%
28
%
-
45
%
3
70
%
64
%
-
76
%
69
%
60
%
-
76
%
72
%
63
%
-
79
%
5
83
%
77
%
-
87
%
84
%
75
%
-
90
%
82
%
74
%
-
88
%
10
90
%
85
%
-
94
%
90
%
81
%
-
95
%
88
%
80
%
-
93
%
C
om
pl
et
e 
R
em
is
si
on
1
5%
2%
-
8%
6%
3%
-
11
%
3%
1%
-
8%
3
24
%
19
%
-
30
%
28
%
20
%
-
37
%
20
%
13
%
-
28
%
5
38
%
31
%
-
45
%
42
%
32
%
-
52
%
34
%
25
%
-
44
%
10
52
%
44
%
-
60
%
60
%
46
%
-
72
%
45
%
34
%
-
56
%
R
el
ap
se
1
13
%
9%
-
19
%
12
%
7%
-
21
%
14
%
8%
-
23
%
3
19
%
14
%
-
26
%
14
%
8%
-
23
%
24
%
16
%
-
35
%
5
27
%
20
%
-
36
%
14
%
8%
-
23
%
39
%
28
%
-
52
%
10
37
%
26
%
-
50
%
38
%
19
%
-
65
%
39
%
28
%
-
52
%
R
en
al
 r
ep
la
ce
m
en
t t
he
ra
py
: i
ni
ti
at
io
n 
of
 c
hr
on
ic
 h
em
od
ia
ly
si
s 
or
 p
er
it
on
ea
l d
ia
ly
si
s 
or
 th
e 
re
ce
ip
t o
f a
 k
id
ne
y 
tr
an
sp
la
nt
. 
T
he
 c
om
bi
ne
d 
pr
im
ar
y 
en
dp
oi
nt
 is
 a
 c
om
bi
na
ti
on
 o
f r
en
al
 r
ep
la
ce
m
en
t t
he
ra
py
 a
nd
 m
or
ta
lit
y,
 w
hi
ch
ev
er
 c
am
e 
fir
st
. P
ar
ti
al
 
re
m
is
si
on
 is
 d
efi
ne
d 
as
 a
 5
0
%
 r
ed
uc
ti
on
 in
 p
ro
te
in
 :
 c
re
at
in
in
e 
ra
ti
o 
to
 3
.5
 g
 p
er
 1
0
 m
m
ol
 c
re
at
in
in
e 
or
 le
ss
 w
it
h 
a 
st
ab
le
 s
er
um
 
cr
ea
ti
ni
ne
. R
em
is
si
on
 w
as
 c
on
si
de
re
d 
co
m
pl
et
e 
w
he
n 
th
e 
pr
ot
ei
n 
: 
cr
ea
ti
ni
ne
 r
at
io
 w
as
 le
ss
 th
an
 0
.2
 g
/1
0
 m
m
ol
. R
el
ap
se
 
is
 th
e 
re
oc
cu
rr
en
ce
 o
f p
ro
te
in
ur
ia
 o
ve
r 
3.
5 
g 
pe
r 
10
 m
m
ol
 c
re
at
in
in
e 
an
d 
a 
50
%
 in
cr
ea
se
 fr
om
 th
e 
pr
ev
io
us
 k
no
w
n 
va
lu
e 
of
 
pr
ot
ei
nu
ri
a 
in
 a
 p
at
ie
nt
 w
it
h 
a 
re
m
is
si
on
.
Long term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy
78
Sensitivity analyses
When patients who received immunosuppressive therapy other than 
cyclophosphamide were excluded, primary outcome rates as well as partial and 
complete remission rates remained similar. However, relapse rate was lower at 
14%, 20% and 31% after three, five and ten years, indicating that relapses occurred 
more frequently in patients treated with mycophenolate mofetil and/or ACTH. 
Secondly, we attempted to obtain data on vital status for the 20 patients who were 
lost-to-follow-up. Of the 20 patients seven had died, another seven were still alive, 
and we were unable to ascertain vital status for the final six. Thus, in a worst case 
scenario the estimated five and ten year mortality rates would be 11% (8% to 17%) 
and 17% (11% to 25%). In addition, none of these 20 patients were registered to 
have received renal replacement therapy according to the Dutch renal replacement 
therapy registry (www.renine.nl; personal communication).
Table 3. Adverse events and complications during follow-up
Adverse event Cyclophos-
phamide 
Other 
immuno-
suppression
Conservative 
treatment 
(n=91) (n=33) (n=130)
serious adverse event 35 (38%) 11 (33%) 12 (9%)
resulting in (prolongation of) 
hospitalization 13 (14%) 3 (9%) 2 (2%)
leucopenia 35 (38%) 8 (24%) 2 (2%)
thrombopenia 7 (8%) 2 (6%) 0
liver enzyme abnormalities 7 (8%) 0 0
hyperglycemia 10 (11%) 5 (15%) 1 (1%)
infection 30 (33%) 11 (33%) 1 (1%)
haematuria / cystitis 1 (1%) 0 0
cardiovascular / thrombotic events 18 (20%) 7 (21%) 8 (6%)
subfertility 0 0 0
osteonecrosis 0 0 0
malignancy 14 (15%) 2 (6%) 4 (3%)
Serious adverse events have been defined according to the ICH/GCP guidelines. 
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dIscussIon
Our data provide support for the effectiveness of a restrictive treatment 
strategy in patients with iMN. With the use of this strategy, half of the patients 
were not exposed to potentially harmful immunosuppressive drugs. Still, long 
term outcomes were favorable. Overall renal survival was 86% after ten years. 
Furthermore, a remission of proteinuria was attained in 83% of all patients. Thus, 
our data provide evidence for the recommendations in the KDIGO guidelines for 
the treatment of iMN.
A strength of the study is the standard treatment protocol, which closely 
resembles the recently published KDIGO guideline.6 In fact, the strategy reported 
in the present study was even more restrictive than the guideline, as treatment was 
not necessarily started “if proteinuria was over 4 grams per day and remained over 
50% of baseline value, and did not show progressive decline during supportive 
therapy over a period of six months.” Therefore, our data suggests that a watchful 
waiting policy can safely be extended beyond six months of follow-up if kidney 
function is stable and patients do not have severe symptoms from nephrotic 
syndrome. In addition, clinically relevant long term endpoints were recorded and 
the duration of follow-up was sufficiently long for these endpoints to be attained. 
Moreover,  safety of the treatment strategy was evaluated. Finally, surrogate 
endpoints such as remission of proteinuria were also evaluated, thus allowing 
practitioners to assess effectiveness of the therapeutic regimen in an individual 
patient at an early stage of follow-up. 
Our findings suggest that a substantial number of patients with iMN only 
need supportive therapy. From this we conclude that any future trials that study 
immunomodulating therapeutic interventions should be restricted to high risk 
patients only. Furthermore, this study confirms previous reports that complete 
remission of proteinuria is a good indicator of a favorable prognosis.13 In addition, 
patients who showed severe kidney failure were more likely to progress to renal 
replacement therapy. However, even in these patients immunosuppressive therapy 
may still stabilize and even improve kidney function , although compared to 
patients with preserved kidney function, efficacy may be reduced.
In the recently published KDIGO guidelines for iMN, a restrictive treatment 
strategy in patients with iMN is recommended.6 According to these guidelines, 
initial therapy should only be started if proteinuria is persistently over 4 grams 
per day after six months of conservative therapy and does not show a tendency to 
decline, or if serum creatinine concentration has risen by more than 30%, or in the 
presence of severe, disabling or life threatening symptoms related to the nephrotic 
syndrome. Although the decision to start treatment was not based on proteinuria 
in our cohort, the renal function criterion and severity criteria were comparable to 
the guidelines. The KDIGO recommendation was based on studies that included 
a relatively small number of patients with a limited follow-up duration. When 
compared to previously published cohorts, the present study included substantially 
more patients, and patients were, on average, followed for a longer period of 
time.8-10 Nevertheless, both remission and renal survival rates in the present study 
were similar or even higher. Additionally, the overall renal survival attained in our 
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population was similar to survival in the intervention arms of the trials by Ponticelli 
et al. and Jha et al. 4,5 Therefore, our results add to the notion that treatment with 
immunosuppressive therapy should be withheld in patients with a well preserved 
kidney function, despite the (sometimes prolonged) presence of the nephrotic 
syndrome. 14 Recently , Howman et al. reported the results of a randomized 
controlled trial that compared chlorambucil and prednisone to ciclosporin 
monotherapy or conservative treatment.15 Immunosuppressive therapy was 
initiated in patients with established deterioration of renal function. Chlorambucil 
significantly improved renal outcome, thus confirming that late start (or restrictive 
use) of immunosuppressive therapy is effective. However, since deterioration of 
kidney function continued in 58% of the chlorambucil treated patients this study 
may question the overall efficacy of restrictive therapy with chlorambucil. Clearly, 
outcome in our treated patients was better, and there may be several explanations.  
Rather than using chlorambucil, we treated patients with cyclophosphamide, which 
is better tolerated. As a result patients may be more likely to receive an optimally 
efficacious dose.16,17 Furthermore, the UK trial provided chlorambucil for three 
months, whereas our patients were treated with cyclophosphamide for six to twelve 
months continuously. Finally ,in the UK trial, patients had an average creatinine 
clearance, calculated with the Cockcroft and Gault formula, of 50 ml/min, whereas 
the mean creatinine clearance by the Cockcroft and Gault formula was 62 ml/
min at the start of treatment in our cohort. In summary, our patients were treated 
earlier, longer and with a drug which is often better tolerated.
In the present study, 23% of patients suffered a serious adverse event anywhere 
during follow-up. Approximately half of these events were due to infections and 
most of these occurred in patients treated with immunosuppressive agents, despite 
antibiotic prophylaxis.11 We observed a similar rate of infections and leucopenia 
compared to other patient populations often treated with cyclophosphamide. Here, 
the probability of an infection was approximately 20% compared to 15% to 60% 
in lupus nephritis. 18 Similarly, the chance of leucopenia in our patients was 20% 
compared to 15 to 50% in lupus nephritis patients. We observed an 13% chance 
of cardiovascular and thrombotic complications. By comparison, Lionaki et al. 
observed an 8% venous thrombosis risk in iMN patients.19 However, their definition 
of thrombotic events did not include cardiovascular events. 
Malignancy is undoubtedly the most feared long term complication of 
cyclophosphamide. In our current cohort malignancy occurred in 20 patients (8%), 
and was significantly more frequent in patients treated with cyclophosphamide 
(n=14, 15%). Our treatment schedule used from 1995 onward, being 1.5 mg/kg for 
twelve months and resulting in a cumulative dose of 36 to 46 grams, was based on 
the study by Bruns et al.,20 as the Ponticelli regimen had not proven its efficacy in 
high risk patients. With the twelve month course of cyclophosphamide, we were 
able to report good results in high risk patients who had renal insufficiency.10 Based 
on the available literature at the time, we considered a cumulative dose less than 
50 grams acceptable.21 Recent data questioned this threshold value and suggested 
that cumulative doses over 36 grams should be avoided. 22 Our experience and 
the results presented in the current study confirm this observation. Therefore, 
we have recently changed our treatment schedule from twelve to six months 
cyclophosphamide therapy, halving the cumulative dose.23 Finally, we observed an 
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overall mortality rate nearly double of that in the general population. However, our 
data compared favorably to the 6% to 26% five year mortality rate reported in other 
iMN cohorts.8,24,25 
A limitation of the present study is its observational nature. No causal 
inferences about the efficacy of the strategy nor about the efficacy of individual 
drugs can be made with the current design. Additionally, there is a possibility of 
selection bias, as most patients were referred and did not present directly. Patients 
with an evidently poor prognosis or patients whose disease course is expected to 
be benign may not have been referred. Furthermore, we were unable to collect 
complete follow-up data for all patients. However, the potential impact of missing 
data was addressed with a sensitivity analysis. Additionally, one may argue that the 
favorable ten year outcomes may not adequately reflect survival over longer periods 
of time, as 26 patients did show severe kidney failure. In a more detailed analysis 
we observed nine progressive patients among the 19 patients who had severe kidney 
failure but did not require renal replacement therapy. In a worst case scenario, 
one would thus expect sixteen cases of RRT instead of the seven we observed, 
increasing the ten year cumulative incidence to about 8%. Moreover, the results 
presented here are only valid for our cyclophosphamide based strategy. Inferences 
on other immunosuppressive regimens should be made with caution. Finally, given 
that risk prediction for iMN patients has substantially improved throughout the 
last decade,2,26,27 and patients who do require immunosuppressive treatment may 
be better off when treatment is started at an early stage, the strategy described here 
may be improved. On the other hand, no differences in outcome were observed in a 
trial comparing early versus late initiation of therapy.11 In other words, the optimal 
timing of therapy still needs to be elucidated.
Conclusion
A restrictive therapeutic regimen yields favorable long term outcomes. 
Additionally, it results in half of the patients not requiring toxic drugs. Short term 
and long term side effects remain an important issue and risks of adverse effects 
should be balanced against the potential benefits of treatment. Overall, our study 
supports the recommendations in the recently published KDIGO guideline.
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AbstrAct
Background and objective: Cyclophosphamide treatment improves renal survival 
in patients with idiopathic membranous nephropathy (iMN). However, use 
of cyclophosphamide is associated with cancer. We evaluated the incidence of 
malignancies in patients with iMN and estimated the cancer risk associated with 
cyclophosphamide use. 
Design, setting and participants: Patients who attended our clinic were included 
prospectively from 1995 onward. A crude incidence ratio (IR) for the occurrence 
of malignancy was calculated. IRs were subsequently standardized to potential 
confounders. Latency between cyclophosphamide therapy and the occurrence of 
cancer was estimated by stratifying for time since the start of treatment. Finally, 
Poisson regression was used to obtain a multiple adjusted IR, and to investigate the 
dose response relationship between cyclophosphamide and cancer. 
Results: Data were available for 272 patients, who had a mean age of 51 years, 
and 70% of whom were male. Median follow-up was 6.0 years (inter quartile 
range 3.6 to 9.5), and 127 patients were treated with cyclophosphamide. Cancer 
incidence was 21.2 per 1000 person years in treated patients compared to 4.6 per 
1000 person years in patients who did not receive cyclophosphamide, resulting in 
crude and adjusted IRs of 4.6 (95% confidence interval 1.5 to 18.8) and 3.2 (95% 
confidence interval 1.0 to 9.5), respectively. 
Conclusion: Cyclophosphamide therapy in iMN gives a threefold increase in cancer 
risk. For the average patient this translates into an increase in annual risk from 
approximately 0.3% to 1.0%. The increased risk of malignancy must be balanced 
against the improved renal survival.
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IntroductIon
Idiopathic membranous nephropathy (iMN) is a common cause of nephrotic 
syndrome in adults. Current guidelines advise treatment with steroids and 
alkylating agents in patients who are at high risk for end stage renal disease (ESRD) 
or who have severe, persistent nephrosis.1 However, many physicians and patients 
are reluctant to use cyclophosphamide, because of the increased risk of cancer 
after cyclophosphamide therapy in patients with granulomatosis with polyangiitis 
(formerly Wegener’s granulomatosis), rheumatoid arthritis and non-Hodgkin’s 
lymphoma.2-4 Ascertaining the association between cyclophosphamide therapy and 
malignancy in iMN is challenging due to concomitant immunosuppressive therapy, 
relative rarity of malignancies and the fact that membranous nephropathy may 
occur secondary to cancer.5,6 As a result, data on cancer risk in cyclophosphamide 
treated iMN patients is sparse. Obviously, such information is important when 
balancing risks and benefits of immunotherapy in iMN. Therefore, we studied 
the incidence of cancer in a cohort of iMN patients and investigated the role of 
cyclophosphamide as a risk factor.
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PAtIents And methods
A detailed description of patients and methods is given in the supplementary 
appendices online.
We included adult patients with biopsy proven iMN who visited our outpatient 
clinic between 1995 and 2009. Patients were either referred by a family doctor in 
our catchment area or by an allied centre. Secondary causes were ruled out per 
standard policy.7 Written informed consent was obtained. The study was conducted 
in accordance with the declaration of Helsinki and approved by our hospital’s 
review board. 
Most patients were treated according to our restrictive regimen, detailed 
elsewhere.7 In summary, patients underwent a standardized, timed urine 
measurement,8 and received supportive treatment. Immunosuppressive therapy 
was advised when patients reached a serum creatinine concentration above 1.5 mg/
dL or when patients suffered severe or life threatening symptoms of nephrotic 
syndrome. Oral cyclophosphamide and pulse intravenous methylprednisolone 
in combination with high dose oral prednisone was the preferred treatment. 
Occasionally, alternative immunosuppressive drugs were prescribed.9,10 
The outcome for the present study was incident malignancy, recorded from 
medical records and including the date of diagnosis. Mortality and the date of the 
final consultation were recorded as well. 
We pre-specified potential confounders, being age at time of biopsy, gender, 
ever smoking, having a first degree relative with a history of malignancy, chronic 
kidney disease stage and nephrotic syndrome. Immunosuppressive therapy was 
considered a possible confounder if it was initiated prior to cyclophosphamide 
therapy. Immunosuppressive therapy after cyclophosphamide could have acted 
as an intermediary, and therefore adjustment could result in underestimation of 
possible malignancy risk. Gender, date of birth and height were recorded during the 
urinary analysis, whereas biopsy and follow-up laboratory data were obtained from 
medical records. We recorded family history, smoking, cyclophosphamide exposure 
(including total cumulative dose) and the use of other immunosuppressive drugs 
over the entire follow-up duration.  
Statistical methods
Baseline data are presented as mean ± standard deviation, median and inter 
quartile range (IQR) or frequencies and proportions. X2 test was used to evaluate 
differences in frequencies. The difference in means for normally distributed 
variables was compared using t-test. Wilcoxon’s rank sum test was used to compare 
medians for skewed variables.
Person time was calculated from the start of therapy until the occurrence of 
malignancy or the last consultation date in the cyclophosphamide exposed group. 
For unexposed patients, person time was calculated from biopsy until malignancy 
or the last consultation. Ideally, one would start measuring person time for controls 
at the moment that they would have started treatment. To mimic this moment 
of exposure, the median time between biopsy and initiation of therapy in the 
cyclophosphamide group was estimated and deducted from the person time for 
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each control. Controls who had negative person time as a result were excluded from 
the analyses.  
Subsequently, the cumulative incidence of malignancy was calculated, assuming 
that death was competing with malignancy risk. Incidence rates were calculated 
and used to estimate the incidence ratio (IR) of malignancy after cyclophosphamide 
exposure. In order to estimate the latency between cyclophosphamide exposure 
and cancer, incidence ratios were calculated by two year strata of person time. 
Standardized incidence ratios were calculated by weighting for the distribution 
of the confounders in the cyclophosphamide treated group.11 Multiple imputation 
by chained equations was used to impute missing data on smoking status, family 
history and cumulative cyclophosphamide dose.12 Poisson regression was used to 
obtain a multiple adjusted IR for the association between cyclophosphamide and 
malignancy, taking the imputations into account. In addition, the dose-response 
relation between cumulative cyclophosphamide exposure and the occurrence of 
malignancy was investigated by creating 20 gram categories of cumulative exposure 
and including these in an adjusted Poisson regression. For all analyses, 95% 
confidence intervals (95%CI) around the incidence ratios were calculated.
Membranous nephropathy can be incorrectly classified as idiopathic 
when it occurs secondary to an undetected malignancy. These patients are 
unlikely to respond to supportive therapy, and therefore more likely to receive 
cyclophosphamide. This would inflate the association between cyclophosphamide 
and cancer. To address this issue, we analyzed the serum samples of all patients 
with a malignancy for the presence of antibodies against the phospholipase A2 
receptor (antiPLA2R) in serum. Samples were obtained at the time of urine analysis 
and stored at -80°C and analyzed using a immunofluorescence test (Euroimmun 
AG, Lübeck, Germany).
In sensitivity analyses, the multivariate analysis was repeated including only 
patients with complete data. Secondly, we excluded patients who had received 
immunosuppressive drugs other than cyclophosphamide. Finally, cancer incidence 
was standardized by age and gender to the general population using incidence 
estimates obtained by the Netherlands Cancer Registry over the past decade.13 
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results
Between 1995 and 2009, 305 patients with iMN visited our centre. Twenty 
patients were lost to follow-up. Eleven patients with negative person times after 
correction for time-not-at-risk and two cyclophosphamide treated patients were 
excluded (figure 4.2.1).The present study includes 272 patients (table 4.2.1). 
The majority of patients was male and the mean age was 51 ± 14 years. Most 
patients presented with nephrotic syndrome (88%) and well preserved kidney 
function (mean eGFR 68 ± 24 ml/min per 1.73m2). During follow-up, 127 patients 
(47%) received cyclophosphamide, 123 (45%) patients did not receive any 
immunosuppression, whereas 22 patients did receive immunosuppressive therapy, 
yet were never treated with cyclophosphamide. Cyclophosphamide treated patients 
were more likely to be male, older, and had more severe proteinuria and a lower 
eGFR at the initial visit compared to untreated patients. The median time between 
biopsy and start of cyclophosphamide treatment was 12 months (IQR: 5 to 26). 
Figure 4.2.1. Flowchart for inclusion in the cohort. *The median time between 
biopsy and start of cyclophosphamide exposure was deducted from the exposure 
time of controls in order to adjust for time not at risk. As a result, eleven patient 
had negative exposure times and were therefore excluded from the analyses (see 
statistical methods). Two cyclophosphamide treated patients were excluded, one 
because of a lung carcinoma in situ prior to treatment and the other was lost to 
follow-up after the initiation of therapy.
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Table 1: Population characteristics at baseline. 
Variables Cyclophosphamide 
treated 
(n=127)
Not treated with 
cyclophosphamide 
(n=145)
P
At baseline
males (n, %) 101 (80%) 89 (61%) 0.001
BMI (kg / m2) 26.6 ± 3.6 27.1 ± 5.0 0.40
age (years) 53 ± 13 49 ± 15 0.05
year of biopsy 2001 ± 7 2002 ± 6 0.10
follow-up duration (years) 7.0 (4.0 – 11.4) 5.4 (3.0 – 8.4) 0.26
positive family history for 
malignancy* 12/82 (15%) 12/98 (12%) 0.64
current/former smoker* 56/94 (60% ) 55/107 (51%) 0.24
eGFR-MDRD4 (ml/min/1.73m2) 60 ± 24 75 ± 22 <0.001
serum creatinine (mg/dl) 1.2 (1.0 – 1.6) 1.0 (0.8 – 1.1) <0.001
serum albumin (g/dl) 2.2 ± 0.68 2.7 ± 0.63 <0.001
nephrotic syndrome at 
presentation 121 (95%) 119 (82%) 0.001
protein : creatinine ratio (g / g) 8.9 (5.7 – 11.1) 4.6 (3.0 to 7.6) <0.001
ACEi/ARB use 112 (88%) 134 (92%) 0.24
statin use 81 (64%) 87 (60%) 0.52
other BP lowering medication 39 (31%) 22 (15%) 0.002
Therapy
interval from baseline to start of 
therapy (months) 12 (5 – 26)
serum creatinine at start of 
therapy (mg/dl) 1.6 (1.2 – 2.0)
prior immunosuppressive therapy 27 (21%) 22 (15%) 0.19
cumulative cyclophosphamide 
dose (g) 37 (21 – 46) n/a
Outcomes
Death 17 (13%) 7 (5%) 0.01
Malignancies 16 (13%) 4 (3%) 0.002
*The denominator differs from the total number of patients due to missing data 
for this variable. Data are presented as mean ± standard deviation, median 
(inter quartile range) or percentages where appropriate. BMI: Body mass 
index; eGFR-MDRD4: estimated glomerular filtration rate, calculated with the 
abbreviated Modification of Diet in Renal Disease equation for mass spectrometry 
standardized creatinine; ACEi: angiotensin converting-enzyme inhibitor; ARB: 
angiotensin II receptor blocker; BP: blood pressure. 
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During follow-up (median 6.0, IQR 3.6 to 9.5 years), 20 patients (7%) developed 
a malignancy and 24 patients (9%) died, five of whom due to a malignancy. 
The cumulative incidence of cancer was 11% (95%CI: 7% to 18%) after 10 years 
(figure 4.2.2). Malignancy incidence was 21.2 per 1000 person years in the 
cyclophosphamide group compared to 4.6 per 1000 person years in the controls, 
resulting in an unadjusted incidence ratio of 4.6 (95%CI 1.5 to 18.8). There was no 
clear relation between incidence ratio and the time of follow-up (figure 4.2.3). Table 
2 shows a decrease in the incidence ratio of malignancy after cyclophosphamide 
exposure when standardized to age, gender and prior immunosuppressive therapy, 
smoking and positive family history (table 4.2.2). 
Missing values for smoking (n=71, 26%), family history of malignancy (n=92, 
34%) and cumulative cyclophosphamide dose (n=15, 6%) were estimated and 
imputed. After the imputations, the proportion of smokers decreased to 54%, 
whereas the proportion of patients with a family history of cancer remained 
13%. First a multiple adjusted IR of 3.1 (95%CI 0.9 to 9.9) for cyclophosphamide 
exposure was calculated by entering all possible confounders in a Poisson 
regression. However, the association between cyclophosphamide treatment and 
cancer in the Poisson regression was not substantially influenced by smoking 
status, prior immunosuppressive therapy, family history of malignancy, CKD stage 
or presence of the nephrotic syndrome. The most parsimonious model included 
only age and gender as confounding factors and gave an IR for cyclophosphamide 
exposure of 3.2 (95%CI 1.0 to 9.5). 
Figure 4.2.4 shows the adjusted relation between cumulative cyclophosphamide 
dose in 20 gram categories and malignancy. The respective median cumulative 
doses per category were 0, 12, 36, 46 and 71 grams. Compared to the untreated 
patients, the age and gender adjusted incidence ratios by increasing dose category 
Figure 4.2.2. Cumulative incidence of malignancy for the total cohort of iMN 
patients, the solid line is the point estimate and the dashed lines are the 95% 
confidence interval for the cumulative incidence. Death was considered competing 
for malignancy risk. 
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were 4.5 (95%CI 1.1 to 18.4), 2.6 (95%CI 0.7 to 9.4), 3.9 (95%CI 1.0 to 14.7) and 1.7 
(95%CI 0.2 to 15.4). 
Detailed information on the patients who developed a malignancy is given 
in table 4.2.3. Three cyclophosphamide treated and two untreated patients 
died due to a malignancy. Baseline anti-PLA2R was positive in thirteen (65%) 
patients, negative in five (25%) and unknown in two (10%) patients. There was 
no association between time to the occurrence of a malignancy and anti-PLA2R 
serostatus. 
In a sensitivity analysis, limited to 201 patients with complete data for smoking 
and family history of malignancy, the adjusted incidence ratio was slightly higher 
at 3.3 (95%CI 0.9 to 12.0). In a second sensitivity analysis we excluded all patients 
treated with other immunosuppressive drugs, therefore 78 cyclophosphamide 
exposed and 123 unexposed patients remained. The resulting adjusted incidence 
ratio was 5.1 (95%CI 1.2 to 21.5). When we standardized by age and gender to the 
general population an incidence ratio of 1.7 (95%CI: 0.9 to 2.6) was observed. 
Remarkably, the incidence ratio for malignancy in the unexposed patients was 0.5 
(95%CI 0.01 to 0.9). Details of the sensitivity analyses are presented in the online 
appendices.
Table 2: Standardized incidence ratios for malignancy after cyclophosphamide 
exposure by potentially confounding variables.
Risk factor Incidence Ratio 95% confidence 
interval
Unadjusted 4.6 1.5 - 18.8
Univariate adjusted:
Age 3.3 1.0 - 10.6
Male gender 3.3 1.1 - 10.0
Smoking 5.8 1.6 - 20.8
Prior therapy 4.2 1.3 - 13.4
Family history of malignancy 7.1 1.6 - 32.0
CKD stage 5.0 1.5 - 18.8
Nephrotic syndrome 4.3 1.3 - 14.1
Age and gender adjusted 3.2 1.0 - 9.5
Age was categorized as <45, 45 to 54, 55 to 64, 65 to 74 and ≥75. The first row 
shows the unadjusted incidence ratio. The following rows are incidence ratios 
for cyclophosphamide exposure adjusted for the individual confounder. Ever 
smokers were compared to patients who never smoked. Prior therapy was 
defined as immunosuppressive drug therapy other than prednisone before 
cyclophosphamide therapy was initiated. A multiple adjusted incidence ratio 
of 3.1 (95%CI 0.9 to 9.9) was obtained with a Poisson regression after multiple 
imputation of missing values for smoking and family history of malignancy. The 
most parsimonious model was adjusted only for  gender and age, the latter as a 
continuous variable. The model showed a moderate fit (R2=0.15).
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Figure 4.2.3. Unadjusted incidence ratio of malignancy in iMN patients by time 
since cyclophosphamide exposure in two year strata. Vertical lines represent the 
95% confidence intervals around the estimated incidence ratio. The horizontal 
lines signify inter quartile range of follow-up time within each two year stratum.
Figure 4.2.4. The dose-response relation between cumulative cyclophosphamide 
exposure in categories (not treated, 1 to 20, 21 to 40, 41 to 60 and >60 grams) and 
the adjusted incidence ratio of malignancy in iMN patients. The untreated group 
has been chosen as the reference, and thus the incidence ratio for malignancy is 
1 in that group. The vertical lines represent the 95% confidence intervals around 
the incidence ratios. The dashed horizontal lines represent the range within the 
categories for the cumulative cyclophosphamide dose. 
C
hapter 4.2
95
dIscussIon
The present study shows that the incidence of malignancy in cyclophosphamide 
treated iMN patients was approximately three times higher compared to patients 
not exposed to cyclophosphamide. For a 55 year old patient this translates into 
an increase in annual cancer risk from approximately 0.3% to 1.0%.13 Previous 
studies have shown that treatment with alkylating agents reduced the incidence 
of ESRD three to five fold.14-17 At first glance this decreased renal risk is matched 
by an increased risk of cancer. However, relative association measures may 
be misleading. The 10 year ESRD risk of 30% to 40% in untreated patients is 
best compared to the 10 year malignancy risk of 7% to 18% in treated patients. 
Moreover, only five of the 20 patients with cancer died as a consequence, and 9% 
of all patients died during follow-up. By comparison, mortality risk is 50% after 
only five years in patients with ESRD (Dutch Dialysis and Transplantation Registry: 
www.renine.nl, personal communication). Moreover, dialysis as well as kidney 
transplant patients are more likely to die from cardiovascular or infectious causes 
than malignancy. Admittedly, different types of cancer tend to occur in dialysis and 
transplant patients.18 These malignancies may have a different prognosis from the 
ones observed after cyclophosphamide therapy. Nonetheless, the risks associated 
with ESRD may still outweigh those of the cyclophosphamide treatment in patients 
with progressive iMN. Finally, others have shown that very low serum albumin 
levels as a result of severe nephrosis can result in life threatening thrombo-embolic 
complications.19 In these patients attenuating the immediate complication risk 
outweighs the long term malignancy risk.
A strength of the present study is the prospective inception of the cohort, 
reducing the likelihood of selection bias. Secondly, patients in our cohort have been 
followed long enough for cancer to occur. In addition, possibly confounding risk 
factors were taken into account. Moreover, as patients were treated according to 
a uniform strategy closely adhering to recent guidelines,20 the data presented here 
can be generalized to current clinical practice. In addition, sensitivity analyses were 
performed in which patients treated with other immunosuppression were excluded. 
In all analyses similar associations between cyclophosphamide use and cancer were 
observed. 
The incidence ratio reported here was similar to that in other patient 
populations.2-4,21 Surprisingly, malignancy risk was only 1.7 times higher in 
cyclophosphamide treated patients compared to age and gender matched persons 
in the general population. The incidence for unexposed patients was lower than 
in the general population. A  ikely explanation for this finding is that our patients 
were screened for cancer at baseline. In addition, residual confounding (e.g. due 
to smoking) may be present when comparing to the general population, whereas 
confounding was adjusted for in the Poisson regression. Therefore, the results from 
the regression analysis are most valid. 
Remarkably, only two out of twenty observed malignancies were bladder 
cancers,22 and no skin cancers were observed. Lefaucheur et al. studied malignancy 
in iMN patients and did not report skin cancer either.5 On the other hand, 
increased risk of skin cancer was observed in patients with rheumatoid arthritis 
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and ANCA associated vasculitis.2,21 However, those patients were treated with 
multiple drug regimens and for prolonged periods. Perhaps they are more prone 
to virally induced cancers. Finally, we cannot exclude that small skin cancers were 
underreported in our study. Conversely, hematologic malignancies were relatively 
common in our cohort. Therefore, we feel that physicians should maintain 
awareness for signs of malignancy, including (but not limited to) bladder cancer, in 
cyclophosphamide treated patients. 
We observed some early onset malignancies. We hypothesized that this may 
be due to inclusion of patients with secondary MN in whom an early diagnosis of 
cancer was missed. This is unlikely, as the frequency of anti-PLA2R seropositivity 
in patients with a malignancy was approximately equal to the reported prevalence 
of anti-PLA2R antibodies in iMN patients.23 In addition, there was no apparent 
association between the presence of anti-PLA2R auto-antibodies and the time 
to malignancy. Several authors have reported the onset of bladder cancer within 
one year after the start of cyclophosphamide therapy.24,25 Obviously, reported 
early cases may reflect incidental findings. Note that our limited data do not allow 
for further inferences on the association between anti PLA2R antibodies and 
malignancy risk.
A clear dose response relationship between cyclophosphamide exposure and 
malignancy risk has been reported in non-Hodgkin’s lymphoma.4 In these patients, 
risk increased 2.4 fold and 14.5 fold when the cumulative dose was less than 20 
and over 50 grams, respectively. Reported cumulative doses in rheumoid arthritis 
and vasculitis were higher still, averaging over 80 grams in patients who developed 
cancer.27 By comparison, the mean cumulative dose in our patients was 37 grams 
and only 20% of the patients received more than 50 grams. We did not observe a 
clear dose response relation, possibly due to the uniform treatment that patients 
received.
When weighing the risks and benefits of cyclophosphamide treatment 
other complications should be considered. About one in three patients suffers 
a serious adverse event,20 being mostly leucopenia, infections and thrombotic 
complications shortly after the start of therapy. Particularly worrisome for patients 
of a reproductive age is the risk of infertility. In these patients the duration 
of cyclophosphamide therapy is limited to three months, which results in a 
relatively safe cumulative dose of less than 10 grams.27 Other drugs have been 
suggested as first line treatment, such as MMF, cyclosporin A, tacrolimus and 
rituximab.28,29 Although these drugs induce remission of proteinuria, they have 
not been unequivocally shown to be as effective as cyclophosphamide in a direct 
comparison of long term outcome. Moreover, MMF and calcineurin inhibitors have 
been associated with malignancy in the transplantation setting, possibly via viral 
mediators.19 For rituximab on the other hand, data on long term risks are limited.30 
Thus, more data is needed on the efficacy and safety of other immunosuppressive 
drugs before replacing cyclophosphamide in the treatment of iMN.
When interpreting the data a few issues have to be taken into account. Although 
screening for malignancy in patients with membranous nephropathy is standard 
clinical practice, we cannot exclude that malignancies at the time of diagnosis 
may have been missed. Conversely, there was no standard screening for cancer 
during follow-up. Because of its known carcinogenic effects, physicians may have 
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been more proactive in screening patients treated with cyclophosphamide.2-4 
This may have inflated incidence ratios. Although missing values for potential 
confounders were dealt with in accordance with best practice, incomplete reporting 
may have led to misclassification of confounder status. Additionally we cannot 
exclude, residual confounding due to unknown or unrecorded confounders (e.g. 
alcohol use or environmental exposures). Twenty patients were lost to follow-up 
shortly after urine analysis. This may have resulted in selection bias of unknown 
direction. Finally, there were some empty cells in the latency analysis. In order 
to deal with this in a conservative manner, a single event was added to both the 
cyclophosphamide and unexposed groups. 
Conclusion
We showed that cyclophosphamide therapy gives a threefold increase in risk 
of cancer within ten to fifteen years after the start of treatment in idiopathic 
membranous nephropathy. For a 55 year old patient this translates into an increase 
in annual risk from approximately 0.3% to 1.0%. The data presented here help 
weighing the benefits against the risks of cyclophosphamide therapy in idiopathic 
membranous nephropathy, thus enabling physicians and patients to make an 
informed decision on treatment modality.
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AbstrAct
Background: Treatment with cyclophosphamide improves renal survival in 
patients with idiopathic membranous nephropathy. However, these drugs 
can give severe side effects. Thus, KDIGO recommend restricting therapy to 
high risk patients. However, such a restrictive regimen has not been evaluated 
experimentally.  Likewise, long term outcomes after renal replacement therapy and 
cost-effectiveness of therapeutic regimens have not been considered previously. In 
the present study we compared the cost-effectiveness of four alternative treatment 
strategies for idiopathic membranous nephropathy.
Design, setting and participants: We performed a cost-effectiveness analysis 
from a healthcare perspective to compare (1) treating all patients with 
cyclophosphamide, (2) treatment according to the KDIGO guidelines, (3) a 
restrictive regimen based on a prognostic test with urinary β2-microglobulin 
excretion (uβ2m), and (4) treating all patients  conservatively. We created a Markov 
model for which we obtained transition probabilities, costs and utilities from 
previous studies and a literature search. 
Results: The base case was a 55 year old patient presenting with nephrotic 
syndrome. The uβ2m based regimen was most cost-effective at a mean cost of  
€19 963 for an average of 13.94 quality adjusted life years (QALY). Treating all 
patients with cyclophosphamide, the KDIGO strategy and conservative therapy 
were more costly and less effective, and therefore considered inferior. Sensitivity 
analyses showed that treating all patients with cyclophosphamide was cost-effective 
at higher age and higher discounting rates. The results of a second order sensitivity 
analysis were similar to the base case analysis.
Conclusion: Restrictive cyclophosphamide therapy based on a prognostic test with 
urinary β2-microglobulin was the most cost-effective than treatment for idiopathic 
membranous nephropathy.
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IntroductIon
The clinical course of idiopathic membranous nephropathy (iMN) is variable. 
Approximately 30% to 40% of all patients presenting with the nephrotic syndrome 
progress to end stage renal disease (ESRD) or die prematurely,1,2 whereas the 
remainder show spontaneous remission of proteinuria within a few years.3 
Treatment with alkylating agents, most notably cyclophosphamide, is effective in 
preventing ESRD and mortality.1,2,4,5 However, alkylating agents may have severe 
short and long term side effects such as infections and malignancy. Therefore, 
current KDIGO guidelines recommend that treatment with oral cyclophosphamide 
should be initiated in patients whose proteinuria persists over 4 grams per day 
and over 50% of baseline for at least six months without showing signs of decline; 
or whose serum creatinine has risen by 30% or more within twelve months from 
the time of diagnosis; or in the presence of severe, disabling or life threatening 
symptoms of the nephrotic syndrome.6 However, such a restrictive treatment 
strategy has not been evaluated experimentally. Moreover, competing restrictive 
strategies have been proposed. For example, we recently showed that a more 
restrictive strategy gives similar clinical outcomes whilst limiting the number of 
patients exposed to potential harmful effects of cyclophosphamide.7 Additionally, 
some have argued that the risk of malignancy due to treatment with alkylating 
agents may outweigh the benefit on renal survival.8,9 Despite the lack of direct 
experimental evidence for some of these issues, data from multiple experimental 
and observational studies can be synthesized to compare long term outcomes for 
these alternative treatment strategies. 
Moreover, resources are sparse in healthcare, either due to a lack of 
infrastructure in some countries, or due to budgetary concerns in others. Therefore, 
the optimal treatment strategy needs to be cost-effective as well. Long term 
outcomes such as mortality, the need for renal replacement therapy and oncologic 
care are major determinants for healthcare related expenses. Thus, alternative 
treatment strategies need to be compared on cost-effectiveness beyond the 
horizon of survival until end stage renal disease.  Therefore, we compared the long 
term cost-effectiveness of four alternative strategies: 1) treating all patients with 
cyclophosphamide, 2)  restrictive treatment according to KDIGO guidelines, 3) 
deciding appropriate treatment based on a prognostic test, as described previously,7 
4) and treating patients with conservative therapy only. 
Cost-Effectiveness of a restrictive treatment strategy in idiopathic membranous nephropathy
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methods
We performed a cost-effectiveness analysis from a healthcare perspective. The 
target population was adult patients with new onset biopsy proven idiopathic 
membranous nephropathy and who presented with nephrotic syndrome and well 
preserved kidney function in an outpatient hospital setting. The base case was a 
55 year old patient, as this was the approximate mean age in previous studies.7 
Patients with a decreased kidney function are at high risk for ESRD and should 
be treated with immunosuppression. On the other hand, patients who do not 
have nephrotic syndrome are unlikely to show progressive kidney function loss. 
Therefore, prognostic prediction based on either the KDIGO criteria or urinary 
β2-microglobulin (uβ2m) excretion does not apply to these groups. The study was 
reported according to available guidelines.10
Treatment strategies
We evaluated four treatment strategies, shown in the decision tree in figure 
5.1. The first strategy we considered was based on the Ponticelli regimen. We 
assumed that the immunosuppressive therapy consisted of oral cyclophosphamide 
(1.5 mg/kg daily for six months) and pulse intravenous methylprednisolone 
(1 gram on days one to three, 61 to 63 and 121 to 123) in combination with 
high dose oral prednisone (0.5 mg/kg every other day for five months before 
tapering). This is our current treatment strategy, and differs somewhat from the 
original Ponticelli schedule in providing oral cyclophosphamide continuously 
instead of during alternating months. Secondly, we considered the KDIGO 
recommendations. Patients were first treated conservatively. However, if partial 
remission of proteinuria did occur within one year, patients were treated with 
immunosuppressive therapy. We chose partial remission, as these data were 
available from a previous study,11 and we considered a proteinuria of 3.5 g/
day sufficiently close to 4 g/day, the recommended level of proteinuria at which 
treatment should be started. We based the third strategy on a prognostic prediction 
using uβ2m excretion and subsequent allocation to an immunosuppressive 
regimen or conservative treatment. If patients had a uβ2m greater than 1.0 µg/
min, patients were considered test positive. The positive and negative predictive 
values were 73% and 76%, respectively.11 In the present simulations, these patients 
were allocated to immunosuppressive treatment. Test negative patients were 
allocated to conservative therapy. However, if a patient receiving conservative 
therapy showed a rise in serum creatinine to a level >135 µmol/l (≈ 1.5 mg/dl), 
that patient was treated with cyclophosphamide as well.11 Finally, we included a 
strategy based on conservative therapy only. Conservative treatment consisted of 
angiotensin converting enzyme inhibitors and/or angiotensin II receptor blockers 
in combination with other blood pressure lowering drugs if needed. Statins were 
used to treat hypercholesterolemia, and platelet aggregation inhibitors were used to 
prevent thrombosis in patients with deep hypoalbumineamia. 
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The Markov model
We created a decision tree and a Markov process with a one year cycle length. 
The Markov model ran 10 000 trials. Figure 5.1 shows the possible health states, 
being death (the absorption state), kidney transplantation, dialysis, remission and 
nephrotic syndrome. All patients started in the nephrotic state. For simplicity’s 
sake, we considered complications and cancer temporary states which could occur 
within a cycle. However, we allowed transition probabilities and rewards to vary 
by age by means of look-up tables, which can be found in the supplementary 
information.
Figure 5.1. Top panel: Decision tree for the cost effectiveness analysis of 
cyclophosphamide in iMN. Bottom panel: Markov states for the decision model. 
Complications and/or cancer may occur within a Markov cycle and influence the 
probability of dying, healthcare related costs and QALYs gained. However, these 
are not terminal states and are therefore not shown in the Markov model.
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Outcomes we considered were quality adjusted life years (QALYs) and healthcare 
related costs, and the incremental cost-effectiveness ratio (ICER). The ICER was 
calculated as the difference in mean cost divided by the difference in mean QALYs. 
The strategy which was least costly was chosen as the reference for the calculation 
of ICERs. We deemed a strategy that was more costly and gave fewer QALYs than 
the reference ‘dominated.’ If a strategy resulted in higher costs and more QALYs 
gained, or if a strategy was less costly, but resulted in fewer QALYs gained, we 
considered it cost-effective if the ICER was greater than the willingness-to-pay 
threshold.12 We chose a willingness-to-pay threshold of €80 000 per QALY gained, 
based on Dutch guidelines.13 By comparison, willingness to pay thresholds are 
$62 000 (≈€46 000) is the USA and £23 000 (≈€29 000) in the UK. The lifetime 
horizon of the Markov process was 30 cycles, similar to the mean life expectancy 
for 55 year old persons in the Netherlands.14 All analyses were performed using 
TreeAge Pro 13 (www.treeage.com).
Data sources and model assumptions
Table 5.1 shows the transition probabilities used in the model and the literature 
sources from which these probabilities were obtained. We made some assumptions 
in order to estimate transition probabilities. Most notably, we assumed the risk for 
malignancy after cyclophosphamide treatment not to be dose dependent within the 
ranges used in iMN.15 In addition, we considered thrombo-embolic complications 
most frequent and important in the nephrotic state. Therefore, we took the rate 
of deep venous thrombosis in the general population as the comparator risk 
of complications in the remission state. In addition, leucopenia and infections 
requiring hospitalization are the most common immediate complications of 
cyclophosphamide treatment. We added these as a possible one time risk and 
associated costs in treated patients.  
Table 5.2 shows the rewards linked to the different Markov states. We deemed 
spontaneous remission the preferred state, and therefore set it to reflect nearly 
perfect health (utility of 0.95 to 1.0). Conversely, we took death as the least 
preferred state and set its utility to 0. We obtained utilities for nephrotic syndrome 
and receiving cyclophosphamide treatment from the trial by Jha et al.2 The authors 
used a visual analog scale to measure health related quality of life. However, 
the visual analog scale is known to underestimate quality of life compared to 
other measurement tools, like for example time trade off and standard gamble. 
Therefore, we recalibrated these utilities to utility obtained by time-trade off.16 
Literature sources which obtained quality of life estimated with instruments other 
than VAS scales, were used for all other utility estimates. As the most frequent 
minor complications are infections due to immunosuppression, we used utility 
scores for chronic bronchitis as indicators for the quality of life when a patient 
suffered a minor complication. Similarly, we considered utility scores for a major 
complication similar to those of neutropenia requiring hospitalization, a transient 
thrombotic event, hypertension and/or diabetes. 
Scenarios on which healthcare related cost estimates were based can be 
found in the supplementary information online. We recalculated all costs to the 
consumer price index for 2012.17 We estimated healthcare related costs for medical 
procedures from the Dutch hospital reimbursement system (www.nza.nl, accessed 
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August 2013). In addition, we obtained cost prices of drugs from average consumer 
reimbursement prices calculated by the Dutch Board for Health Insurance 
Companies (www.medicijnkosten.nl, accessed August 2013). Both utilities and 
costs were discounted at a 3.5% rate per year according to National Institute for 
Health and Care Excellence (NICE) guidelines.
Model validation and sensitivity analyses
Model validation
 First, we checked the model’s face validity based on its structure. Next, we ran 
10 000 simulations for 10 cycles. Subsequently, we obtained ten year probabilities 
for mortality, end stage renal disease and remission as predicted by the model, 
and compared these to the actual probabilities observed in the trial by Ponticelli et 
al.1 We set the baseline age to 45 years for this analysis to be able to compare the 
results obtained from the model to the results of the Ponticelli trial. 
Sensitivity analyses
We submitted parameters in the model that were not of a stochastic nature 
but might influence the outcomes to sensitivity analysis in order to explore the 
uncertainty surrounding these variables. First the age at the time of diagnosis for 
the reference case was varied with one year intervals between 20 and 80 years 
in a one-way sensitivity analysis, as we believed that age might be an important 
modifier of end stage kidney disease risk. Secondly, we varied the annual discount 
rate for future costs and QALYs gained from 0% to 10% in intervals of 0.1%. 
We suspected that discounting of long term gains and risks might particularly 
important when considering the risk and benefits of cyclophosphamide therapy.
We carried out a second order sensitivity analysis by using 1000 patient level 
Monte Carlo simulations. We modeled parameter uncertainty by taking estimated 
distributions for all transition probabilities, health utilities and costs. Respective 
distribution parameters can be found in the supplementary information online. 
We used second order Monte Carlo simulations to estimate healthcare costs and 
QALYs gained, and determined the cost effectiveness plane and 95% credibility 
ellipse. Furthermore, we plotted a cost-effectiveness acceptability curve to assess 
cost effectiveness of the differing strategies over a range of willingness-to-pay 
thresholds from €0 to €100 000. Finally, we added perfect test (sensitivity 
and specificity of 100%) to the second order sensitivity analysis to estimate the 
acceptable additional cost for cost neutral implementation. We calculated the 
acceptable cost as:
Pnew = Pold + (Cold - Cnew) + WTP(Enew - Eold), 
where Pnew and Pold are the prices for perfect test and uβ2m testing, respectively. 
Cold are costs following uβ2m testing, Cnew costs after the perfect test; WTP is 
willingness to pay threshold, Enew and Eold stand for effectiveness in terms of QALYs 
after the perfect test and uβ2m, respectively.
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results
Model validity
Table 5.3 shows the cumulative ten year mortality or end stage renal disease, 
and remission probabilities predicted by the Markov model. Compared to the study 
by Ponticelli et al.,1 the model appeared to overestimate mortality and ESRD risk 
slightly. However, the frequency of events was reasonably similar to that described 
by Ponticelli and colleagues, and therefore we considered the face validity of the 
model sufficient to proceed with the cost-effectiveness analyses.
Table 5.3. Model validation: Predicted 10 year outcomes of the base case analysis 
for the treatment strategies.
Strategy Mortality and ESRD Remission
Obs Exp Obs Exp
Conservative 36% 31% 28% 36%
Treat all 8% 7% 84% 76%
ESRD: end stage renal disease. Obs: observed probability of the outcome in the 
Markov model. Exp: expected probability based on the trial by Ponticelli et al.1
Base case analysis
Table 5.4 shows the results of the base case analysis. The strategy based on 
a prognostic test with uβ2m resulted in the lowest mean costs (€19 963) and 
13.94 QALYs gained. The KDIGO, universal cyclophosphamide and conservative 
treatment strategies resulted in higher costs and fewer QALYs gained than the 
prognostic testing strategy. Therefore, both strategies were considered dominated. 
In addition, we compared the cost effectiveness of the KDIGO strategy to universal 
cyclophosphamide treatment. The KDIGO strategy saved €711 compared to treating 
all patients, but resulted in 0.27 fewer QALYs, giving an ICER of €2 633 per QALY. 
As the savings were less than €80 000 per QALY, the KDIGO strategy was not cost-
effective compared to treating all patients.
Table 4. Cost-effectiveness for four alternative treatment strategies for a 55 year old 
iMN patient who presented with the nephrotic syndrome. 
Strategy Cost (€) QALYs gained ICER
Predict prognosis with uβ2m before 
treatment allocation 19 963 13.94
Treat all patients with cyclophosphamide 24 153 13.90 dominated
Treat according to KDIGO guidelines 23 442 13.64 dominated
Conservative treatment 86 186 11.25 dominated
QALY: quality adjusted life year. ICER: incremental cost-effectiveness ratio. 
Alternatives which were more costly and resulted in fewer QALYs gained were 
considered ‘dominated’. The willingness-to-pay threshold was €80 000 per QALY 
for the present study.13 Therefore, treating all patients with cyclophosphamide 
was not considered cost-effective.
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Sensitivity analyses
Figure 5.2 shows the cost effectiveness planes for the four strategies obtained 
from the second order simulations. The scatter plot shows that testing for uβ2m 
prior to deciding upon a treatment remained the most cost effective alternative on 
average, after taking parameter uncertainty and heterogeneity between patients 
into account. 
Figure 5.3 shows the results for the sensitivity analyses for age at the time of 
diagnosis, the discount rate for long term costs and QALYs gained. The incremental 
cost effectiveness ratios are compared to the prognostic testing strategy with uβ2m. 
Treating all patients with cyclophophamide was cost-effective when the patient’s 
age at biopsy was higher than 60 years. Both the KDIGO strategy and conservative 
treatment strategy were dominated throughout the age and discounting ranges. 
Likewise, treating all patients was cost-effective when the annual discounting rate 
was over 6.2%. 
Figure 5.2. Cost effectiveness planes and 95% credibility ellipses for conservative 
treatment, the KDGIO strategy, universal cyclophosphamide therapy and the 
prognostic uβ2m test prior to treatment allocation. The long dashed lines are 
reference lines to determine cost effectiveness compared to the prognostic testing 
strategy, which was most cost-effective. The short dashed line signifies the 
willingness-to-pay threshold at €80 000 per QALY gained. At this threshold, both 
the conservative and KDIGO strategy were dominated by the prognostic testing 
strategy. The universal cyclophosphamide strategy was cost-effective in 33.9% of 
the cases. Costs are presented in €1 000 units, QALY: Quality adjusted life year.  
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Figure 5.3.One way sensitivity analyses for the incremental cost-effectiveness 
ratio for universal cyclophosphamide treatment by age (top panel and annual 
discount rate (bottom panel). The incremental cost effectiveness ratios are 
compared to the prognostic testing strategy with uβ2m. Both the KDIGO strategy 
and conservative treatment strategy were dominated throughout the age and 
discounting ranges, and are therefore not shown. The black short dashed line is 
the willingness to pay threshold. If the incremental cost-effectiveness ratio are 
lower than the willingness to pay, the alternative is deemed cost-effective. 
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The cost effectiveness acceptability curve (figure 5.4) for the restrictive strategy 
declined with increasing willingness-to-pay, whereas the curve for universal 
cyclophosphamide increased. However, throughout the willingness-to-pay range, 
the uβ2m based alternative remained most likely to be acceptable. At a willingness 
to pay threshold of €80 000 per QALY, the universal cyclophosphamide strategy 
was the most cost-effective alternative in 35.3% of the simulations.
Finally, a perfect test was added to the second order simulations. Compared 
to testing for uβ2m excretion, a perfect test would result in €605 saved and 
0.07 QALYs gained. Therefore the maximum additional costs for cost neutral 
implementation would be 605 + 80 000 x 0.07 = €6 205 compared to uβ2m testing. 
Figure 5.4. Cost-effectiveness acceptability plot. he black line marks the 
cyclophosphamide therapy; the grey line is the universal cyclophosphamide 
therapy. The plots shows the probability that a strategy is the most cost effective 
alternative by varying willingness to pay thresholds. TThe KDIGO strategy and 
the conservative strategywere never cost-effective. Willingness-to-pay is the 
maximum extra cost a payer is willing to accept to gain a life year in perfect 
health. 
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dIscussIon
In the present study we describe a cost-effectiveness analysis for four alternative 
treatment strategies for idiopathic membranous nephropathy in adult patients 
presenting with nephrotic syndrome and a well preserved kidney function. We 
compared conservative treatment, treatment according to the KDIGO guidelines, 
and universal cyclophosphamide therapy to a prolonged watchful waiting strategy 
based on a prognostic test with urinary β2-microglobulin excretion.
7 The KDIGO 
guidelines recommend that treatment should be initiated in patients not showing 
signs of improving after a watchful waiting period of six to twelve months.6 
Recently, we showed that this watchful waiting period can safely be extended up 
to approximately three years.7 Consequently, even fewer patients may be exposed 
to the possible harmful effects of cyclophosphamide therapy. The present cost-
effectiveness study supports this conclusion.
To the best of our knowledge, this is the first study that includes cancer risk 
after cyclophosphamide treatment as well as cancer risk on dialysis or after kidney 
transplantation. In addition, we took short and long term complications, ESRD 
and mortality risk into account. Thus, we give a comprehensive overview of patient 
outcome beyond the short term consequences of a decision to treat or not to treat. 
Transition probabilities, healthcare costs and health related utilities were obtained 
from previous work and available literature, which allowed us to makes realistic 
estimations and take heterogeneity between patients, and uncertainty surrounding 
costs, benefits and risks into account. To do so, we performed a series of sensitivity 
analyses and evaluated the model’s robustness. 
Remarkably, one way sensitivity analysis for age showed that the differences 
in costs and effectiveness between the four alternatives decreased with increasing 
age. In particular, treating all patients with cyclophosphamide became a viable 
alternative. As the age at which patients are diagnosed with iMN increases, so does 
the baseline risk of death. In fact the probability of mortality becomes far greater 
than ESRD and cancer risk in persons aged over 70.14,18,19 As a result, the relative 
contribution of living with the nephrotic syndrome to the number of QALYs gained 
becomes much larger. For example, if a patient spends three years in the nephrotic 
state, that patients will lose 0.78 QALYs. This is a 7.8% reduction when the life 
expectancy is 10 years. However, if the life expectancy is three years, almost a third 
of the QALYs is lost. This would also explain why universal cyclophosphamide 
therapy is more favorable when discounting rates increase. Here too, the initial 
gains in QALYs weigh more heavily compared to long term loss of QALYs due 
to cancer, for example. On the other hand, the risk of short term complications 
of cytotoxic therapy appears to increase with increasing age.20 We have not 
incorporated age dependent complication rates into the Markov model. Therefore, 
we cannot exclude that the number of QALYs gained in the cyclophosphamide 
strategy has been overestimated. Additionally, in everyday clinical practice 
treatment would be started in case of unresponsive nephrotic syndrome or deep 
hypoalbuminemia. In the present model; however, treatment was either started if 
spontaneous remission was not achieved (KDIGO strategy) or if serum creatinine 
increased (patients with low uβ2m who do show progression). Thus the duration of 
C
hapter 5
121
nephrotic syndrome was likely overestimated in both strategies. In summary, the 
results for the universal cyclophosphamide strategy may be overly optimistic in this 
model.
The present study does have some limitations. First, we only modeled the 
healthcare perspective. Both patient and societal perspectives require more 
assumptions, adding much uncertainty to the model. As a result, the model would 
become less reliable, limiting its value. Moreover, our conclusions are unlikely 
to be influenced by changing the perspective. We expect that adding the patient 
perspective would result in more costs to be added to cyclophosphamide treatment, 
as a result of extra travel to the hospital, for example. However, patient costs due 
to ESRD would be far greater. Dialysis, kidney transplantation and cancer all 
require frequent hospital visits and thus lead to higher transportation costs and 
opportunity costs due to work hours lost. Similarly, from a societal perspective, 
costs due to productivity loss from poor long term outcome are likely to increase 
the difference in cost-effectiveness between the therapeutic strategies. In the 
current study, the healthcare perspective offered a conservative estimate of 
difference in cost effectiveness between strategies. Second, the costs have been 
estimated in the Dutch setting. Treatments may be similar in other Western 
settings, costs may not. However, renal replacement therapy and cancer treatment 
are very costly regardless of the setting. Moreover, in countries where access to 
both renal replacement therapy and oncologic care is limited, the restrictive uβ2m 
strategy is even more likely to result in a larger amount of QALYs gained compared 
to the other alternatives. Therefore, the results from the present study are likely 
to be generalizable to other countries. Third, we only modeled cyclophosphamide 
based therapeutic strategies, as alkylating agents have been shown to be efficacious 
in randomized controlled trials, and are thus recommended by KDIGO guidelines. 
Inferences from cyclophosphamide strategies do not necessarily generalize to other 
therapeutic regimens. Moreover, some assumptions were made to simplify the 
Markov model. First and foremost, the consequences of complications and cancer 
were modeled as being immediate. As a result the number QALYs gained in persons 
who died from cancer or complications were likely underestimated. Conversely, 
QALYs accrued by patients who survived cancer or complications may have been 
overestimated. Finally, estimates for transition probabilities, utilities and costs 
were not based on an exhaustive literature review. However, we believe that the 
most important literature in the field of membranous nephropathy has been 
covered. Nevertheless, the model uncertainty may in fact be somewhat larger than 
estimated in the sensitivity analyses. 
In addition to comparing currently available treatment strategies, we calculated 
the price at which a perfect prognostic test can be implemented cost neutrally. A 
test close to 100% sensitivity and specificity could be implemented at a price of  
€6 000 per patient, or $5 200 in the USA, and £2 100 in the UK. Therefore 
commercial assay development may be worthwhile. Finally, we reported the 
analyses in such a way that they can be used as a framework by others to determine 
the cost effectiveness of novel prognostic markers and new therapeutic options in 
the treatment of iMN.
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Conclusion
Restrictive cyclophosphamide therapy based on a prognostic test with urinary 
β2-microglobulin resulted in lower costs and more quality adjusted life years gained 
than the therapy currently recommended in the KDIGO guidelines. The model 
presented here may be used as a framework to evaluate future prognostic markers 
and treatments.
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summAry
As described in chapter 1, idiopathic membranous nephropathy (iMN) is the 
most common cause of nephrotic syndrome in adults. The prognosis of iMN 
is variable. Without immunosuppressive therapy up to half of all nephrotic 
patients will show progressive kidney function loss, and ultimately require renal 
replacement therapy. Both dialysis and kidney transplantation have a great impact 
on a patient’s health and quality of life, and are very costly. Immunosuppressive 
therapy with alkylating agents has been proven effective. Unfortunately these 
drugs are associated with severe side effects. Up to half of all patients with 
nephrotic syndrome may develop spontaneous remission of proteinuria. Therefore 
international guidelines recommend that immunosuppressive treatment should 
be restricted to patients at the highest risk of progressive kidney failure. According 
to these guidelines, high risk patients are those who have nephrotic syndrome 
for six to twelve months, or a deteriorating kidney function. However, these 
recommendations are based on very little evidence. The following questions arise 
and were addressed in this thesis:
1. How well can we predict prognosis in idiopathic membranous nephropathy?
2. Can we improve prediction of prognosis?
3. Is restrictive therapy with cyclophosphamide effective?
4. What is the malignancy risk of cyclophosphamide therapy?
5. Do the benefits of restrictive cyclophosphamide therapy outweigh the risks and 
costs?
In order to answer these questions, epidemiological studies and a decision 
analysis have been performed based on data collected in our prospective registry of 
patients with glomerular diseases. An introduction of the methodology is given in 
chapter 2.
Chapter 3 includes two studies on the prediction of prognosis in iMN. In the 
first study (chapter 3.1) we validated the prognostic accuracy of urinary excretion 
of low molecular weight markers β2-microglobulin and α1-microglobulin in a cohort 
of 129 patients who presented to our clinic with a well preserved kidney function 
and nephrotic syndrome. We showed that the rate of urinary excretion of these low 
molecular weight proteins can discriminate with 80% accuracy between patients 
who show progressive kidney function loss and those who do not. Moreover, we 
concluded that a cumbersome timed urine analysis may not be needed. Our data 
indicate that spot urine samples, and subsequent calculation of the ratio of urinary 
low molecular weight proteins and creatinine can suffice. More importantly, in 
an exploratory analysis of a subgroup of 44 patients, we showed that a repeated 
measurement of β2-microglobulin within six to twelve months may improve its 
accuracy. Progression risk was 100% if β2-microglobulin excretion was over 1.0 
µg/min at both measurements. Likewise, progression risk was about 80% when 
β2-microglobulin excretion was elevated once. If both values were below 1.0 µg/min 
progression did not occur at all. The use of repeated measurements still requires 
validation. In the second study (chapter 3.2) we compared the predictive power 
of urinary excretion of low molecular weight proteins to an algorithm that is often 
used as an alternative, the Toronto Risk Score. This algorithm predicts prognosis 
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based on creatinine clearance and the level of proteinuria over a follow-up period 
of six months during which proteinuria is at its highest level. We did not find a 
substantial difference in accuracy. Interestingly, we found that not the level of 
proteinuria, but rather creatinine clearance and its change over the course of six 
months were the biggest contributors to the prognostic power of the Toronto Risk 
Score. As creatinine clearance does not accurately reflect glomerular filtration 
rate in patients suffering from the nephrotic syndrome, we adapted the Toronto 
Risk Score to include the estimated glomerular filtration rate according to the six 
variable version of the Modification of Diet in Renal Disease equation. Finally, we 
showed that, instead of waiting for the period of maximum proteinuria, the Toronto 
Risk Score can be calculated during the first six months of follow-up and still 
provide a reasonably accurate prediction of prognosis. 
In Chapter 4, we describe two studies on the long term outcome of iMN 
patients who were treated according to a restrictive regimen practiced at the 
Radboud university medical center since the late 1990s. Based on close monitoring 
of serum creatinine levels of patients with iMN who presented with nephrotic 
syndrome, patients who showed initial progression were identified and treated 
with immunosuppressive drugs, whereas low risk patients received conservative 
treatment only. We studied the long term outcome of 254 patients who were 
referred to our centre and treated according to this restrictive regimen. The results 
are described in chapter 4.1. Only 124 of the 254 (49%) patients were treated with 
immunosuppressive drugs. Overall, 3% of all patients required renal replacement 
therapy and 10% died during follow-up. By comparison, 8% of the treated patients 
in the trial by Ponticelli and coworkers suffered one of these outcomes, and 40% 
of the untreated patients in that trial needed dialysis or died. In other words, our 
restrictive treatment strategy gave results similar to a regimen that administered 
immunosuppressive drugs to all patients, while sparing half of the patients 
from toxic treatment. Importantly, our results suggest that the watchful waiting 
period prior to initiating immunosuppressive treatment can be safely extended 
to up three years. Almost 70% of the supportively treated patients developed a 
spontaneous remission of proteinuria during that time. In addition, one thirds of 
all patients who were treated with immunosuppression had a serious adverse event, 
which resulted in a hospitalization in 40% of these patients. The most notable 
complications were low white blood cell count, and infections as a consequence. 
Notably, the incidence of malignancies appeared to be increased in patients who 
were treated with cyclophoshamide. In a follow-up study, detailed in chapter 4.2, 
we quantified the cancer risk following cyclophosphamide treatment in patients 
with iMN. In total 272 patients were included, 127 of whom were treated with 
cyclophosphamide. The crude cancer incidence was 21.2 per 1000 person years in 
treated compared to 4.6 per 1000 person years in untreated patients. This resulted 
in an incidence ratio of 4.6 with a 95% confidence interval of 1.5 to 18.8. When we 
took confounding factors into account, the incidence ratio was attenuated to 3.2 
(95% confidence interval: 1.0 to 9.5). For an average patient, presenting at the age 
of 55, this would mean that the annual cancer risk increases from 0.3% to 1.0%.
Finally, we used the results of these studies and data gathered from the 
literature to create a decision model in which we weighed the risks and benefits of 
the restrictive cyclophosphamide therapy, detailed in chapter 5. We compared four 
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alternative treatment strategies, being:
1. Treating all with cyclophosphamide (according to the Ponticelli regimen);
2. Treating patients as recommended by international guidelines;
3. Treating only high risk patients identified by a prognostic test with urinary β2-
microglobilin;
4. Treating all patients conservatively with ACEi/ARBs.
The decision analysis showed that the restrictive cyclophosphamide regimen 
based on the prognostic test resulted in the highest number of quality adjusted life 
years gained at the lowest costs. 
In conclusion, by using currently available prognostic tools such a urinary β2- 
or α1-microglobulin or the Toronto Risk Score, we can predict the prognosis in 
patients with iMN who present with nephrotic syndrome with approximately 80% 
accuracy. Repeated measurements of urinary low-molecular weight proteins within 
the first year of follow-up may substantially improve prognostic accuracy. The 
restrictive treatment strategy is effective and spares half of all iMN patients from 
possible treatment related side effects. In total, one in three patients who receive 
cyclophosphamide suffers an adverse event. The most notable complications are 
leucopenia, infections and cancer. The cancer risk is three times higher compared 
to untreated patients. Finally, decision analysis showed that a restrictive regimen 
based on a prognostic test with urinary β2-microglobulin and an extended watchful 
waiting period was the most cost-effective alternative compared to treating all 
patients with cyclophosphamide, treatment according to current international 
guidelines and treating all patients conservatively. 
Future perspectives in idiopathic membranous 
nephropathy
A major change in the field of iMN occurred while performing the studies 
described in this thesis. As mentioned in chapter 1, the discovery of the 
phospholipase A2 receptor (PLA2R) as the target antigen in iMN has opened 
to door to new opportunities and insights regarding diagnosis, prognosis and 
treatment.1,2 It is now well established that 70% of all patients with iMN have 
circulating auto-antibodies for PLA2R.1 In fact, the concept of ‘idiopathic 
membranous nephropathy’ as a disease may be outdated, instead it should be 
considered a kidney specific auto immune disease. Measurements of antibodies 
against PLA2R, either circulating or in a kidney biopsy, will aid the diagnosis of 
membranous nephropathy, and can also be used to exclude secondary causes 
of MN. Moreover, antibody assays may be valuable in predicting prognosis and 
guiding therapy. Hofstra et al. showed that the titer of circulating anti-PLA2R 
antibodies correlated well with the presence of proteinuria and clinical status.3 In a 
later study, Beck et al. showed that treatment with rituximab resulted in decreasing 
titers of anti-PLA2R antibodies which preceded a decrease in proteinuria.4 
More recently, a collaborative European study showed that patients with high 
levels of auto-antibodies were less likely to develop a spontaneous remission 
of proteinuria.5 Additionally, a pilot study showed that persisting presence of 
anti-PLA2R antibodies in serum of patients during treatment predicted worse 
outcome.6 Moreover, antibodies disappeared at a lower rate when patients were 
treated with mycophenolate mofetil compared to cyclophosphamide. In turn, 
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outcome in the mycophenolate mofetil treated patients was worse compared to 
the cyclophosphamide patients. In conclusion, measuring anti-PLA2R antibodies 
may be helpful in predicting prognosis, deciding on treatment start and guiding the 
duration of immunosuppressive therapy. 
Even though evidence has only recently been provided, idiopathic membranous 
nephropathy has long been hypothesized to be an auto-immune disease. Therefore, 
immunosuppressive treatment has been considered since the 1980s. Cytotoxic 
agents such as cyclophosphamide have unequivocally been shown to be effective 
in randomized controlled trials,7-9 and are therefore recommended as first line 
immunosuppressive treatment in iMN.10 However, the serious side effects of 
cyclophosphamide therapy necessitate the development of new, effective and less 
toxic therapies. Therefore, the group of Remuzzi started experimental treatments 
with rituximab at the turn of the century.11 Rituximab is a monoclonal anti-body 
against the CD20 receptor found on B lymphocytes. It has already been used in 100 
consecutive patients in the Italian cohort, and with apparent success.12 However, 
it was an uncontrolled study, and therefore causal inferences cannot be reliably 
made. A formal comparison between rituximab and cyclosporin A is currently 
underway in the USA (clinicaltrials.gov, NCT01180036). In addition to that trial, a 
direct comparison between cyclophosphamide, the current standard therapy, and 
rituximab is needed as well. 
In conclusion, the treatment of idiopathic membranous nephropathy is set 
to change in the near future. Anti-PLA2R antibody titers may be used to identify 
which patients to treat and for how long. Secondly, new treatments such as 
rituximab may offer a viable alternative to cyclophosphamide. The first data has 
only recently started to emerge. More extensive and robust studies are going to be 
needed to provide evidence to support these novel treatment regimens.
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Idiopathische membraneuze nefropathie is een ernstige nierziekte. Het is de meest 
voorkomende oorzaak van nefrotisch syndroom bij volwassenen. Patiënten die 
lijden aan nefrotisch syndroom verliezen grote hoeveelheden eiwit via de urine. Dit 
komt doordat antilichamen neerslaan in de de glomeruli, de filtereenheden van de 
nier. De glomeruli raken dan beschadigd. Eiwitten die normaal in de bloedbaan 
blijven lekken door de beschadigde filter naar de voorurine. Het natuurlijk beloop 
van membraneuze nefropathie wisselt sterk. In de helft van de gevallen gaan 
de symptomen vanzelf over. We spreken dan van een spontane remissie. In de 
andere helft van de gevallen treedt verdere schade op. Uiteindelijk verliezen deze 
patiënten hun nierfunctie helemaal. Dan hebben zij dialyse behandeling of een 
niertransplantatie nodig.
Behandeling met afweeronderdrukkende medicijnen is bewezen effectief om 
nierschade te voorkomen en nefrotisch syndroom in remissie te laten gaan. Een 
van de belangrijkste afweeronderdrukkende middelen is cyclophosphamide. Helaas 
heeft cyclophosphamide soms ernstige bijwerkingen. Behandeling kan bijvoorbeeld 
leiden tot een verhoogd risico op kanker. Daarom gaan we er vanuit dat het 
beperken van de behandeling tot patiënten bij wie we verwachten dat de nierfunctie 
achteruitgaat, de beste strategie is. Om na te gaan of dit echt zo is, moeten we de 
volgende vragen beantwoorden:
1. Hoe goed kunnen we voorspellen bij welke patiënten de nierfunctie achteruit 
zal gaan?
2. Kunnen we deze voorspelling verbeteren?
3. Is het beperken van afweeronderdrukkende behandeling tot patiënten met een 
hoog risico op nierfunctieverlies effectief?
4. Hoe groot is het risico op kanker na behandeling met cyclophosphamide?
5. Wegen de voordelen van het beperken van cyclophosphamide behandeling op 
tegen de mogelijke nadelen en kosten?
Om deze vragen te beantwoorden hebben we een aantal epidemiologische 
studies en een besliskundige analyse uitgevoerd. In hoofdstuk 2 beschrijven we de 
basis principes van deze vormen van onderzoek. 
In hoofdstuk 3 beschrijven we twee studies waarin we de prognose van 
patiënten voorspellen. We hebben de urineuitscheiding van kleine eiwitten 
gemeten bij alle patiënten die verwezen zijn naar het Radboud universitair medisch 
centrum. We meten de uitscheiding van deze kleine eiwitten, α1-microglobuline 
en β2-microglobuline, met een getimede urine meting. We laten in hoofdstuk 3.1 
zien dat we kort na diagnose met 80% zekerheid kunnen voorspellen of een patiënt 
nierfunctie verlies zal ontwikkelen of niet. Dat is een duidelijke verbetering ten 
opzichte van de fifty-fifty kans die een patiënt voor de meting heeft. Daarnaast 
laten we zien dat de ingewikkelde, getimede urine meting niet nodig is. In 
plaats daarvan bepalen we α1- of β2-microglobuline concentratie en delen deze 
door de kreatinine concentratie in het zelfde urine monster. Kreatinine is een 
merkstof, gemaakt in de spieren, die met constante snelheid door de nier wordt 
uitgescheiden. Daarom kunnen we de concentratie van kreatinine gebruiken om 
te corrigeren voor verdunning van de urine. Tenslotte laten we zien dat we de 
nauwkeurigheid van onze voorspelling verder kunnen verbeteren door de meting 
van β2-microglobuline na zes tot twaalf maanden te herhalen. Patiënten bij wie de 
uitscheiding bij beide metingen verhoogd is, verliezen nierfunctie. Tegengesteld, 
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patiënten bij wie de uitscheiding van β2-microglobuline bij beide metingen niet 
verhoogd is, hebben geen nierfunctieverlies. 
In hoofdstuk 3.2 vergelijken we de voorspelling aan de hand van kleine urine 
eiwitten met een veelgebruikt algoritme, de Toronto Risico Score. Deze risico score 
gebruikt de hoogte van eiwitverlies en kreatinineklaring, een maat voor nierfunctie, 
om een schatting te maken van de prognose. In tegenstelling tot het meten van 
kleine eiwitten, is een lange vervolg periode nodig om de Toronto Risico Score te 
kunnen berekenen. Toch geven dit algoritme en de uitscheiding van α1- en β2-
microglobuline een even goede voorspelling van de prognose. We laten zien dat de 
kreatinineklaring en niet het eiwitverlies het meeste bijdraagt aan de voorspelling 
door de Toronto Risico Score. Omdat kreatinineklaring geen goede maat is voor 
nierfunctie bij mensen met nefrotisch syndroom, hebben we vervolgens een betere 
schatting van nierfunctie gebruikt om de Toronto Risico Score te herzien. Tevens 
hebben we alleen gegevens verzameld tijdens de eerste zes maanden na diagnose 
gebruikt om nierfunctie verlies te voorspellen. We laten zien dat daarmee een 
vroegere maar even goede voorspelling van de prognose mogelijk is.
Naast de studies naar de prognose van iMN hebben we bekeken of het 
beperken van behandeling met afweeronderdrukkende medicijnen tot patiënten 
die het meeste risico lopen op nierfalen even goede resultaten geeft als alle 
patiënten met deze middelen behandelen. In hoofdstuk 4.1 beschrijven we de 
lange termijn uitkomsten van restrictieve behandeling. Volgens dit regime 
krijgen alleen patiënten met nierfunctieachteruitgang of ernstig nefrotisch 
syndroom afweeronderdrukkende therapie met cyclophosphamide. Sinds 1995 
zijn 254 patiënten die zijn verwezen naar het Radboudumc behandeld volgens 
het restrictieve regime. Slechts de helft van deze patiënten heeft uiteindelijk 
cyclophosphamide gekregen. De tien jaars overleving van alle patiënten samen was 
90%. Drie procent van de patiënten had nierfunctievervangende therapie nodig. 
Ter vergelijking, in studies waarin alle patiënten werden behandeld overleefde 92% 
van de patiënten zonder noodzaak tot nierfunctievervanging. Met andere woorden, 
het restrictieve regime geeft vrijwel dezelfde overlevingswinst, maar spaart bij de 
helft van de patiënten behandeling met afweeronderdrukkende medicijnen uit. Ook 
blijkt dat we behandeling veilig kunnen uitstellen tot drie jaar na diagnose.
Behandeling met afweeronderdrukkende medicijnen geeft bijwerkingen. 
Cyclophosphamide therapie geeft risico op een tekort aan witte bloedcellen en 
daarmee een grotere kans op infecties. Dit leidde tot ziekenhuisopname in 13% van 
de behandelde patiënten. Een andere, belangrijke bijwerking is een verhoogd risico 
op kanker. In hoofdstuk 4.2 beschrijven we een studie waarin we maat en getal 
aan dat risico geven. In deze studie hebben we 272 patiënten gevolgd waarvan er 
127 hebben cyclophosphamide behandeling kregen. We laten zien dat de kans op 
kanker verdrievoudigd na behandeling met cyclophosphamide. Dit betekent dat 
voor een patiënt van 55 jaar het risico op kanker toeneemt van 0.3% tot 1.0% per 
jaar. 
Met de gegevens uit voorgaande studies en resultaten van andere 
wetenschappers is het mogelijk om een besliskundige analyse uit te voeren. We 
hebben in hoofdstuk 5 een simulatiestudie uitgevoerd waarin we vier mogelijke 
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behandelstrategieën met elkaar vergelijken:
1. Iedereen behandelen met cyclophosphamide.
2. Behandeling volgens internationale richtlijnen.
3. Behandeling volgens het restrictieve regime beschreven in hoofdstuk 4.1. 
4. Conservatieve behandeling met bloeddruk verlagende middelen.
Internationale richtlijnen schrijven voor dat alleen patiënten die zes tot twaalf 
maanden na diagnose nog steeds nefrotisch syndroom hebben cyclophosphamide 
therapie hoeven te krijgen. Patiënten bij wie de ziekte gedurende deze periode 
vanzelf in remissie gaat, behoeven alleen ondersteunende behandeling. Het is dus 
ook een restrictieve behandeling, maar er wordt minder lang gewacht voordat 
afweeronderdrukkende medicijnen worden voorgeschreven dan in het regime van 
het Radboudumc. 
Uit onze analyse blijkt dat behandelen volgens het restrictieve regime van het 
Radboudumc de meeste gewonnen levensjaren in volledige gezondheid oplevert 
tegen de laagste kosten.
Tenslotte bespreken we in hoofdstuk 6 ook de toekomstperspectieven 
voor het onderzoek naar en de behandeling van idiopathische membraneuze 
nefropathie. De ziekte was decennialang ‘idiopathisch,’ dat wil zeggen dat de exacte 
oorzaak onbekend is. Echter, recent is ontdekt dat 70% van alle patiënten met 
idiopathische membraneuze nefropathie antistoffen hebben tegen de fosfolipase 
A2 (PLA2) receptor. Deze receptor is bij patiënten te vinden op de podocyt, 
een van de belangrijke cellen in de glomeruli. Dit betekent dat idiopathische 
membraneuze nefropathie in feite een auto-immuun ziekte is. Het afweersysteem 
maakt antistoffen aan tegen de lichaamseigen PLA2 receptor. Bij patiënten met 
actieve ziekte circuleren antistoffen tegen de PLA2 receptor in de bloedbaan. 
Verschillende onderzoekers laten zien dat afname van de antistofconcentratie 
door afweeronderdrukkende behandeling vooraf gaat aan remissie van nefrotisch 
syndroom. Het bepalen van PLA2 antilichaamconcentraties zou in de nabije 
toekomst kunnen helpen om de behandeling van membraneuze nefropathie 
verder te personaliseren. Een tweede interessante ontwikkeling is het gebruik 
van rituximab als behandeling in idiopathische membraneuze nefropathie. 
Rituximab is een antistof tegen B-cellen, de voorlopers van plasmacellen. 
Plasmacellen maken antistoffen. Dus door B-cellen uit te schakelen zou ook de 
productie van antistoffen tegen de PLA2 receptor verdwijnen en de ziekte in 
remissie gaan. De eerste resultaten zijn veel belovend, maar er zijn nog geen 
gecontroleerde studies uitgevoerd. Een directe vergelijking tussen rituximab en 
restrictieve cyclophosphamide behandeling moet nog volgen. Tot die tijd blijft 
cyclophosphamide behandeling de standaard behandeling bij hoog risico patienten.
In conclusie: we kunnen beschikbare merkstoffen, zoals β2-microglobuline, 
gebruiken om te voorspellen welke patiënten hoog risico lopen op nierfalen. We 
hoeven alleen deze hoog risico patiënten te behandelen met afweeronderdrukkende 
medicijnen. Zo doende beperken we het risico op bijwerkingen en halen we goede 
lange termijn resultaten. Deze aanpak levert de meeste gewonnen levensjaren in 
volledige gezondheid op, tegen de laagste kosten. 
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dAnkwoord
Als eerste wil ik mijn dank betuigen aan patiënten, medische en administratieve 
staf van de afdelingen nierziekten of interne geneeskunde van de ziekenhuizen 
die hebben meegewerkt aan de registratie van patiënten met glomerulaire 
ziekten. Met uw hulp hebben we de behandeling van patiënten met membraneuze 
nefropathie de afgelopen jaren weten te verbeteren. Verder wil ik u bedanken voor 
de gastvrijheid waarmee mijn collaga’s en ik zijn ontvangen wanneer we op bezoek 
kwamen om data te verzamelen uit medische statussen. 
Ten tweede mijn promotor, professor doctor Jack Wetzels. Toen ik mijn 
epidemiologie stage bij de afdeling nierziekten liep, was ik diep onder de indruk 
van hoe veel jij uit de meest eenvoudige beschrijving van data wist af te lezen. 
Ik realiseerde me hoe veel ik zou kunnen leren van jou. Dat geldt na ruim 5 jaar 
onderzoek onder jouw supervisie nog steeds. Ik wil je bedanken voor je geduld -ik 
kan af en toe koppig en slordig zijn. Jouw toewijding en onaflatende streven naar 
het best mogelijke onderzoek zijn inspirerend. Je hebt mij altijd weten te motiveren 
om niets dan het beste te accepteren. Ik geniet nog steeds van de overleggen waarin 
we mijmeren over de staat van nieronderzoek en filosoferen over welke kant dat 
onderzoek op zou moeten gaan. Ik hoop dat we nog lang kunnen samenwerken en 
dat ik nog veel meer van je mag leren.
Ik wil doctor Julia Hofstra bedanken. De manier waarop jij klinisch werk, 
toponderzoek en moederschap weet te combineren is ongelooflijk. Je bent een 
ontzettend intelligente en getalenteerde onderzoeker, veel meer dan je zelf toegeeft. 
Toen ik een paar jaar geleden -vlak na jouw promotie, vroeg of je interesse had 
om mijn copromotor te worden, zei je van niet. Je zou naar eigen zeggen niet 
genoeg bijdragen. Ik ben blij dat je van gedachten bent veranderd. Je bent bij ieder 
onderzoek in mijn proefschrift betrokken en hebt ieder manuscript in dit boekje 
vele malen gelezen en verbeterd. Als dat niet genoeg is, weet ik niet wanneer het 
ooit genoeg zou zijn. Ik kijk uit naar je toekomstige werk.
Ik wil in het bijzonder professor doctor Martin den Heijer bedanken. Je 
bent zonder twijfel de meest vriendelijke persoon die ik ooit heb ontmoet. Mijn 
promotietraject is er heel anders uit komen te zien dan gepland. Je hebt het 
Radboud ziekenhuis verlaten voor een hoogleraarschap aan het VU medisch 
centrum aan het begin van mijn promotieonderzoek. Toch heb je in de korte tijd 
ik met je heb mogen samenwerken een flinke impact gehad. Dankzijn jou ruilde 
ik SPSS in voor Stata. Je hebt me aangemoedigd om veel nieuwe technieken en 
methodes te proberen. Dat resulteerde in aanklooien en heel veel fouten maken 
voordat iets lukte. Uiteindelijk heb ik van iedere fout geleerd en alles wat de eerste 
keer mislukte, heb ik in latere studies succesvol kunnen toepassen. Ten slotte heb 
je mij kennis laten maken met het Nijmegen Centre for Evidence Based Practice, 
nu het Radboud Institute for Health Sciences, en een Trainings- en Supervisieplan. 
Geen plan overleeft het eerste contact met de vijand, maar het heeft wel geholpen 
in de rest van mijn promotie traject.
Hilde, Rutger, Ilse, Annemiek en Simone en alle anderen die de urinemetingen 
uit hebben gevoerd en nog steeds doen. Zonder jullie harde werk zou dit 
proefschrift nooit tot stand zijn gekomen, bedankt.
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Peter van Dijk, je heb de bulk van data verzameld voor de studies in hoodstuk 4. 
Bedankt voor je bijdrage. Ik weet zeker dat je een goede dokter en wetenschapper 
zult worden. Veel succes met je eigen promotieonderzoek.
Louis Reichert, Amanda Branten en Peggy Du Buf- Vereijken. “Als ik verder 
hebben kunnen zien, dan was dat omdat ik op schouders van reuzen stond.” 
Jullie zijn mijn reuzen. Gerard Du Buf, ik ken je niet persoonlijk, maar heb wel 
de vruchten van jouw werk geplukt. Bedankt dat je de Proteinurie database hebt 
gebouwd. We hebben er bijna twee decennia van genoten, maar we gaan hem nu 
toch echt vervangen. 
Ik wil mijn zus, Hanny van den Brand bedanken voor de prachtige illustraties 
die zij heeft gemaakt. Je hebt van mijn vage ideeën fantastische schetsen 
gemaakt. Hopelijk is deze eerste opdracht een mooie opmaat naar je cariere als 
wetenschappelijk illustrator 
Ik wil alle leden van de NCEBP PhD council met wie ik het plezier heb gehad 
samen te mogen samenwerken bedanken. Jullie waren een leuke afleiding in het 
alledaagse leven van een promovendus. Ik wil ook de leden van het management 
team van het NCEBP bedanken: Gerdi Egberink, Marieke de Visser, Karin Berens, 
Paul Smits en Bart Kiemeney. Jullie hebben me een uniek kijkje in de keuken van 
een groot onderzoeksinstituut gegeven. Ongetwijfeld zal die ervaring helpen bij 
mijn carrière in de wetenschap. 
Natalie, Elke, Christine, Pierre, Olivier, Christophe, Ross, Hans, Andy and 
Dick. Without exception, you guys make the ASN Kidney Weeks and ERA-EDTA 
workshops happy reunions. I hope to being seeing a lot more of you in the coming 
years. Good luck on your studies. 
Ik wil alle mensen van wie ik heb mogen leren en met wie ik heb samengewerkt 
in de afgelopen paar jaar bedanken. Ik had jullie bij naam moeten noemen, mijn 
excuses dat ik dat niet heb gedaan.
Pa en ma, bedankt voor de goede opvoeding die jullie me hebben gegeven. Ik 
heb het niet altijd makkelijk gemaakt, maar gelukkig hebben jullie me een flinke 
portie gezond verstand bijgebracht. Bedankt dat jullie altijd voor me klaar staan. Ik 
ben trots op jullie en hou van jullie. 
Ten slotte, bedankt Kim. Ik zou met gemak een boek ter grootte van dit 
manuscript kunnen schrijven over wat je voor me betekent. Dat is niet nodig. Alles 
wat ik te zeggen heb, kan toch niet met woorden worden gevangen. 
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other PublIcAtIons by the Author
1
Nurse Practitioner Care Improves Renal Outcome in Patients 
with CKD 
Mieke J. Peeters, Arjan D. van Zuilen, Jan A.J.G. van den Brand, Michiel 
L. Bots, Marjolijn van Buren, Marc A.G.J. ten Dam, Karin A.H. Kaasjager, 
Gerry Ligtenberg, Yvo W.J. Sijpkens, Henk E. Sluiter, Peter J.G. van de 
Ven, Gerald Vervoort, Louis-Jean Vleming, Peter J. Blankestijn, and Jack 
F.M. Wetzels
Journal of the American Society of Nephrology Volume: 25 Issue: 2 Pages: 
390-398 Published: 2014
2
A retrospective study of focal segmental glomerulosclerosis: 
clinical criteria can identify patients at high risk for recurrent 
disease after first renal transplantation
Maas, R. J. H.; Deegens, J. K. J.; van den Brand, J.A.J.G.; Cornelissen, 
E.A.M; Wetzels, J.F.M.
Bmc Nephrology Volume: 14 Published: 2013 
3
Validation of the kidney failure risk equation in European CKD 
patients
Peeters, Mieke J.; van Zuilen, Arjan D.; van den Brand, Jan A. J. G.; Bots, 
M.L.; Blankestijn, P.J.; Wetzels, J.F.M. on behalf of the MASTERPLAN 
study group.
Nephrology Dialysis Transplantation Volume: 28 Issue: 7 Pages: 1773-1779 
Published: 2013 
4
Differences between hospitals in attainment of parathyroid 
hormone treatment targets in chronic kidney disease do not 
reflect differences in quality of care
Peeters, M. J.; van Zuilen, A. D.; van den Brand, J.A.J.G.; Blankestijn, 
P.J.; Wetzels, J.F.M. 
Bmc Nephrology Volume: 13 Published: 2012 
6
Epidemiology of Contrast Material-induced Nephropathy in the 
Era of Hydration
Balemans, Corinne E. A.; Reichert, Louis J. M.; van Schelven, Bert I. H.; 
van den Brand, J.A.J.G.; Wetzels, J.F.M.
Radiology Volume: 263 Issue: 3 Pages: 706-713 Published: 2012 
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7
Intra-individual variability of serum hepcidin-25 in 
haemodialysis patients using mass spectrometry and ELISA
Peters, H. P. E.; Rumjon, A.; Bansal, S. S.; Laarakkers, C.M.; van den 
Brand, J.A.J.G.; Sarafidis, P.; Musto, R.; Malyszko, J.; Swinkels, D.W.; 
Wetzels, J.F.M ; Macdougall, I.C.
Nephrology Dialysis Transplantation Volume: 27 Issue: 10 Pages: 3923-
3929 Published: 2012 
8
Segmental and Global Subclasses of Class IV Lupus Nephritis 
Have Similar Renal Outcomes
Haring, C. M.; Rietveld, A.; van den Brand, J.A.J.G.; Berden, J.H..
Journal of the American Society of Nephrology Volume: 23 Issue: 1 Pages: 
149-154 Published: 2012 
9
High urinary excretion of kidney injury molecule-1 is an 
independent predictor of end-stage renal disease in patients 
with IgA nephropathy
Peters, Hilde P. E.; Waanders, Femke; Meijer, Esther; van den Brand, 
J.A.J.G.; Steenbergen E.J.; van Goor, H.; Wetzels, J.F.M.
Nephrology Dialysis Transplantation Volume: 26 Issue: 11 Pages: 3581-
3588 Published: 2011 
10
Introduction of the CKD-EPI equation to estimate glomerular 
filtration rate in a Caucasian population
van den Brand, J.A.J.G.; van Boekel, G. A. J.; Willems, H. L.; Kiemeney, 
L.A.L.M.; Den Heijer, M; Wetzels, J.F.M.
Nephrology Dialysis Transplantation Volume: 26 Issue: 10 Pages: 3176-
3181 Published: 2011 
11
Urinary excretion of low-molecular-weight proteins as 
prognostic markers in IgA nephropathy
Peters, H. P. E.; van den Brand, J. A. J. G.; Wetzels, J. F. M.
Netherlands Journal of Medicine Volume: 67 Issue: 2 Pages: 54-61 
Published: 2009 
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grAduAte trAInIng overvIew
Name PhD student: AJG van den Brand
Department: Nephrology
Graduate School: Radboud Institute for Health 
Sciences
PhD period:  
1-4-2010 – 22-1-2015
Promotor(s):  
JFM Wetzels
Co-promotor(s):  
Dr. JM Hofstra
Year(s) ECTS
Training Activities
Courses & Workshops
Winterschool Dutch Kidney Foundation
Genetic Epidemiology – Radboudumc 
BROK course - Radboudumc
Start qualification in education - Radboudumc
Basic qualification in education: Research Internships 
– Radboudumc
NCEBP (now RIHS) Introduction course
Academic Writing – Radboud University
Personal Profile building – Radboud in’to Languages
Nephrology Dialysis Transplantation: Reviewers-to-be
Erasmus Winter Programme: Advanced Topics in 
Decision Making in Medicine – Erasmus MC
Writing a successful ZonMW grant application – 
ZonMW and Radboudumc
Scientific Integrity – Radboudumc
Molecular Epidemiology of Chronic Diseases – M2E2 
Maastricht
2010
2010
2010
2010
2010
2010
2010
2012
2012
2013
2013
2013
2014
1.0
5.7
1.4
0.3
1.0
1.4
2.9
0.3
1.4
1.4
0.3
1.4
2.0
Seminars & lectures
American Society of Nephrology (ASN): 
Glomerulonephritis update
Amgen ASN Review 2012 (oral presentation)
European Renal Association – European Dialysis and 
Transplantation Association (ERA-EDTA) CME course: 
GFR2013 (invited lecture)
Seminar on Research Integrity / Inaugural Lecture 
Prof. Dr. L Bouter – VUmc
2011
2012
2013
2014
0.6
0.3
0.3
0.1
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Symposia & congresses
ASN Renal Week 2010 (oral presentation)
NCEBP PhD Retreat 2011 
ASN Kidney Week 2011 (poster presentation)
Dutch Federation for Nephrology: Nephrology days 
2012 (oral presentation)
NCEBP PhD Retreat 2012
Dutch Federation for Nephrology: Scientific meeting 
(oral presentation)
ASN Kidney week 2012 – (oral and 2 poster 
presentations)
NCEBP Science Day 2013
NCEBP PhD Retreat 2013
Symposium Scientific Integrity – VUmc
ERA-EDTA convention 2014
RIHS science day – (oral presentation)
International symposium: GFR assessment in the year 
2014 – Charité, Berlin, Germany (invited lecture)
ASN Kidney Week 2014
2010
2011
2011
2012
2012
2012
2012
2013
2013
2014
2014
2014
2014
2014
1.4
0.4
1.4
0.3
0.4
0.3
1.4
0.3
0.4
0.3
1.0
0.3
0.3
1.4
Other
Journal club: Junior Researchers Epidemiology 
(weekly)
Journal club: Department of Internal Medicine 
(monthly)
Periodic lectures: Research meeting for the Department 
of Nephrology
Journal club: Department of Nephrology
2010-2014
2010-2014
2012-2014
2010-2014
5.7
2.9
1.4
1.4
Teaching Activities
Lecturing
Supervision of group assignments: 
   writing a research proposal
   body measurements 
2012-2014
2013
1.0
0.1
Supervision of internships / other
E Raho – Correcting kidney function for body 
composition
MJE Verhoef – Invloed van albumine synthese, 
-filtratie en –resorptie op serum en urine albumine
M van Rijn – Mediation analysis to identify successful 
components of a multifaceted treatment in chronic 
kidney disease
2011
2012
2014
2.0
2.0
3.5
Total 51.6
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currIculum vItAe
Jan van den Brand werd geboren op 30 oktober 1984 te Eindhoven. Hij 
behaalde in 1997 zijn VWO diploma aan het gymnasium Bernrode te Heeswijk-
Dinther. Daarna startte hij met de bachelor opleiding Biomedische wetenschappen 
aan het Universitair Medisch Centrum Sint Radboud in Nijmegen. Hij verrichte 
gedurende deze opleiding een stage bij het Nederlands Instituut voor onderzoek 
van de gezondheidszorg (NIVEL) in Utrecht onder leiding van prof dr Walter 
Devilé. Vervolgens volgde hij de masteropleiding Biomedische wetenschappen 
met als hoofdvak epidemiologie en bijvak International Health en een consultancy 
profiel. Tijdens de masteropleiding heeft hij stage gelopen bij het Muhimbili 
University College in Dar-es-Salaam, Tanzania. Als hoofdvakstage nam hij deel 
aan het onderzoek van Hilde Peters, onder supervisie van prof dr Jack Wetzels, 
hetgeen uitmondde in de publicatie Urinary excretion of low-molecular-weight 
proteins as prognostic markers in IgA nephropathy. Als laatste liep hij stage bij 
Integraal Toezicht Jeugdzaken, een samenwerkingsverband van vijf rijksinspecties. 
Binnen deze stage voerde hij een beleidsonderzoek uit naar de aanpak van 
overgewicht onder kinderen en jongeren. Zijn masteropleiding, tevens opleiding tot 
epidemioloog A, rondde hij in 2009 met goed gevolg af. Vanaf april 2009 werkte 
hij deels bij Integraal Toezicht Jeugdzaken als data analist en inspecteur, en deels 
als junior onderzoeker bij de afdeling nierziekten van het UMC Sint Radboud. In 
april 2010 is hij gestart met zijn promotieonderzoek, hetgeen gesteund werd door 
een aan Jack Wetzels toegekende subsidie van Nierstichting Nederland. Jan is 
getrouwd met Kim Bunthof.
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IdIoPAthIc membrAnous nePhroPAthy
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Supplementary Table 3.1.2. Regression coefficients of the predictive model for the 
progression of idiopathic membranous nephropathy.
 Regression coefficient 95% Confidence Interval
Model 1: uβ2m
ln(uβ2m) 0.54 0.22 - 0.86
ln(screat) 3.06 0.33 - 5.8
ln(schol) 2.53 1.00 - 4.05
Intercept -18.82 -32.10 - -5.53
Model 2: uα1m
ln(uα1m) 1.19 0.49 - 1.91
ln(screat) 3.67 1.05 - 6.28
ln(schol) 2.32 0.81 - 3.83
Intercept -25.59 -37.89 - -13.28
ln: natural logarithm (elogn), uβ2m: urinary excretion of β2-microglobulin (μg/
min), uα1m:  urinary excretion of α1-microglobulin (μg/min), screat: serum 
creatinine (μmol/l), schol: serum cholesterol (mmol/l).
Supplementary Table 3.1.3. Classification of patients according to uβ2m, outcome 
and tubulo-interstitial lesions.
Classification Tubulo-intersitial lesions Total
None Few Moderate Severe
No progression, uβ2m < 1.0 μg/min 9 10 1 0 20
No progression, uβ2m ≥ 1.0 μg/min 1 4 0 0 5
Progression, uβ2m < 1.0 μg/min 4 2 1 0 7
Progression, uβ2m ≥ 1.0 μg/min 0 7 6 2 15
Total 14 23 8 2 47
vSupplementary Table 3.1.4. Patient characteristics at baseline and repeat 
measurement.
Variables Baseline Repeated 
Measurement
Total study 
population
p
n (% male) 44 (64%) 44 (64%) 129 (68%) 0.58
age at time of biopsy (years) 49 (38 - 59) 49 (38 - 59) 51 (43 – 61) 0.25
time between biopsy and urine 
analysis (months)
2 (1 - 3) 12 (8 - 15) 2 (1 – 4) 0.74
Survival time (months) 29 (15 - 53) 29 (15 - 53) 25 (13 – 51) 0.55
MAP  (mmHg) 95 (85 - 107) 89 (84 - 102) 97 (86 – 106) 0.72
Laboratory
serum creatinine (µmol/l) 85 (75 - 95) 97 (81 - 113) 88 (76 – 103) 0.19
serum albumin (g/l) 23 (19 - 28) 25 (20 - 30) 23 (19 – 28) 0.93
serum cholesterol (mmol/l) 7.8 (6.2 - 9.4) 6.0 (5.0 - 7.3) 7.3 (5.7 – 9.2) 0.26
eGFR-MDRD4 (ml/min/1.73m2) 77 (66 - 91) 68 (55 - 82) 75 (60 – 87) 0.32
Urine samples:
proteinuria (g / 10 mmol 
creatinine)
7.6 (5.1 - 10.4) 6.8 (4.3 - 10.4) 8.0 (5.6 – 10.7) 0.41
β2-microglobulin (µg/min) 0.5 (0.1 - 1.4) 1.1 (0.3 - 2.9) 0.6 (0.2 – 4.8) 0.05
α1-microglobulin (µg/min) 33 (21 - 45) 30 (15 - 69) 41 (23 – 72) 0.10
IgG (mg/24h) 229 (121 - 349) 182 (92 - 341) 257 (116 – 490) 0.07
Outcomes
Progression 55% 55% 47% 0.36
50% rise in serum creatinine 
(n)
13 13 30
25% rise and serum creatinine 
≥ 135 μmol/l (n)
8 8 24
clinical progression (n) 3 3 6
Spontaneous remission 47% 0.46
partial remission:< 2.0 g / 10 
mmol 41% 41% 61
partial remission: <3.5 g / 10 
mmol and ≥50% reduction
41% 41% 63
complete remission 16% 16% 26
Data are presented as median (interquartile range). MAP: mean arterial 
pressure. ACEi: angiotensin converting enzyme inhibitor. ARB: angiotensin-II 
receptor blocker. eGFR-MDRD4: estimated GFR calculated with the abbreviated 
MDRD formula. P values are given for the comparison of baseline characteristics 
for the total population and the 44 patients with repeated measurements. T- or X2 
tests were used. 
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Supplementary Table 3.2.5. Baseline characteristics of patients with idiopathic 
membranous nephropathy by year of referral. 
Variables 1995-2002 2003-2008 p
n (% male) 58 (81%) 71 (58%) 0.005
age at time of biopsy (years) 49 (38 – 60) 56 (44 – 63) 0.09
time between biopsy and urine analysis 
(months)
2 (1 – 6) 2 (1 – 3) 0.01
MAP  (mmHg) 98 (88 – 110) 97 (84 – 104) 0.08
Laboratory
 serum creatinine (µmol/l) 92 (79 – 113) 85 (76 – 95) 0.03
serum albumin (g/l) 23 (20 – 29) 24 (17 – 28) 0.10
serum cholesterol (mmol/l) 8.4 (6.9 – 9.7) 6.2 (5.3 – 8.1) <0.001
eGFRMDRD4 (ml/min/1.73m2) 73 (58 – 87) 76 (64 - 87) 0.97
Urinary samples
proteinuria (g / 10 mmol creatinine) 9.0 (5.6 – 11.0) 7.3 (5.3 – 10.7) 0.44
β2-microglobulin (µg/min) 0.5 (0.2 – 7.3) 0.7 (0.2 – 3.9) 0.14
α1-microglobulin (µg/min) 40 (18 – 72) 41 (23 – 80) 0.34
IgG (mg/24h) 296 (116 – 539) 232 (112 – 487) 0.64
Medication
ACEi/ARB use at time of biopsy 31% 14% 0.03
Statin use at time of biopsy 19% 7% 0.05
Outcomes
progression 57% 38% 0.03
partial remission:< 2.0 g / 10 mmol 40% 54% 0.12
Data are presented as median (interquartile range). MAP: mean arterial 
pressure. The validation study by Branten et al (JASN 2005). included patients up 
to December 2002. 
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xSupplementary Figure 4.1.1. Course of kidney function in patients who showed 
severe loss of kidney function but did not develop end stage kidney disease. 
Patients 3, 4, 7, 9, 11, 12, 13, 16 and 19 were considered to be at high risk of 
requiring renal replacement therapy in the near future. The arrow heads indicate 
the time treatment with immunosuppressive therapy was initiated.
xi
Supplementary Figure S4.1.2. Relative change of proteinuria since baseline in 
patients who achieved a spontaneous partial remission. The solid line is the 
median change; the dark shaded area is the inter quartile range; and the light 
shaded area in the range between the 5th and 95th percentiles.
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suPPlements for chAPter 4.2: cAncer rIsk After 
cycloPhosPhAmIde treAtment In IdIoPAthIc membrAnous 
nePhroPAthy
Full description of Patients and Methods
We included adult patients with biopsy proven idiopathic membranous 
nephropathy who visited our outpatient clinic between 1995 and 2009. Patients 
were either referred by a family doctor in our catchment area or by an allied centre. 
Secondary causes were ruled out per standard policy.1 Specifically, diagnostic 
procedures included chest X-rays, serology (ANA) to exclude systemic disease, and 
tests for hepatitis B and C. A mammography was performed in women over the 
age of 50 years and prostate specific antigen was obtained in men over 50 years of 
age. Additional investigations were undertaken if clinical suspicion for malignancy 
was raised by history, physical examination, other diagnostic test or, specifically, 
the presence of iron deficiency anemia. Written informed consent was obtained, 
and the study was conducted in accordance with the declaration of Helsinki and 
approved by the Radboud University Medical Centre medical ethics committee. 
Most patients were treated according to our restrictive immunosuppressive 
regimen, detailed elsewhere.1 In summary, patients underwent a standardized, 
timed urine measurement.2 Subsequently, all patients received supportive 
treatment. This consisted of blood pressure control and proteinuria reduction 
with ACEi and/or ARBs, and further blood pressure lowering drugs to achieve 
target levels below 130/80 mmHg. Additionally, statins were given to treat 
hypercholesterolemia, and anti-coagulant therapy was considered in patients with 
severe hypoalbuminemia (<2.0 g/dl). In patients who reached a serum creatinine 
concentration above 1.5 mg/dL, immunosuppressive therapy was advised. 
Severe or life threatening symptoms of nephrotic syndrome were considered 
an indication to start treatment with immunosuppressive agents as well. Oral 
cyclophosphamide (1.5 mg/kg daily for twelve months) and pulse intravenous 
methylprednisolone (1 gram on days one to three, 61 to 63 and 121 to 123) in 
combination with high dose oral prednisone (0.5 mg/kg every other day for five 
months before tapering) was the preferred treatment. Occasionally, alternative 
immunosuppressive drugs were prescribed either as part of a clinical trial or when 
cyclophosphamide was contraindicated.3,4 In patients of reproductive age, the 
duration of cyclophosphamide therapy was reduced to three months, followed by 
nine months of azathioprine or mycophenolate mofetil. The resulting cumulative 
cyclophosphamide dose was less than 10 grams, which is considered safe to 
preserve fertility. From 1999 onward, trimethoprim-sulfamethoxazole was added to 
the regimen to prevent pneumocystis jiroveci pneumonia.
The outcome for the present study was incident malignancy, recorded from 
medical records and including the date of diagnosis. Mortality and the date of the 
final consultation were recorded as well 
We pre-specified potential confounders, being age at time of biopsy, gender, 
ever smoking, having a first degree relative with a history of malignancy, chronic 
kidney disease stage (CKD, including substages 2a/b and 3a/b) and presence 
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of nephrotic syndrome at the time of biopsy. Immunosuppressive therapy was 
considered a possible confounder if it was initiated prior to cyclophosphamide 
therapy. Immunosuppressive therapy after cyclophosphamide could have acted as 
an intermediary, and thus adjustment could result in underestimation of possible 
malignancy risk. Gender, date of birth and height were recorded during urinary 
analysis at our center, whereas biopsy and follow-up laboratory data were obtained 
from medical records by two of the authors (PvD and JvdB). We recorded family 
history, smoking history, cyclophosphamide exposure (including total cumulative 
dose) and the use of other immunosuppressive drugs over the entire follow-up 
duration, including immunosuppressive drugs after cyclophosphamide treatment. 
Specifically we registered chlorambucil, azathioprine, mycophenolate mofetil, 
ciclosporin A, tacrolimus, methotrexate, prednisone and/or methylprednisone and 
experimental drugs (e.g. synthetic adrenocorticotropic hormone or rituximab), 
were obtained from medical records as well. 
Statistical methods
Baseline data are presented as mean ± standard deviation (SD), median and 
inter quartile range (IQR) or frequencies and proportions. X2 test was used 
to evaluate differences in frequencies. The difference in means for normally 
distributed variables was compared using t-test. Wilcoxon’s rank sum test was used 
to compare medians for the skewed variables.
Person time was calculated as the time from start of therapy until the occurrence 
of malignancy or the end of follow-up in the cyclophosphamide exposed group. 
Ideally, one would like to start measuring person time for controls at the moment 
that they would have started treatment. To mimic this moment of exposure, the 
median time between biopsy and initiation of therapy in the cyclophosphamide 
group was estimated and deducted from the time between biopsy and malignancy 
or end of follow-up in the control group. Consequently, time during which the 
exposed group was not actually at risk for malignancy due to cyclophosphamide 
exposure was not falsely included in the control group. If controls had negative 
person time as a result, they were excluded from the analyses.  
Subsequently, the cumulative incidence of malignancy was calculated, assuming 
mortality prior to the occurrence of cancer was competing with malignancy risk. 
Unadjusted incidence rates were calculated and used to estimate the incidence 
ratio (IR) of malignancy after cyclophosphamide exposure. In order to estimate 
latency between cyclophosphamide exposure to outcome, the incidence ratio 
of malignancy was calculated by two year strata of person time. If empty cells 
were encountered when calculating the within stratum incidence ratios, a single 
event was added to both the cyclophosphamide and unexposed group. Potential 
confounding was investigated by stratifying according to age, gender, ever-
smoking, prior immunosuppressive therapy , family history of malignancy, CKD 
stage and presence of the nephrotic syndrome. Age was categorized as under 44, 
45 to 54, 55 to 64, 65 to74 and over 75 years. Standardized incidence ratios (SIR) 
were calculated by weighting for the distribution of the potential confounders in the 
cyclophosphamide treated group, as described by Rothman, Greenland and Lash.5 
Note that no events were added to empty cells when SIRs were calculated. 
Multiple imputation by chained equations was used to impute missing data on 
smoking status, family history and cumulative cyclophosphamide dose. Data on 
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malignancies, age, gender and prior immunosuppressive therapy were complete 
and used in the imputation model, as these variables were also considered for the 
final analysis model. In addition, baseline serum creatinine, serum albumin, mean 
arterial pressure, body mass index and baseline presence of nephrotic syndrome 
were included. The natural logarithm of continuous variables was taken in order 
to stabilize variance. Forty imputations were created using logistic regression for 
smoking status and family history, and linear regression for cumulative dose. The 
imputed data was checked visually using scatter plots. Poisson regression was used 
to obtain a multiple adjusted IR for the association between cyclophosphamide 
and malignancies, whilst taking the imputations into account. In addition, the 
dose-response relation between cumulative cyclophosphamide exposure and 
the occurrence of malignancy was investigated by creating 20 gram categories of 
cumulative exposure and including these in an adjusted Poisson regression. For all 
of the analyses above, 95% confidence intervals around the incidence ratios have 
been calculated.
Membranous nephropathy can occur secondary to cancer and can be incorrectly 
classified as idiopathic when that cancer is not yet detected. These patients are 
unlikely to respond to conventional therapy, and thus more likely to receive 
cyclophosphamide. As a result the association between cyclophosphamide and 
cancer (especially early cancers) may be inflated. Therefore, we checked for serum 
antiphospholipase A2 receptor antibodies (anti-PLA2R) at the time of referral, 
assuming that, if patients with early malignancies were predominantly seronegative 
for anti-PLA2R, the association between early cancers and cyclophosphamide 
would be the result of previously undiagnosed cancers. The serum samples were 
obtained at the time of urine analysis and stored at -80°C. Anti-PLA2R status 
was measured using a commercially available indirect immunofluorescence test 
(Euroimmun AG, Lübeck).
In sensitivity analyses, a Poisson regression was performed using only patients 
with complete data for smoking and family history. Secondly, analyses were 
repeated excluding patients who had received immunosuppressive drugs other than 
cyclophosphamide. Finally, age and gender cancer specific incidence in the present 
cohort was standardized to the general population using incidence estimates 
obtained by the Netherlands Cancer Registry over the past decade.6 To do so, 
person time was stratified according to age and gender. The expected number of 
cases within each stratum was calculated. Subsequently, a standardized incidence 
ratio was obtained by dividing the observed by the expected number of cases.
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Supplementary results
Supplementary Table 4.2.1. Immunosuppressive therapy with drugs other than 
cyclophosphamide by cyclophosphamide exposure.
Timing of 
treatment
Cyclophosphamide  
exposed (n=127)
Not exposed to  
cyclophosphamide 
(n=145)
Initial treatment* 
(before CP)
Chlorambucil
MMF 
ACTH
High dose 
corticosteroids 
(Coggins)
5
11
4
7
Chlorambucil
MMF 
ACTH
High dose 
corticosteroids 
(Coggins)
Aza
1
9
7
4
1
Total initial 
treatment 27 (21%) 22 (15%)
Additional 
treatment*
(after CP)
MMF
ACTH
Aza
CsA
ACTH & Tacrolimus
ACTH & MMF
CsA & Aza
MMF & Aza
MMF, Tacrolimus 
& Aza
13
2
7
2
3
1
1
2
1
Total secondary 
treatment 32 (25%)
MMF: mycophenolate mofetil, ACTH: synthetic Adrenocorticotropic Hormone, 
Aza: azathioprine, CsA: cyclosporin A.*Ten patients have received other 
immunosuppressive therapy both prior to and after cyclophosphamide 
therapy and have been counted double in this table. The median duration of 
cyclophosphamide therapy was 12 (IQR 12 to 16) months in cyclophosphamide 
treated patients. Patients treated with other immunosuppresion, and not 
cyclophosphamide, were treated for a median of 9 (IQR 5 to 12) months. 
Patients who received both CP and other immunosupression were treated with 
cyclophosphamide for 12 (IQR 6 to 15) months and other drugs for 12 (IQR 8 to 
22) months, resulting in a total treatment duration of 27 (IQR 17 to 59) months. 
Coggins’ regimen consists of high dose oral prednisone for 8 weeks. Chlorambucil 
was given as part of the Ponticelli regime (0.2 mg/kg daily orally). MMF was 
given as part of a clinical trial, if patients had a pregnancy wish or if they 
experienced severe side effects of cyclophosphamide. The regular MMF dose was 
500mg to 1000mg twice daily orally for 9 to 12 months. ACTH was administered 
for nine months during a clinical trial (clinicaltrials.gov: NCT00694863). 
Patients received 1 mg by intramuscular injections in increasing dose with a 
maximum of 1 mg twice weekly. Azathioprine was given in case of side effects of 
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cyclophosphamide. Dose was usually 100mg per day. It was decreased to 50 mg 
per day over time in most patients and stopped after a year of treatment.
Cyclosporin A was occasionally given if patients refused alkylating agents, 
dosage varied between 100 and 300mg daily. Tacrolimus was given instead of 
cyclosporin in more recent years.
Sensitivity analyses
Patients who received immunosuppressive drugs other than 
cyclophosphamide were excluded. Of the cyclophosphamide treated patients, 
17 received other immunosuppression prior to cyclophosphamide, 22 
received other immunosuppression afterwards, and 10 patients received other 
immunosuppression both before and after cyclophosphamide treatment. In total, 
201 patients were included, 78 were treated with cyclophosphamide, 123 patients 
were not treated with immunosuppression at all. The population characteristics 
are presented in the table below. We then performed univariate, standardized 
and multiple adjusted analyses, the latter using Poisson regression. The adjusted 
analyses were preformed after multiple imputation of missing values for family 
history and smoking. Table 3 shows the incidence ratio ratios for cancer after 
cyclophosphamide exposure: unadjusted, standardized to potential confounders 
and after multiple adjustment.
xviii
Supplementary Table 4.2.2: Baseline population characteristic after exclusion of 
patients treated with other immunosuppressive drugs.
Variables Cyclophosphamide 
treated (n=78)
Not treated with 
cyclophosphamide 
(n=123)
P
At time of biopsy
males (n, %) 61 (78%) 77 (63%) 0.02
BMI (kg / m2) 26.9 ± 3.6 27.2 ± 5.2 0.58
age (years) 56.1 ± 11.1 49.2 ± 14.7 <0.001
year of biopsy 2001 ± 5.1 2002 ± 6.5 0.81
follow-up duration (years) 6.0 (3.7 - 10.7) 5.5 (2.9 - 8.4) 0.73
positive family history for 
malignancy* 9/52 (17%) 10/84 (12%) 0.38
current/former smoker* 37/61 (61%) 49/89 (55%) 0.46
eGFR-MDRD4 (ml/min/1.73m2) 62 ± 21 77 ± 20 <0.001
serum creatinine (mg/dl) 1.2 (1.0 – 1.5) 0.9 (0.8 – 1.1) <0.001
serum albumin (g/dl) 2.0 (1.7 – 2.5) 2.8 (2.4 – 3.1) <0.001
nephrotic syndrome at 
presentation 75 (96%) 100 (81%) 0.002
protein : creatinine ratio (g / g) 8.8 (5.9 – 11.1) 4.5 (2.7 – 6.6) <0.001
ACEi/ARB use 68 (87%) 113 (92%) 0.28
statin use 49 (63%) 73 (59%) 0.62
other BP lowering medication 24 (31%) 17 (14%) 0.004
Therapy
interval from baseline to start of 
therapy (months) 9 (4 - 16) n/a .
serum creatinine at start of 
therapy (mg/dl) 1.4 (1.1 – 1.9) n/a .
cumulative cyclophosphamide 
dose (g) 37 (27 - 46) n/a .
Outcomes
death 11 (14%) 6 (5%) 0.02
malignancies 11 (14%) 3 (2%) 0.002
*The denominator differs from the total number of patients due to missing data 
for this variable. Data are presented as mean ± standard deviation, median 
(inter quartile range) or percentages where appropriate. BMI: Body mass 
index; eGFR-MDRD4: estimated glomerular filtration rate, calculated with the 
abbreviated Modification of Diet in Renal Disease equation for mass spectrometry 
standardized creatinine; ACEi: angiotensin converting-enzyme inhibitor; ARB: 
angiotensin II receptor blocker; BP: blood pressure. 
xix
Supplementary Table 4.2.3: Incidence ratios for malignancy after 
cyclophosphamide exposure by possible confounders. Analysis limited to patients 
without immunosuppression other than cyclophosphamide.
Risk Factor Incidence Ratio 95% Confidence 
Interval
Unadjusted 6.3 1.7 - 35.1
Univariate adjusted: 
Age 3.8 0.8 - 17.1
Male gender 4.6 1.3 - 16.7
Smoking 5.3 1.4 - 19.9
Family history of malignancy 7.4 1.6 - 35.0
CKD stage 10.3 2.8 - 38.0
Nephrotic syndrome 6.2 1.4 - 27.3
Multiple adjusted* 5.1 1.2 - 21.5
*After multiple imputation, complete case analysis: (n=150; IRR=3.4 [95%CI: 0.8 
- 14.9]). The analysis was adjusted for age, gender and ever smoking in both the 
imputed and complete case analyses. 
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Scenarios for cost calculation
Costs were obtained from the budget for the department of nephrology of the 
Radboud University Medical Centre, courtesy of drs A. van Lieshout, managing 
director. Medication costs were calculated using the Dutch Healthcare Insurance 
Board’s price estimates (www.medicijnkosten.nl):
Death
We assumed a patient to be admitted to the intensive care unit two days prior 
to death. The minimal costs scenario entails an admission fee and two days stay 
without intubation and mechanical ventilation according to reimbursement group 
1 (www.nza.nl). The likely cost scenario was admission and two days stay with 
intubation and mechanical ventilation within reimbursement group 2.
Finally, the maximum cost scenario was comparable to the likely cost scenario, 
except for reimbursement group 3.
Graft loss
We assumed that patients experiencing graft loss would receive anti-rejection 
therapy. Otherwise the costs are comparable to the initial costs of dialysis.
Initial costs of transplantation
The number of procedures performed have been taken from the 2012 budget for 
the department of nephrology of the Radboud University Medical Centre, courtesy 
of drs A. van Lieshout, managing director. 
Procedure minimal costs likely costs maximum costs
screening donor 616.78 2 535.21 5 127.17
screening recipient 1 175.87 1 175.87 3 0781.17
operation (nephrectomy and 
implantation)
8 386.01 15 905.56 23 595.02
Post-op admission recipient 4 035.57 4 035.57 19 906.43
Readmission within one year 8 086.97 8 086.97 3 6242.50
Outpatient follow-up 629.23 629.23 5 330.63
Total €24 173.86 €24 427.17 €103 307.27
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Medication minimal 
costs
likely costs maximum 
costs
Cotrimoxazol (480 mg dd 3 months) 9.42 9.42 10.62
Valganciclovir (450mg eod 2 months) 776.14 776.14 776.14
ceftriaxon (2000mg 1 time pre-op) 19.06 19.06 19.91
tacrolimus (15mg dd 1 year) 8 744.79 8744.79 1 0581.00
prednisone (8mg dd 1 year) 27.88 27.88 28.65
mycophenolate mofetil (2000 mg dd 6 
months) 180.05 180.05 988.52
metoprolol (200mg dd 1 year) 15.14 15.14 23.79
Total €9 772.48 €9 772.48 €12 428.63
Annual costs of transplantation
The annual hospital and physician costs of transplantation were assumed to be the 
comparable to readmissions and outpatient follow-up.
Procedure minimal costs likely costs maximum costs
Readmission 4 035.57 4 035.57 19 906.43
Outpatient follow-up 629.23 629.23 5 330.63
Total €4 664.80 €4 664.80 €25 237.06
Medication minimal costs likely costs maximum costs
tacrolimus (15mg dd 1 year) 8 744.79 8 744.79 10 581.00
prednisone (8mg dd 1 year) 27.88 27.88 28.65
metoprolol (200mg dd 1 year) 15.14 15.14 23.79
Total €8 787.81 €8 787.81 €10 633.44
Therefore the annual costs of kidney transplantation were estimated at:  
€13 452.61, with a minimum of €13 452.61 and a maximum of €35 870.50.
Cyclophosphamide therapy
The costs for cyclophosphamide therapy were calculated based on the following 
therapeutic regime: Patients were admitted to daycare for a methylprednisolone 
infuction 9 times 1000mg (days 1,2 and 3; 61,62 and 63; and 120,121 and 122). 
They received 150 to 200mg of cyclophosphamide daily for 6 months and 40mg of 
prednisone every other day for five months before tapering. 
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Procedure/medication minimal 
costs
likely costs maximum costs
admisstion to daycare + IV (9x) 1 540.90 1 540.90 1 540.90
methylprednisone (9x 1000mg) 298.17 298.17 298.17
cyclophosphamide (150 to 200mg 
dd 6 months)
108.91 108.91 147.55
prednisone (40mg eod 6 months) 34.84 34.84 35.81
Total €1 982.82 €1 982.82 €2 022.43
Conservative therapy
Costs for conservative therapy were calculated based on 4 outpatient visits, 
treatment with an ACEi or ARB, a statin and a diuretic.
Procedure/medication minimal costs likely costs maximum costs
Outpatient visits 763.50 763.50 763.50
ACEi /ARB (daily 1 year) 5.49i 5.49 151.37ii
Statin (daily 1 year) 6.49iii 6.49 172.95iv
Diuretic (daily 1 year) 5.65v 5.65 11.05vi
Total €781.13 €781.13 €1098.84
i Enalapril 20mg, ii Irbesartan 75mg, iii Simavastatin 20mg, iv Atorvastatin 20mg, 
v Hydrochlorthiazide 25mg, vi Furosemide 20mg.
Initial costs of dialysis
Prior to the actual initiation of dialysis, patients will be monitored more 
closely. We assumed the initial costs of dialysis be consist of costs made during the 
predialysis phase.
Procedure/medication minimal costs likely costs maximum 
costs
Predialysis outpatient visits 779.86 779.86 7093.00
Placing A/V shunt 63.16 105.26 126.32
Erythropoiesis stimulating agents 1 289.70 1 289.70 1 289.70
Calcium supplement 161.80 161.80 161.80
Vitamin D 184.92 184.92 184.92
Total €2 479.44 €2 521.54 €8 855.72
Annual costs of dialysis
The annual costs of dialysis have been taken from the budget of the department 
of nephrology, Radboud University medical centre. 2 379 out of 3 093 (77%) 
registered claims were up to three dialysis sessions per week. These were thus taken 
as the minimum and likely costs. 540 (17%) reimbursement claims were four to five 
sessions per week. Other instances, such as in hospital dialysis were considered so 
rare (at most 57 claims) that these were not considered for cost calculation. The 
reimbursed costs include hospital, physician and medication costs.
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Procedure minimal costs likely costs maximum costs
Dialysis €69 554.00 €69 554.00 €86 083.00
Complications
Complications considered for cost estimate were pneumonia, thrombosis, 
pulmonary embolism, CVA and CVD (including peripheral vascular disease). For 
the first two were considered potentially least costly, as these may be treated with 
antibiotics and without admitting the patient. The other three were considered 
reasons for admission.
Complication minimal costs likely costs maximum costs
Pneumonia 118.83 366.38 366.38
Thrombosis 379.80 2 848.30 7 109.10
Pulmonary embolism 1 365.50 2 755.50 3 360.90
CVA 1 242.70 3 195.60 6 591.00
CVD 678.20 1 808.50 2 147.60
Mean €757.01 €2 194.86 €3 915.00
Cancer
The most common forms of cancer in iMN patients are lung, lymphoma, 
leukemia, colon, prostate, mamma and bladder cancer. Costs for cancer diagnosis 
and treatment were calculated based on costs estimations for hospital in-patient, 
out-patient and daycare day. The estimated number of days per patient by disease 
were are presented in the table. Respective costs were €425 ±81, €111 ±50 and 
€201 ±82 per inpatient, outpatient and daycare day.
Lung cancer
The diagnosis, treatment and aftercare for lung cancer were based on the Dutch 
guidelines for small cell lung cancer. The diagnosis requires two outpatient visits 
for history, lab and imaging and a daycare visit for a lung biopsy. Treatment was 
considered to be chemotherapy with six doses of cis- or carboplatin requiring a 
daycare admission and etoposide 50 mg/m2 for three weeks per cycle. Aftercare 
consisted of four outpatient visits within the first year after treatment.
Hospital costs: 7 x €201 + 6 x €111 = €2073.00 
Medication costs: 6x €204.79 + 6x €366.18 = €3425.82
Lymphoma and leukemia
The diagnosis of lymphomas and leukemia is assumed to require two outpatient 
visits and a daycare visit for biopsy. Treatment is assumed to be 6 cycles of 
R-CHOP21 for a patient with a body surface area of 1.8m2. Thus medication 
was 675mg rituximab, 1400 mg cyclophosphamide IV, 90 mg doxorubicin IV, 
vincristine 2 mg IV on the first day of each cycle and 100 mg prednisone on days 1 
through 5. Aftercare required two outpatient visits in the first year.
Hospital costs: 7 x €201+ 4x €111 = €1851
Medication costs: 6x €3168.29 = €19009.74
Colon cancer 
Diagnosis is by means of coloscopy and biopsy in an outpatient setting. 
Treatment consists of laparoscopic surgery (7 inpatient days assumed) and 
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adjuvant chemotherapy (FOLFOX: oxaliplatin 85 mg/m2 (€1222.49), folinic acid 
200 mg/m2 (€8.79) and fluorouracil 1000 mg/m2 (€6.55) = €1237.83).  Aftercare 
consists of two outpatient visits per year.
Hospital costs: 7 x €425 + 2 x €111 = €3197
Medication costs: €1237.83
Prostate cancer
Diagnosis of prostate cancer is assumed to require a biopsy, which can be 
performed in an outpatient setting. In the treatment of prostate cancer radical 
prostatectomy, TURP and TURT are considered the first line treatments. The 
average length of stay is assumed to be 3 days. Aftercare consists of 5 outpatient 
visits.
Hospital costs: 3 x €425 + 6 x €111 = €1941
Breast cancer
Diagnostic procedures consist of mammography, echography and biopsy all 
performed during an outpatient visit. Treatment was assumed to be restricted 
mastectomy and sentinel node resection, 3 days admission on average. Adjuvant 
chemo was considered as well (6 courses of TAC à €3443.88) in a daycare setting. 
Aftercare consists of annual mammography.
Hospital costs: 3  x €425 + 6 x €201 + 2 x €111 = €2703
Medication: 6x €3443.88 = €20663.28
Bladder cancer
Diagnosis requires cytologic investigation and cystoscopy, performed in the 
outpatient clinic. Treatment may consist of radical cystectomy (€1396) or TURP 
(€1265) and 3 days admission. Aftercare consists of two outpatient visits per year.
Hospital costs: €1265 or €1396 + 3 x €425 + 3 x €111 = €2873 to €3004 
Estimated cost distribution for cancer
Cancer Hospital costs Medication Total
Lung €2 073.00 €3 425.82 €5 498.82
Lymphoma/leukemia €1 851 €19 009.74 €20 860.74
Colon €3 197 €1 237.83 €4 434.83
Prostate €1 941 0 €1 941.00
Breast €2 703 €20 663.28 €23 336.28
Bladder €2 873 0 €2 873.00
Minimal costs: €1 941, mean costs €8 420.67, maximum costs: €23 336.28.
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Look-up tables
Look-up table 1. Probability of death following kidney transplantation 
Age Probability of death
1 year after NTx 5 years after NTx 10 years after NTx
20-29 0.032 0.088 0.315
30-39 0.029 0.073 0.297
40-49 0.031 0.078 0.326
50-59 0.042 0.101 0.395
>60 0.064 0.155 0.558
Look-up table 2. Probability of death due to cancer (general population)
Age Probability 
of death
20-44 0.09
45-54 0.17
55-64 0.21
65-74 0.26
>75 0.34
Look-up table 3. Death on dialysis
Age Probability 
of death
20-64 0.03
65-74 0.11
>75 0.23
Look-up table 4. Probability of receiving a kidney transplantation (initial or after 
dialysis)
Age Probability of 
receiving a kidney 
transplant
20-44 0.46
45-65 0.37
>65 0.24
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Look-up table 5. Risk of cancer in the general population
Age Probability 
of cancer
20-24 0.00056
25-29 0.00087
30-34 0.00128
35-39 0.00203
40-44 0.00335
45-50 0.00525
50-54 0.00782
55-59 0.01171
60-64 0.01651
65-69 0.02140
70-74 0.02528
75-79 0.02782
≥80 0.02749
Look-up table 6. Probability of mortality in the general population 
Age Probability 
of death
20-29 0.00055
30-39 0.00055
40-49 0.0011
50-59 0.0032
60-69 0.0079
70-79 0.0222
80-89 0.0646
≥90 0.1805
